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Cancer results from the accumulation of genetic mutations in a normal cell that
ultimately result in the expression (or overexpression) of oncogenes. The design of drugs
having high affinity for specific DNA sequences or structural motifs is vital to gaining a
better understanding of gene expression and to the development of new cancer treatments
that are based on turning off oncogene expression. This dissertation presents studies of
the binding of two ligand families, Berenil (DMZ), and ruthenium polypyridyl complexes
(RPCs), to B-DNA and G-quadruplex (G4) DNA. The structure-function relationships for
the interaction of these ligand families with DNA were probed by functional group
substitution, truncation, or modification of the DMZ amidine groups, and by changing
one of the RPC ruthenium ligands from phenanthroline to dipyridophenazine (dppz) or
tetraazatetrapyrido-pentacene (tatpp), and lastly by adding a second Ru(Phen)2 core to the
tatpp bridging ligand.
Removal of one or both amidine groups from DMZ drastically reduces its binding
to both B-DNA and G4-DNA. DMZ analogs in which one amidine was replaced by an
alkyne group were synthesized with the expectation that the additional π-bonding

character of the alkyne group would increase G4 affinity. All of the DMZ alkyne
compounds were found to bind preferentially to G4-DNA (over B-DNA) and a few of
these compounds demonstrated significant anticancer activity.
RPCs with progressively longer ruthenium bound ligands were found to bind with
differing affinities to B-DNA and G4-DNA. Monoruthenium RPCs exhibited a
preference for binding to B-DNA, while binding the diruthenium RPC to G4-DNA was
more complicated exhibiting both tighter and a weaker binding modes in comparison to
the B-DNA complex. The diruthenium complex was found to bind more tightly to G4DNA by approximately 3 kcal mol-1.
The binding of small molecules to DNA resulting in the disruption of oncogene
transcription represents a powerful approach to the treatment of cancer.
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CHAPTER I
INTRODUCTION
1.1

Background
Cancer is the second leading cause of death in the United States and 2017 expects

an estimated 1,688,780 new cases of cancer with an estimated 600,920 deaths. [1] Of
these new cases arising in the male population, 116,990 cases of lung and/or bronchus
cancer and 161,360 cases of prostate cancer are expected. [1] The female population is
expected to exhibit 105,510 new cases of lung and/or bronchus cancers and 252,710 new
cases of breast cancer. [1] Lung and bronchus cancers are expected to cause a total of
155,870 deaths in 2017. [1] The cancer incidence rate is 20% higher in men than in
women for all sites combined and the cancer death rate is 40% higher.[1] It is now
understood that most if not all cancers have a set of functional capabilities that permit (1)
self-sufficiency in growth signals, (2) insensitivity to growth-inhibitory (antigrowth)
signals, (3) evasion of programmed cell death (apoptosis), (4) limitless replicative
potential, (5) sustained angiogenesis (development of new blood vessels), and (6) tissue
invasion and metastasis (development of secondary malignant growths).[2] Each of these
physiological changes act to bypass the anticancer defense mechanisms of the human
body. DNA damage is known to be a cause of cancer and common mechanisms of
damage include oxidation, [3] ultraviolet induced strand breakage, [4] and exposure to
carcinogens[5]. DNA offers an attractive target for anti-cancer drug design and aspects of
1

DNA replication, [6] repair, [7] and translation [8] are commonly explored targets for
therapeutic intervention.
1.2

DNA
Deoxyribonucleic acid is the genetic material required for nearly all of cellular

organisms’ life processes. It stores instructions that may be interpreted by specialized
molecules to typically synthesize proteins to perform a task. DNA is located in the
nucleus of eukaryotic organisms where it commonly displays several classic
conformations including A, B, and Z form. Other types of DNA are known to exist and
include the G-quadruplex (G4), intercalated motif (i-motif), cruciform, hairpin, and
triplex conformations.
DNA is comprised of sequential deoxyribose molecules connected at the 3’
carbon with a phosphate to the 5’ carbon of the next deoxyribose sugar. Purine or
pyrimidine bases are attached to deoxyribose at the 1’ carbon. In canonical DNA two
strands of DNA are oriented antiparallel to one another as determined by the 5’3’
strand directionality, and engage in hydrogen bonds matching purine bases adenine (A)
and guanine (G) with pyrimidine bases thymine (T) and cytosine (C) respectively as
shown in Figure 1.1. The A-T combination possesses two hydrogen bonds while the G-C
interaction is of three hydrogen bonds. The A-T rich regions of DNA are more weakly
associated than the G-C rich regions due to π-π stacking interactions and the hydrophobic
effect.[9]
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Figure 1.1

Structures and numbering scheme of the DNA bases and the typical
hydrogen bonds formed in duplex DNA.

The numbering scheme is indicated for all nucleic acid bases. The numbering scheme of
deoxyribose is indicated on the Adenine bound sugar.
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Figure 1.2

DNA base pairs in the context of double stranded DNA.

Adenine (top left) hydrogen bound to thymine (top right) and guanine (bottom left)
hydrogen bound to cytosine in the context of B-DNA. Hydrogen bonds are shown in
green.
1.2.2

DNA Replication
Replication of DNA is a semiconservative process in which the two strands are

separated and act as templates for the formation of daughter strands.[9] The directionality
of the enzymes that synthesize the strands results in the continuous synthesis of one
“leading” daughter strand and one “lagging” strand. The lagging strand is synthesized in
discontinuous “Okazaki” fragments which are then joined through the activity of
4

Ligase.[9] The replication of DNA is a tightly regulated process. Point mutations in the
genome may cause certain diseases such Parkinson’s disease[10], Tay-Sachs Disease[11],
and sickle cell anemia[12]. The DNA parent strand is methylated prior to replicating so if
the unmethylated daughter strand contains an error, proofreading enzymes present in the
cell know which strand to correct.[13]
DNA replication usually begins at sites known as origins of DNA replication.[14]
These origins provide a location for the assembly of multiprotein complexes that
facilitate synthesis.[14] The initial unwinding establishes replication forks. RNA
helicases are loaded onto either one or both exposed strands of DNA and translocate
unidirectionally along the strand to melt the DNA.[14] Helicases moving in the 3’ to 5’
direction are said to move in the direction of the “leading strand” template while those
moving in the 5’ to 3’ direction are along the “lagging strand” template.[14]
DNA polymerases extend chains of DNA but are incapable of starting chains
anew and require a primer to initiate synthesis. The primer is typically a short RNA chain
that marks the site of initiation.[14] Eukaryotic cells contain specialized DNA
polymerase enzymes which possess either highly processive activity as would be
expected for leading strand elongation or relatively nonprocessive activity, as would be
consistent with lagging strand synthesis.[14] DNA Polymerase I in E. coli is able to
remove RNA primers due to its intrinsic 5’ to 3’ exonuclease activity.[14] Eukaryotic
polymerases are unable to perform this function so other factors are involved in the
processing of Okazaki fragments and primer removal.[14] Exonuclease activity for
proofreading the DNA ensures a faithful reproduction of the parent strand.[14] Once
DNA chains have been extended to close gaps formed by RNA primer removal and
5

Okazaki fragment formation, DNA Ligase covalently links the 5’ and 3’ ends of DNA to
yield closed daughter strands.[14]
As replication of DNA progresses, DNA ahead of the replication fork may
become supercoiled and the torsional strain introduced may lead to inhibition of fork
movement and therefore cessation of DNA replication.[14] To avoid this problem, Type I
topoisomerase introduces single-strand breaks in the DNA which relaxes it.[14] In the
event of intertwined molecules that may not be separated by relaxing the DNA, Type II
topoisomerase activity may be required to introduce a double stranded DNA break.[14]
1.2.3

DNA Transcription
The pathway of information flow of DNA RNA Protein is known as the

central dogma of molecular biology.[13] Transcription is the process by which DNA is
“read” and converted to complementary messenger RNAs (mRNAs).[13] Ribosomal
RNAs (rRNAs) constitute the ribosomes which make up the “cellular machinery” that is
the site of protein synthesis.[13] Transfer RNAs (tRNAs) read the mRNAs and deliver
amino acids in the correct sequence to the growing polypeptide chain in a process known
as translation.[13] A codon for which there is no complementary tRNA in a normal cell
causes the amino acid chain to dissociate from the ribosome and is known as a
termination or “stop” codon.[13] The polypeptide chain folds to yield a protein which is
typically transported to where it is needed in the cell or packaged for transport outside of
the cell. The protein may require additional processing to yield an active conformation as
is common with proteolytic enzymes.
Transcriptional processes are under tight control by the gene’s promotor region.
RNA polymerase holoenzyme binds weakly to the DNA double helix and travels in a
6

processive manner, forming transient hydrogen bonds with exposed donor and acceptor
groups of DNA base pairs until a promotor is located and the initiation stage of
transcription is executed.[9] These exposed bonds are located in the grooves of DNA and
do not require denaturation of the helix for the protein to sample. Figure 1.1 shows the
location of the major and minor grooves relative to the nucleotide base pairs and the
exposed locations for hydrogen bond formation are visible.
A segment of DNA must be unwound by RNA Polymerase for DNA base pairing
with incoming ribonucleoside triphosphates.[9] No primer is required for RNA synthesis
and the mRNA strand undergoes the process of elongation in the 5’3’ direction.[9] At
the conclusion of elongation, the strand must be terminated. A simple strategy is the
encoding of GC repeats that forms a hairpin DNA followed by a uracil (U) rich region. It
is likely that DNA Polymerase will pause after the transcription of a GC rich hairpin and
the weak U-A hydrogen bonds lead to dissociation of the mRNA and therefore
termination of transcription.[9]
1.3

B-DNA
B type DNA is characterized by a right handed helical structure containing 10.5

residues per helical turn.[15] The axial rise per residue is 0.34 nm and the length of one
turn of the helix is 3.57 nm.[15] The helix is 2.0 nm in diameter and the nucleotide
phosphate spacing is 0.7 nm.[15] The rotation per residue is 34.3° and the base pair tilt is
-6°.[15]
The grooves of DNA may provide a wealth of information for a DNA interactive
protein to determine the sequence of bases without unwinding the DNA and reading the
individual base pairs, as mentioned briefly in Chapter 1.2.3. The major groove possesses
7

a characteristic pattern based on the presence of A:T or G:C base pairs. Differences in the
Hydrogen bond network present in the major and minor grooves of DNA is illustrated in
Figure 1.1. Exposed hydrogen binders in the major groove include the hydrogen bond
acceptor carbonyl group on C4 of thymine, hydrogen bond donor amino group on C6 of
adenine and hydrogen bond acceptor N7 of adenine. Thymine also possesses a bulky
hydrophobic methyl group. The N7 of guanine is a hydrogen acceptor, as is its carbonyl
group on C6. The amino group on C4 of cytosine is a hydrogen bond donor. There is also
a small non-polar hydrogen on C5 of cytosine.[16] By sampling the hydrogen bonds, a
protein will be able to “read” a sequence of DNA before deciding if the DNA requires
denaturation for transcription, replication, etc. The minor groove is less useful for
distinguishing the sequence of the DNA chain since A:T base pairs read as hydrogen
bond acceptor, nonpolar hydrogen, hydrogen bond acceptor as a palindrome. The same
problem applies to G:C base pairs where the sequence is hydrogen bond acceptor,
hydrogen bond donor, hydrogen bond acceptor. [16]
1.3.1

B-DNA Minor Groove binders
Groove binders are usually small molecules that are able to adopt a crescent shape

to associate with the minor groove of DNA and take advantage of intermolecular
interactions.[17] Groove binding is predominantly an entropically driven process and the
interaction minimally perturbs duplex structure.[18] Typical groove binders netropsin and
distamycin share a crescent shape and positive charge which associates with the
negatively charge phosphate backbone of DNA to aid in binding.[18] The binding of
netropsin to a short DNA duplex is shown in Figure 1.3.

8

Figure 1.3

Example minor groove binder in complex with B-DNA.

PDB File 2LWH. DNA Duplex 5'-GGATATATCC-3' in complex with minor groove
binder netropsin. The structure of netropsin is shown on the right. Note that rotation
around single bonds allows netropsin to adopt a crescent shape that fits in the minor
groove of DNA.
1.3.2

B-DNA Intercalating agents
DNA intercalation was first proposed by Lerman in 1961 in his paper which

examined the structure of DNA in complex with acridines.[19] Lerman noted that
binding resulted in the following: (i) the mass per unit length is diminished, (ii) the
molecule in fiber of the complex are more closely packed than B DNA, (iii) the spacing
along the helix is retained, (iv) the molecule is straighter in solution, in opposition to the
electrostatic effect and structurally dissimilar substances fail to elicit the straightening,
9

and (v) the regular helical structure is lost.[19] Lerman proposed a number of schemes by
which acridine may bind DNA of which only intercalation into the helix by extension of
the backbone was found to be fully satisfactory.[19]
Molecules capable of intercalating into DNA are now known to typically be
planar aromatic compounds in which insertion between DNA base pairs is accomplished
by unwinding and lengthening the DNA helix.[18] Intercalation is primarily an
enthalpically driven process, typically against an unfavorable entropic contribution.[18]
The typically planar, conjugated ligands exhibit π-orbital overlap with the DNA base pairs
resulting in favorable π-π interactions.[20] Typical DNA intercalators include Ethidium

Bromide, Quinavrine, and Daunomycin.[21] The binding of an anticancer drug, XR5944,
to DNA is shown in Figure 1.4. This anticancer drug is comprised of two intercalating
ligands with a short tether connecting them. The figure depicts the straightening of the
duplex to accommodate the intercalator which acts as a “false coin” placed into a roll of
pennies (base pairs) as described by Williams et al.[22] The straightening or elongation
of the duplex must occur in order to create the necessary space to place the intercalating
moiety into the helix.

10

Figure 1.4

Example intercalating ligand in complex with B-DNA.

PDB File 2MG8. Anticancer drug XR5944 complexed with TFF1 Estrogen Response
Element. Note the elongation of the duplex DNA to accommodate the intercalating
motifs of the ligand and the major groove binding character of the linker chain. The
Structure of XR5944 is shown to the right.
1.3.2.2

Neighbor exclusion
The unwinding of the DNA helix to accommodate an intercalating ligand has

limits. Adjacent sites are said to be anticooperative in nature. Williams et al. proposed a
model in which intercalation of a small molecule causes the adjacent base pairs to buckle
into the adjacent site on the DNA chain resulting in an inability to intercalate in the
collapsed site.[22] They propose the helical twist of DNA to be determined by a balance
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of electrostatic repulsion between adjacent phosphate groups acting to wind the helix and
base stacking interactions tending to unwind the helix.[22]
1.4

G4-DNA
G-quadruplex (G4) structures have emerged as attractive targets for in vivo

regulation of diverse processes. G4-DNA is a non-canonical structure formed by the
association of runs of guanine residues in DNA. Four guanines associate into a planar
tetrad via Hoogstein hydrogen binding and three (or more) tetrads stack via π-π
interactions to form a G4 motif as seen as a cartoon in Figure 1.5 and illustrated from
Protein Data Bank (PDB) files in Figure 1.6.

Figure 1.5

Cartoon of a G-tetrad and typical G-quadruplex motifs.

G-tetrad (top) highlighted in green. Cartoon G-quadruplexes illustrating the several
possible conformation including (from left to right) tetramolecular parallel,
tetramolecular antiparallel, tetramolecular mixed parallel/antiparallel, and unimolecular
antiparallel. Metal cations are represented by gold spheres only in the tetramolecular
parallel G4 cartoon but are present in each G4.
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Figure 1.6

G-quadruplex crystal structures demonstrating several possible
conformations.

Top left PDB File 2F8U. Mixed parallel/antiparallel quadruplex from the human Bcl-2
promoter; Top right PDB File 2MBJ. Mixed parallel/antiparallel quadruplex from the
human telomeric repeat in sodium ion solution; Bottom left PDB File 5I2V. Parallel
quadruplex from the human KRAS promoter; Bottom right PDB File 5LIG. Parallel
quadruplex from the c-MYC NHE III1 promoter.
Monovalent cations coordinate between stacked G-tetrads and enhance the
stability of the G4. A cartoon depicting the coordination location is shown in Figure 1.5.
A general trend observed for stabilization is K+ > Na+ > Rb+ > NH4+ > Cs+ > Li+ with K+
13

possessing “ideal” characteristics to effectively coordinate in the center of two Gtetrads.[23] Changes in the metal identity are able to influence the conformation of the
G4-DNA, for example the conversion of a human telomeric DNA from a mixture of the
parallel and antiparallel conformations in K+ solution to an antiparallel conformation in
Na+ solution as evidenced by Circular Dichroism. [24]
Putative G4 forming sequences may be involved in DNA replication as they are
found near approximately 90% of human replication origins.[25] G4 motifs located in
the promotor region of certain genes must be unfolded for transcription to occur as
observed in oncogenes including c-MYC[26] and Bcl-2[27]. A Molecular modeling
simulation of the c-MYC NHE-III1 G4 in the context of duplex DNA is shown in Figure
1.7. The strand complementary to the G4 forming region folds into an i-motif and is also
shown in the simulation.
Owing to the many sequences and folding variations present that may form a G4
motif, numerous modes of ligand binding have been observed. Ligand binding to G4DNA may occur by three typical processes including end stacking, intercalation and loop
interactions.[29]
1.4.2

G4-DNA end binders
Ligands that bind to the ends of a G4 typically associate through π-stacking and

electrostatic interactions as was the case with Telomestatin derivative L2H2-6M(2)OTD
binding to a telomeric G4-DNA peptide.[30] The flexibility of this molecule allows it to
flatten and become more planar relative to the individual guanines in the top G-tetrad
layer to maximize the π-π stacking interactions.[30] Phen-DC3 also binds to the
quadruplex target by taking advantage of π stacking interactions with the top tetrad and
14

Figure 1.7

Molecular models of the average structure of the final 20 ps of the
molecular dynamics simulation of the c-MYC NHE-III1 “silencer” element.
Reproduced from Cashman et al. with permission [28].

The G-Quadruplex structure is at the top-center, and the i-motif is at the bottom-center of
each picture. a “Rotation #1” of the G-Quadruplex, with the T15 loop at the top and rear
and the G19/A20 loop at the top and front of the picture. b “Rotation #2” of the GQuadruplex, with the T15 loop at the top and front of the image, and the G19/A20 loop at
the front and adjacent to the G-Quadruplex/i-motif interface.
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Figure 1.8

Example G-quadruplex interacting ligands interacting with the quadruplex
core in an end binding mode.

Top Left: PDB File 2MB3. Side view of an intramolecular human telomeric G‑
Quadruplex Bound to Telomestatin derivative L2H2-6M(2)OTD; Top Right: PDB File
2MGN. Top view of c-MYC G-quadruplex bound to the bisquinolinium compound PhenDC3. Bottom Left: two views of the L2H2-6M(2)OTD molecule highlighting the planar
nature of the aromatic rings that sit on the G-tetrad. Ligand coordinates were from PDB
File 2MB3. Bottom Right: Two views of Phen-DC3 highlighting the planar nature of the
aromatic rings that sit on the G-tetrad. Ligand coordinates were from PDB File 2MGN.
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orients in such a way as to maximize overlap between each quinolinium moiety and a
guanine residue of the c-MYC quadruplex.[31] Phen-DC3 possesses π-overlap between
its aromatic moieties and all four G-tetrad bases which is more extensive than a number
of G4 interactive ligands in which only one or two guanine bases are overlapped by the
aromatic ligand’s π orbitals.[31]
1.4.3

G4-DNA intercalating agents
The c-MYC NHE-III1 silencer element has been modeled in complex with

TMPyP4 and demonstrates four binding sites in which the ligand may be docked
including two intercalative sites as shown in Figure 1.9. Previous experimental data from
Le et al. demonstrated four bound TMPyP4 molecules per WT 39-mer Bcl-2 G4.[32]
Later experiments in which TMPyP4 was metallated with a either Co(III), Ni(II), Cu(II),
or Zn(II) and titrated into human telomere G4-DNA also demonstrated the 4:1
stoichiometry which suggests the utilization of an intercalative mode of binding and was
reported by DuPont et al.[33] The binding mode attributed by DuPont et al. to be the
result of intercalation demonstrated an enthalpically driven process with a small entropic
contribution with the exception of Cu(II) TMPyP4 binding in Na+ containing buffer
which had a small entropic penalty. This pattern of an enthalpy driven process with a
small entropic contribution or penalty is consistent with the formation of π-bonding
character.
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Figure 1.9

Molecular models of TMPyP4 bound to the G-Quadruplex portion of the
NHE-III1 silencer element. Reproduced from Cashman et al. with
permission [28].

a TMPyP4 docked to the 5′ end, between bases G10/A11 and the G12-G16-G21G25 tetrad. b TMPyP4 intercalated near the 5′ end, between the G12-G16-G21G25 and the G13-G17-G22-G26 tetrads. c TMPyP4 intercalated near the 3′ end,
between the G13-G17-G22-G26 and the G14-G18-G23-G27 tetrads. d TMPyP4
docked to the 3′ end, between bases G28/A30 and the G14-G18-G23-G27 tetrad.
1.4.4

G4-DNA loop interactions
Loops introduce steric effects that may prevent binding of ligands that simply do

not fit onto the quadruplex. Alternatively, loops may provide favorable conditions in
which small molecules or side chains of small molecules are able to bind. The G4 is
known to be a highly dynamic structure in solution and its loops are certainly no
exception. If loops are long enough to be considered “floppy” folding over of loops onto
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the end bound ligands may change the affinity and potentially provide an additional
binding site. Propeller loops on the quadruplex exterior have the potential to change
conformation from the native structure to form discrete binding pockets for substituents
as was noted by Campbell et al.[34] The ability of loops to constrain small molecule side
chain movement and/or placement will be useful considerations in the tuning of
individual/unique quadruplex targeting. [34]
1.5

Outline of this work
The work presented in this dissertation involves studying the binding of small

molecules (ligands) with DNA constructs to understand how binding affinity is altered by
modifications to parent ligands and the type and topology of the DNA sequence under
investigation.
Chapter II introduces diminazene or Berenil, a classic duplex minor groove
binder, and examines its interactions with G-quadruplex DNA, to which it binds far
tighter than to B-DNA. Diminazene was found to bind with to several G-quadruplexes
with dissociation constants on the order of 1 nM, among the strongest to date and 103
tighter than the affinity for AT-rich duplex DNA, of which it was previously considered a
selective binder. The multiple binding modes were consistent with end binding to the
tetrad faces and intercalation into the G-quadruplex structure yielding 8 bound
diminazene ligands per G-quadruplex. The simple synthesis and respectable Gquadruplex binding makes this molecule an attractive scaffold for from which to develop
new G-quadruplex ligands for anticancer applications.
Chapter III examines alkyne substituted diminazene molecules for their Gquadruplex binding and potential anticancer activity. We sought to design G-quadruplex
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binders with low B-DNA affinity so the ligand would not end up interacting with B-DNA
and never make it to the G-quadruplex target. Since both amidine groups are required for
binding B-DNA but G4-DNA retained a low level of affinity, one amidine group was
replaced with an alkyne moiety and in many cases additional π-bonding character and/or
mimics of known drugs were introduced. Though ITC was unable to accurately
characterize binding due to the low solubility of the ligands, FRET experiments and GI50
determinations found respectable anticancer activities against ovarian, prostate, and triple
negative breast cancers.
Chapter IV discusses the impact of changing the length of a B-DNA intercalating
bridging ligand attached to a Ru(phen)2L moiety where L was varied from tatpp to dppz
to phen. Specific RPCs were [Ru(phen)3]2+ (12+), [Ru(phen)2(dppz)]2+ (22+), and
[Ru(phen)2(tatpp)]2+ (32+). The longest tatpp containing ligand bound by an intercalative
mode while 12+ exhibited only groove binding as phenanthroline is not long enough to
intercalate into the B-DNA helix. Racemic and the enantiomerically pure Δ and Λ
compounds were examined and the tightest DNA binding ligand was found to be 32+. The
dppz analog interestingly demonstrated both intercalative and groove binding
characteristics and showed two thermodynamically distinct binding modes. This was the
first presentation of the groove binding mode in the literature as the currently accepted
model is a “canted” orientation for the 22+. We suggested that the canted structures would
have approximately the same thermodynamic profile and the binding modes observed
were wildly different.
Chapter V surveys the thermodynamics of RPC•G-quadruplex DNA (G4)
complex formation. RPCs were [Ru(phen)3]2+ (12+), [Ru(phen)2(dppz)]2+ (22+),
20

[Ru(phen)2(tatpp)]2+ (32+), and [Ru(phen)2(tatpp)(phen)2Ru]4+ (44+) and target DNAs
were c-MYC NHE-III1 promoter sequence mutants forming 1-2-1 and 1-6-1 Gquadruplexes. Formation of the 2:1 RPC•G4 complexes is characterized by entropy
driven RPC binding to the top and bottom of G-tetrad faces and affinity was found to
increase as the G4 interactive ligand was increased in size. The strongest binder was the
diruthenium 44+ compound which demonstrated a high affinity and low affinity mode.
The two binding modes are attributed to preferential binding of one of the 44+
enantiomers (e.g. ΛΛ) over the other isomers (e.g. ΔΔ or ΔΛ). Tighter binding of the
preferred 44+ enantiomer, in comparison to 32+, is due to additional favorable entropy for
locating a second [(phen)2Ru-]2+ moiety in a G4 groove. Weaker binding of the
disfavored 44+ isomers is likely due to a poorer fit of these isomers with the G4 faces.
1.6
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CHAPTER II
DIMINAZENE OR BERENIL, A CLASSIC DUPLEX MINOR GROOVE BINDER,
BINDS TO G-QUADRUPLEXES WITH LOW NANOMOLAR DISSOCIATION
CONSTANTS AND THE AMIDINE GROUPS ARE ALSO CRITICAL
FOR G-QUADRUPLEX BINDING
Reproduced from Jie Zhou, Vu Le, Dimpy Kalia, Shizuka Nakayama, Clinton Mikek,
Edwin A. Lewis* and Herman O. Sintim*. “Diminazene or berenil, a classic duplex
minor groove binder, binds to G-quadruplexes with low nanomolar dissociation constants
and the amidine groups are also critical for G-quadruplex”. Molecular bioSystems 2014
10, 2724. with permission from The Royal Society of Chemistry.
2.1

Abstract
G-quadruplexes have shown great promise as chemotherapeutic targets, probably

by inhibiting telomere elongation or downregulating oncogene expression. There have
been many G-quadruplex ligands developed over the years but only a few have drug-like
properties. Consequently only a few G-quadruplex ligands have entered clinical trials as
cancer chemotherapeutic agents. The DNA minor groove ligand, berenil (diminazene
aceturate or DMZ), is used to treat animal trypanosomiasis and hence its toxicological
profile is already known, making it an ideal platform to engineer into new therapeutics.
Herein, using a plethora of biophysical methods including UV, NMR, MS and ITC, we
show that DMZ binds to several G-quadruplexes with a Kd of ~1 nM. This is one of the
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strongest G-quadruplex binding affinities reported to date and is 103 tighter than the
berenil affinity for an AT-rich duplex DNA. Structure–activity-relationship studies
demonstrate that the two amidine groups on DMZ are important for binding to both Gquadruplex and duplex DNA. This work reveals that DMZ or berenil is not as selective
for AT-rich duplexes as originally thought and that some of its biological effects could be
manifested through G-quadruplex binding. The DMZ scaffold represents a good starting
point to develop new G-quadruplex ligands for cancer cell targeting.
2.2

Introduction
Both DNA and RNA can form many secondary structures, such as G-

quadruplex,[1-3] triplex,[4,5] i-motif,[6,7] and a biological role for these polymorphs,
especially G-quadruplexes,[8-10] has been suggested. There are ~3,760,000 guanine-rich
regions in the human genome, which have the potential to form G-quadruplexes,[11,12]
including those at the telomere end[13] and promoter regions of some cancer-related
genes.[10] Guanine tracts in RNA are known to form G-quadruplexes in vivo[3,14–16]
but the formation of G-quadruplexes in chromosomal DNA has been a matter of debate
due to the fact that the guanine tracts in chromosomal DNA can also form duplexes with
complementary tracts of cytosines. After many years of fierce debate regarding a
biological role for DNA G-quadruplexes in vivo, acceptance is now growing that DNA
G-quadruplexes might indeed form in vivo and that there could be biological
consequences of G-quadruplex formation in chromosomal DNA. Firstly, it has been
demonstrated that fluorogenic G-quadruplex-specific ligands could become fluorescent
inside cells, especially during cell division, when single stranded regions of chromosomal
DNA are created during DNA replication.[17,18] Secondly, seminal works by the
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laboratories of Pluckthun[19] and Balasubramanian[20] resulted in the engineering of Gquadruplex-specific antibodies, which have been used to provide compelling evidence
that G-quadruplexes form in vivo. Additionally, biophysical approaches (mainly
NMR[21,22] and DEER/ENDOR[23,24])have demonstrated that synthetic G-rich
oligonucleotides could form G-quadruplex structures in vivo.
If G-quadruplex formation in vivo has a biological consequence, then small
molecules that target and stabilize these structures could have therapeutic value. In
animal chromosomes, the telomerase enzyme (which is up-regulated in certain cancers) is
responsible for maintaining the telomere length thereby rendering cancer cells
immortal.[25,26] The telomere is G-rich and has been shown via many biophysical
experiments to be capable of forming G-quadruplexes.[27–30] Many compounds that
bind to G-quadruplexes have been shown to inhibit the extension of the DNA substrate
by telomerase and some have even shown interesting anti-proliferative properties when
added to cancer cells.[31–35] In addition to telomeres, G-quadruplexes are present in the
promoter regions of a number of cancer-related genes such as c-MYC,[36] BCL-2,[37]
KRAS,[38] c-kit[39] and VEGF,[40] where they are involved in the regulation of
transcription of these genes by disrupting binding of transcription factors.[41,42] In light
of these potential important biological roles of G-quadruplexes, there is high interest in
discovering G-quadruplex-selective ligands for both fundamental studies (for example,
fluorescent ligands that will allow for studying G-quadruplexes in vivo) and also druglike molecules that will allow for selective targeting of G-quadruplexes related to
cancer[17,32,43,44] and other diseases.[45] In this manuscript, we reveal that DMZ,
which has been shown to bind to the minor groove of AT-rich DNA with a micromolar
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dissociation constant, binds to G-quadruplexes with a nanomolar dissociation constant,
i.e. 3 orders of magnitude stronger affinity for G-quadruplexes than AT-rich duplexes.
The DMZ scaffold is therefore a good starting point to develop potent G-quadruplex
ligands.
2.3
2.3.1

Material and methods
General
4-Aminobenzamidine dihydrochloride, aniline and diminazene aceturate (DMZ or

Berenil) were purchased from Aldrich. All triazenes were stored at 4 °C and in dark since
significant decomposition of triazenes was observed if stored at room temperature and in
presence of light. Sequences of DNA used in this study are shown in Table 2.1. Purified
oligonucleotides 22-mer c-kit1, 18-mer VEGF, 23-mer bcl-2 2345, 15-mer TBA and 20mer 8bp AT were purchased from IDT and analyzed for purity before use. Purified WT
27-mer bcl-2, WT 24-mer c-MYC, WT 22-mer human telomere hTel were purchased
from Midland Oligos (Midland, TX) and used without further purification.
DNA stock solutions were prepared by reconstituting the lyophilized
oligonucleotide into 20 mM Tris buffer with a salt concentration of 100 mM KCl and a
pH of 7.2. Approximately 2 mL of the oligonucleotide was dialyzed (1000 Mw cutoff
membrane) against three changes of buffer solution (1 L, 24 h each) at 4 °C. The
concentrations of stock DNA solutions were verified using UV-Vis. G-Quadruplex
DNAs were annealed by quickly heating the sample to 100 °C, holding at 100 °C for ten
minutes then slowly cooling to 5 °C, over a three hour period. Molar extinction
coefficients of the DNAs were determined using a nearest-neighbor method for single
stranded DNA.48 The extinction coefficients at 260 nm for the WT 27-mer bcl-2, WT 2428

mer c-MYC, WT 22-mer human telomere hTel sequences are 267 200 M−1 cm−1, 248 100
M−1 cm−1, and 228 500 M−1 cm−1 respectively.[49-51] The extinction coefficient at 260 nm
for the 7 base pair hairpin with A2T2 (7bp HP·AT) and the 7 base pair hairpin without
A2T2 (7bp HP) are 165 200 M−1 cm−1 and 159 200 M−1 cm−1 respectively. Cell culture
grade water purchased from Corning was used for all experiments.
Table 2.1

Sequences of DNA and their abbreviations used in the study

Abbreviation Sequence (5′ to 3′)
7bp HPa
GCAGTCCTCTCGGACTGC
7bp HP-ATa
GCAATTCTCTCGAATTGC
a
8bp AT
CGAATTTCAAAAGAAATTCG
TBA
GGTTGGTGTGGTTGG
VEGF
GGGCGGGCCGGGGGCGGG
hTel
AGGGTTAGGGTTAGGGTTAGGG
c-kit1
AGGGAGGGCGCTGGGAGGAGGG
c-MYC
TGGGGAGGGTGGGGAGGGTGGGGA
bcl-2 2345
GGGCGCGGGAGGAATTGGGCGGG
bcl-2
CGGGCGCGGGAGGAAGGGGGCGGGAGC
a
Stem-loop DNA. The bases in italics form the stem part. Bases that are underlined are
the A2T2 sequence, which widely known as the binding site for minor groove binders.
2.3.2
2.3.2.1

Synthesis of Triazene-1 and Triazene-2
Triazene-1
To a cooled (0 °C) and stirred suspension of 4-aminobenzamidine

dihydrochloride (1.0 g, 4.80 mmol) in water (6 mL) and concentrated hydrochloric acid
(1 mL), a solution of sodium nitrite (0.36 g, 5.28 mmol) in water (1 mL) was added
dropwise and the mixture was stirred for 20 minutes. To the resulting diazonium solution,
a solution of aniline (0.43 mL, 4.80 mmol) in MeOH (1 mL) was added followed by
addition of saturated aqueous sodium acetate (6 mL). After being stirred at 0 °C for 1 h,
the resultant yellow solid was filtered off, washed with brine, dried and crystallized with
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MeOH/acetone (1 : 2, 20 mL) to afford analytically pure product (1.2 g, 84%) as an
acetate salt. 1H NMR (DMSO-d6, 400 MHz) δ 7.87–7.83 (m, 2H), 7.57–7.47 (m, 4H),
7.47–7.42 (m, 2H), 7.31–7.26 (m, 1H), 1.72 (s, 3H). 13C NMR (DMSO-d6, 100
MHz,) δ 177.1, 165.8, 148.9, 148.4, 130.2, 130.1, 127.4, 123.4, 120.5, 116.1, 25.8.
HRMS (ESI+) m/z calcd. for C13H14N5 [M + H]+ 240.1249, found 240.1248.
2.3.2.2

Triazene-2
Following the procedure described above for the Triazene-1, diazonium solution

of aniline (0.5 mL, 5.47 mmol) was treated with aniline (0.5 mL, 5.47 mmol) to afford
Triazene-2 (1.1 g, 85%), as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.47–7.39 (m,
8H), 7.20 (tt, J = 6.9, 1.5 Hz, 2H).13C NMR (DMSO-d6, 100 MHz,) δ 150.7, 142.6, 130.1,
127.7, 123.1, 121.6, 114.9. HRMS (ESI+) m/z calcd. for C12H12N3 [M + H]+ 198.1031,
found 198.1031.
NMR spectra for synthesized compounds were recorded with a Bruker AV-400 or
Bruker DRX-400. 1H-NMR chemical shifts are reported as (δ) in ppm and are calibrated
according to residual solvent peaks. 1H NMR coupling constants (J values) are reported
in Hertz (Hz). 13C-NMR chemical shifts are reported as ppm relative to residual solvent
peak. High-resolution mass spectra (HRMS) for synthesized compounds were recorded
with JEOL AccuTOF-CS (ESI positive, needle voltage 1800–2400 eV).
2.3.3

UV titration studies of DNA with the triazene ligands, DMZ and Triazene1
UV measurements for titration studies were done using a JASCO V-630

spectrophotometer. Fluorescence measurements for the displacement assay were done
using a Varian Cary Eclipse fluorimeter. The molar extinction coefficients at 260 nm for
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22-mer c-kit1, 18-mer VEGF, 23-mer bcl-2 2345, 15-mer TBA and 20-mer 8bp AT are as
follows 226 700 M−1 cm−1, 169 800 M−1 cm−1, 227 300 M−1 cm−1, 143 300 M−1 cm−1 and
205 500 M−1 cm−1, respectively. The concentration of ligands used in this study was 10
μM and the DNA concentrations were 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100,
and 150 μM. The buffer contained 250 mM KCl, 50 mM Tris-HCl (at pH 7.5). The
following quadruplex DNA were tested: c-kit1, VEGF, bcl-2 2345, and TBA. Duplex
DNA (8bp AT) was also tested. The sample was first heated up to 95 °C for 5 min
without the ligand and then cooled down to room temperature in 15 min. The ligand was
then added and the mixture was incubated at 4 °C for ∼12 h before recording the data. In
case of Triazene-1 and Triazene-2, the sample mixture contained 1% DMSO.
2.3.4

NMR measurements for DNA binding of triazene ligands
NMR measurements for the binding studies were done using Bruker Avance III

HD 800 spectrometer equipped with Cryo-Probe. The procedures used in the binding
studies were described previously.[46] The ligand concentration was 150 μM, and that of
the DNA (c-kit1 or 8bp AT) was 300 μM. The buffer used was 10 mM potassium
phosphate (pH 7.5) containing 137 mM NaCl, 1 mM EDTA, and also contained 10%
D2O. The sample was initially heated up to 95 °C for 5 min without the ligand and then
cooled down to room temperature in 15 min. Subsequently, the sample was incubated at 4
°C for ∼12 h without the ligand (for G-quadruplex formation). Then, the ligand was
added and incubated for 2 h before the NMR measurement (25 °C). (Note: because of the
high concentrations being used for the NMR, incubating the DNA/ligand for longer
periods caused precipitation, probably due to G-quadruplex polymer formation, which is
catalyzed by the ligand).
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2.3.5

Isothermal titration calorimetry
ITC experiments were performed using a VP-ITC calorimeter (GE-Heathcare). A

typical ITC experiment involved the addition of 28 (10 μL) injections of a nominal 1 mM
ligand solution into ∼1.5 mL of a dilute DNA solution (10 μM). All ITC titration
experiments were done at 25 °C. Corrected titration curves were obtained by subtracting
the blank titration data from the ITC-data for the ligand–DNA titrations. The corrected
ITC titrations were fit to a multiple independent sites binding model using a nonlinear
regression algorithm, CHASM, developed in the laboratory of Edwin A. Lewis.[47]
2.3.6

Circular dichroism (CD)
CD titration experiments were performed with an Olis DSM-20

spectropolarimeter (Bogart, GA). All measurements were done at 25 °C using a 1 cm
quartz cuvette and covering a spectral range of 220–420 nm. All DNA samples were
prepared such that they had a nominal absorbance of less than 1.0 at 260 nm. Stock
solutions of the ligand were added in small amount to reach a molar ratio of 1 : 1, 3 : 1,
6 : 1, and 10 : 1 of ligand per equivalence of DNA.
2.3.7

Electrospray ionization mass spectrometry
ESI-MS experiments on the triazene–DNA complexes were carried out on a

Bruker MicrOTOFQ mass spectrometer. Data acquisition was set to operate in
negative ion mode. All experiments were performed in 50 mM ammonium acetate
buffer containing 20% HPLC grade methanol and adjusted with 1 M KOH solution to
reach pH of 7.0. The WT hTel 22-mer G-quadruplex sample was prepared at a
concentration of approximately 10 μM in the ammonium acetate buffer and was
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exhaustedly dialyzed. Stock solutions of DMZ and Triazene-1 were prepared in the
final dialysate buffer at concentration as high as 300 μM. The ESI-MS samples were
prepared by mixing the DNA and ligand stock solutions to yield a mixture containing
excess of each ligand per equivalence of DNA. The MS capillary voltage was set to
+3500 V, dry N2 gas flow was adjusted to 0.5 L min−1 at 110 °C, and the Gquadruplex/ligand samples were directly infused into the MS by using a kD Scientific
syringe pump set to a flow rate of 200 μL per hour. Data processing was performed by
using the Bruker Daltonics Data Analysis program.
2.4

Results and discussion
Recently, there has been considerable interest in repurposing drugs for new

therapeutic indications.[52,53] Along this line, others have been interested in repurposing
DNA duplex minor groove binders for targeting G-quadruplexes.[54-57] Compounds that
bind minor grooves of DNA duplexes have a track record of clinical efficacy for many
indications including animal trypanosomiasis and babesiosis.[58] Because there are
numerous toxicological data for these drugs, using them as starting points for the
development of G-quadruplex-selective ligands appears to be a reasonable proposition.
Curiously, although several duplex minor groove binders have been tested for Gquadruplex binding, DMZ (Figure 2.1) a prototypical AT-rich minor groove binder,
which is used clinically to treat animal trypanosomiasis has not been thoroughly
investigated for G-quadruplex binding. To date there is only a single report, from our
laboratory, that demonstrated that DMZ aggregates the dinucleotide, c-di-GMP, into an
ill-defined supramolecular aggregate (probably containing G-quadruplexes) via an
uncharacterized mechanism.[59]
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Figure 2.1
2.4.2
2.4.2.1

Structures of DMZ, Triazene-1, and Triazene-2.

DMZ as a G quadruplex ligand
UV spectroscopy studies of DMZ binding to G quadruplexes and duplex
DNA
We initiated our study by testing if DMZ or analogs could compete with a known

G-quadruplex ligand, such as the fluorogenic N-methyl mesoporphyrin IX (NMM), in
binding to c-kit1 (see Figure A.1). Having obtained preliminary results that DMZ could
indeed compete with NMM for c-kit1 binding, we proceeded to perform a series of
experiments to confirm whether the binding of DMZ to DNA G-quadruplexes was real.
This started with studies of the interaction of DMZ with various G-quadruplex DNAs (ckit1, VEGF, bcl-2 2345 and TBA; see Table 2.1 for their sequences) using a conventional
UV-visible absorption titration method employing an AT-rich duplex DNA, 8bp AT, as
positive control. The absorption spectra of DMZ (10 μM) with different concentrations of
G-quadruplex DNA (0–150 μM) are shown in Figure 2.2 and Appendix Figure A.2.
Interestingly, gradually increasing the DNA concentration, resulted in a significant
bathochromic shift (red shift) and a hypochromic effect on the 360 nm DMZ band for all
of the tested G-quadruplexes (Figure 2.2 and Figure A.2). These observed effects in the
UV-absorption spectra provided direct evidence for a strong interaction between DMZ
and the G-quadruplex targets.
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Figure 2.2

UV-titration studies showing binding of DMZ with DNA.

(left) Absorption spectra of DMZ (10 μM) upon titration with c-kit1. The concentrations
of DNA are 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150 μM. In the graph, 10
μM and 150 μM DNA concentrations are specifically emphasized as cyan and red line
respectively. [KCl] = 250 mM, Buffer = 50 mM Tris-HCl (pH 7.5). UV was measured at
20 °C. (right) Plot of absorbance at 360 nm against concentration ratio of DNA and
ligand (DMZ).
2.4.2.2

Importance of amidine moiety in DMZ binding to duplex DNA and Gquadruplexes.
Analysis of the crystal structure of DMZ/duplex DNA[60] complex (Figure 2.3)

revealed that both amidine groups in DMZ make important and extensive contacts with
the minor groove residues. Therefore we reasoned that the modification of one or both of
the amidine groups could give an analog that would be incapable of binding to DNA
minor groove. However it was unclear if the deletion of the amidine group would also
reduce binding to G-quadruplexes.
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Figure 2.3

DMZ interactions with duplex DNA (AT-rich).

The amidine groups of DMZ make important hydrogen-bonding interactions with both
DNA residues and water molecules in the minor groove of DNA (structure is from PDB
File 2DBE).
We synthesized two DMZ analogs (Triazene-1, which has one of the amidine
groups in DMZ deleted and Triazene-2,[61] which does not contain any amidine group,
see Figure 2.3). These DMZ analogs were then evaluated on the basis of their affinity for
binding to both duplex and G-quadruplex DNA. The synthesis of Triazene-1 and
Triazene-2, following precedent,[61] is outlined in Scheme 2.1. First, the diazonium salts
of p-aminobenzamidine and aniline were generated by treating with sodium nitrite
followed by their coupling with aniline to give Triazene-1 and Triazene-2 in good yields.
Both of the synthesized triazenes were characterized by mass and NMR spectroscopy
(see Appendix A for ESI-MS and NMR data).
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Scheme 2.1
2.4.2.3

Synthesis of triazene ligands.
UV spectroscopy studies of Triazene-1 binding to G quadruplexes and
duplex DNA

In qualitative UV-visible titration experiments, the absorbance maxima of
Triazene-1 (10 μM) displayed a red shift with increasing concentrations of various Gquadruplexes (Figure 2.4 and Figure A.3), implying binding, while Triazene-2 exhibited
self-aggregation (data not shown here) and was not considered further. In contrast, when
Triazene-1 was incubated with duplex DNA (Figure A.3), there was no evidence for a
robust interactions between the Triazene-1 and an AT rich duplex DNA. Visual
inspection of the UV titration experiments (compare Figure 2.2, Figure A.2 and Figure
2.4, Figure A.3) revealed that DMZ had a higher affinity to the G-quadruplexes than
Triazene-1, the DMZ analog having only one amidine group. The differences in affinity
(selectivity) between DMZ and Triazene-1 for binding to duplex AT minor groove
sites vs. G-quadruplex stacking or intercalation interactions were quantified using ITC
experiments.
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Figure 2.4

UV-titration studies of binding of Triazine-1 with DNA. (left) Absorption
spectra of Triazene-1 (10 μM) upon titration with c-kit1.

The concentrations of DNA are 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150
μM. In the graph, 10 μM and 150 μM DNA concentration is specifically emphasized as
cyan and red line. [KCl] = 250 mM, Buffer = 50 mM Tris-HCl (pH 7.5). UV was
measured at 20 °C. (right) Plot of absorbance at 360 nm against concentration ratio of
DNA and ligand (Triazene-1).
2.4.2.4

NMR analysis of binding of DMZ and Triazene-1 to DNA
To provide direct evidence for the binding of DMZ and Triazene-1 to c-kit1 (G-

quadruplex) and duplex DNA, we performed 1H-NMR titration experiments. Xu and coworkers used NMR to investigate the binding of a cyanine dye to c-kit1 so we decided to
start with c-kit1, based on this precedent.[18,46] In general, the guanine imino protons
resonate between 10.0 to 12.5 ppm in a quadruplex matrix and this represents guanine
NH⋯O hydrogen bonds in the Hoogsteen alignments of G-quartets. Upon binding of
small molecules, the chemical environment around these imino protons changes, resulting
in changes in their NMR chemical shifts. Figure 2.5A shows a portion of the NMR
spectra of the guanine imino protons of c-kit1 in presence of the ligands, DMZ and
Triazene-1 in 90% H2O/D2O. The chemical shifts for the guanine imino protons in the
spectrum of c-kit1 alone (Figure 2.5A), ([ligand] : [c-kit1] = 0 : 1) was assigned based on
the earlier work.[46] The NMR titration spectra of DMZ and Triazene-1 with c-kit1 show
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significant decreases in the peak intensities and line-broadening in the imino proton
spectra (Figure 2.5A). These results demonstrate direct binding of DMZ and Triazene-1
to c-kit1 (NMR resonances between 11.1 and 11.4 ppm are different between the case
with no ligand added and when DMZ or triazene are added), consistent with our UVvisible titration experiments (Figure 2.2, Figure A.2 and Figure 2.4, Figure A.3). When
DMZ or Triazene-1 was added to c-kit1, the chemical shifts associated with the imino
protons of G6, G10 and G2 did not change, probably excluding end-stacking with the 5′terminal tetrad of the quadruplex. Other NMR titration experiments with other Gquadruplexes, such as VEGF and bcl-2 2345 did not give stable baselines (data not
shown), probably due to aggregation of the ligand–DNA complex. Despite this technical
difficulty, the c-kit1 NMR titration data provide good evidence that DMZ does indeed
bind to G-quadruplex DNA.
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Figure 2.5

H-NMR spectra of DNA incubated with ligands.

1

[DMZ] or [Triazene-1] = 150 μM, [DNA] = 300 μM (ratio ligand : DNA = 0.5 : 1), D2O
= 10%, Buffer = 10 mM K-phosphate buffer (pH 7.5), [NaCl] = 137 mM, [EDTA] = 1
mM. The ligand was incubated with DNA for 2 h at 4 °C before measurement. (A) DNA
= c-kit1. (B) DNA = 8bp AT.
2.4.2.5

DMZ–Triazene-1–hTel22 complexes identified via mass spectroscopy
We have previously reported on the thermodynamic properties for the binding of

several porphyrins and porphyrin derivatives to a variety of oncogene promoter sequence
G-quadruplexes.[62,63] We have repeatedly shown that the cationic porphyrin TMPyP4
binds to a number of G-quadruplexes and forms complexes having a saturation
stoichiometry of (n + 1) where n is the number of G-tetrads in the G-quadruplex motif. In
the case of the c-MYC, bcl-2, and kras promoter sequence G-quadruplexes the saturation
stoichiometry was determined to be 4 moles of TMPyP4 per mole of G440

DNA.[62,63] The DMZ (or Triazene-1) ligands are approximately half the size of
TMPyP4 and we would speculate that two molecules of DMZ (or Triazene-1) could pistack with one G-tetrad (see Figure 2.6). The ESI mass spectra for a solution
containing hTel22 DNA in an excess amount of DMZ (panel A) and/or an excess amount
of Triazene-1 (panel B) indicate that up to 8 molecules of these ligands can bind to one
G-quadruplex. Three important features can be observed from panel A: first, there are no
observable m/z peaks for free DNA; second, there are multiple m/z peaks indicating
stoichiometry values larger than 4 : 1; and third, DMZ·hTel22 complexes are observed
with stoichiometries up to 8 : 1 as evidenced from the m/z peaks at 1843.3 and 2314.0.
Similarly, the ESI mass spectrum shown in Figure 2.7 panel B for a solution
containing hTel22 in an excess amount of Triazene-1 also suggests a maximum
stoichiometry of 8 : 1. However, there are notable differences between the data shown in
panels A and B. The mass spectrum shown in panel B clearly exhibits the presence of
some free or uncomplexed DNA as evidenced by m/z peaks at 1751.5 and 2328. The
presence of free DNA even in excess amounts of Triazene-1 ligand suggests a low
binding affinity for the interaction of Triazene-1 with the hTel22 G-quadruplex DNA.

Figure 2.6

Chemical structures of Diminazene aceturate (DMZ) and Triazene-1 in
comparison to a chemical representation of a G-quartet.
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Figure 2.7

ESI mass spectrum for hTel22 solution containing excess amount of DMZ
(panel A) and ESI mass spectrum for hTel22 solution containing excess
amount of Triazene-1 (panel B).

Y-axis is relative intensity and x-axis is m/z.
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2.4.2.6

Determination of DMZ and Triazene-1 binding constants to DNA using
ITC
Typical raw ITC data for the titration of DMZ into five different DNA samples,

7bp HP·AT, 7 bp HP, 27mer bcl-2, 24mer c-MYC, and 22mer hTel, are shown in Figure
A.4. The thermodynamic parameters for the interaction of DMZ with these DNAs were
obtained directly from the nonlinear regression fits of the raw ITC data to a one site,
fractional one site, or three competitive sites thermodynamic binding model, depending
on the number of species indicated in the thermograms. As shown in Figure A.4, the
binding of DMZ to 7bp HP·AT exhibits two different but independent overlapping
binding modes and is reminiscent of the binding of netropsin (another AT minor groove
binder).[64-67] The interaction of DMZ with the 7bp HP sequence, lacking the A2T2 site,
exhibits weaker complex formation (and only one binding mode). The interactions
between DMZ and 27mer bcl-2 or 24mer c-MYC are best described by at least three
different binding processes. Typical nonlinear regression fits for the analysis of the
binding of DMZ to 7bp HP, 7bp HP-AT and bcl-2, and c-MYC are shown in Figure 2.8.
The solid lines in Figure 2.8 represent the model lines using the best fit thermodynamic
parameters for these ligand DNA interactions.
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Figure 2.8

DMZ titrations of 7bp HP, and 7bp HP·AT

Typical nonlinear regression fits for the DMZ titrations of 7bp HP, and 7bp HP·AT are
shown in panel A. The 7bp HP titration data are fit to a one site model and the
7bp HP·AT data are fit to a fractional two site model. Typical nonlinear regression fits for
the DMZ titrations of 27mer bcl-2 and 24mer c-MYC are shown in panel B. Both the
27mer bcl-2 and the 24mer c-MYC DMZ titration data are fit to a three site model. The
best fit parameters for the data shown in panels A and B are listed in Table 2.2.
The thermodynamic parameters obtained from the ITC experiments (Figure A.4,
ESI and fits Figure 2.8) reveal that DMZ binds to some G-quadruplex DNAs (for
example bcl-2 and c-MYC) with dissociation constants as low as ∼1 nM. This is of a
similar affinity to that exhibited by guanidine phthalocyanines, considered to be one of
the tightest binders of G-quadruplexes with Kd of ∼2 nM.[17] Also the ligand TMPyP4, a
classic G-tetrad binding ligand, binds to G-quadruplexes with Kd ≈ 2 × 10−7 M,[62,68] so
the fact that DMZ binds to G-quadruplexes with 1 nM dissociation constant is interesting.
Of note is the observation that even the second dissociation constant, Kd2 ≈ 5 × 10−8 M,
for the DMZ·c-MYC complex is an order of magnitude smaller than the dissociation
constant (Kd ≈ 1 × 10−6 M) obtained for the DMZ·7bp HP-AT complex. Our Kd value for
the DMZ·7bp HP-AT complex is very similar to the dissociation constant (Kd ≈ 1 ×
10−6 M) determined in NMR experiments previously reported by Jenkins et al. for DMZ
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interactions with several types of B-DNAs containing the AT rich
sequences.[69] Interestingly, Jenkins et al. also mentioned the two overlapping events
exhibited by the interactions of DMZ with AT rich sequences.[69] The phenomenon of
two overlapping sites observed for the AT rich sequence has been well documented and
several possible mechanisms have been suggested, including: (1) two binding
orientations of the minor groove binder in the DNA minor groove or (2) the formation of
a complex in which one or more water molecules are trapped between the ligand binding
in the minor groove and the floor of the DNA groove.[64-66]
The ITC heat data for the titrations of Triazene-1 to four different DNA sequences
(a DNA hairpin and three G-quadruplex DNAs) are shown in Figure A.5. Again, from
visual inspection, it seems that the titration of Triazene-1 into Na+hTel22 is
calorimetrically silent while the addition of Triazene-1 to K+hTel22 results in a
significant exothermic signal. Notable differences between the DMZ and the Triazene-1
DNA titration experiments are that DMZ exhibits a much tighter binding affinity than
Triazene-1, at least for the preferred G-quadruplexes, and Triazene-1 exhibits only a
single binding event for its interactions with the bcl-2, and c-MYC G-quadruplexes. In
addition, the binding affinity for Triazene-1 interacting with K+hTel22 is similar to the
binding affinities for Triazene-1 interacting with either the bcl-2 or c-MYC Gquadruplexes. This result is in sharp contrast to DMZ which exhibits selectivity for
the bcl-2 or c-MYC G-quadruplexes over K+hTel22. Triazene-1 binds to all of the tested
G-quadruplexes with significantly lower affinity (4–5 orders of magnitude lower,
compare Tables 2 and 3) than does DMZ. The binding affinity for of Triazene-1 with
7bp HP-AT is also reduced by a factor of approximately 30. Furthermore, the second
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binding event observed in the DMZ binding to 7bp HP-AT is now eliminated in of the
case of Triazene-1 interacting with the duplex DNA, 7bp HP-AT. Clearly, the removal of
one amidine group from the parent DMZ compound to create the Triazene-1 ligand
results in the loss of A2T2 recognition in the minor groove of the DNA. This was
expected as the presence of two amidine groups is a common feature of several minor
groove binders such as distamycin,[70] netropsin,[64,66,70] DAPI[71] and
pentamidine.[72] However, it remains to be answered why the loss of A2T2 recognition in
the minor groove as exhibited by Triazene-1 also results in much lower binding affinities
for the interactions of Triazene-1 with different G-quadruplexes.
Table 2.2

Thermodynamic data obtained from ITC experiments for the formation of
the DMZ complexes with several different DNAs

Sequences

K 1 (M−1) ΔH1 (kcal mol−1) K 2 (M−1) ΔH2 (kcal mol−1) K 3 (M−1) ΔH3 (kcal mol−1)

7bp HP·AT
7bp HP
27mer bcl-2
24mer c-MYC
22mer hTel Na+
22mer hTel K+

9.8 × 105
—
8.8 × 108
7.6 × 108
Nd
—

−2.2
—
−4.5
−5.5
Nd
—

4.5 × 104
1.8 × 104
1.9 × 106
1.9 × 107
Nd
—

−8.7
−5.3
−2.2
−2.5
Nd
—

—
—
6.4 × 104
2.8 × 105
Nd
5.5 × 104

—
—
−7.3
−4.7
Nd
−3.8

Nd = not determined. Note: K1, K2 and K3 are association constants. Dissociation
constants, Kd = 1/(K1 or K2 or K3).
Table 2.3
Sequences
7bp HP-AT
7bp HP
27mer bcl-2
24mer c-MYC
22mer hTel Na+
22mer hTel K+

Thermodynamic data obtained from ITC experiments for the formation of
the Triazene-1 complexes with several different DNAs
K 1 (M−1) ΔH1 (kcal mol−1)
2.9 × 104
Nd
3.5 × 103
3.6 × 104
Nd
2.1 × 103

−1.9
Nd
−1.8
−1.1
Nd
−2.7
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2.4.2.7

DMZ binding to G quadruplexes studied by circular dichroism (CD)
To determine the structural effects of the interactions between the DMZ and G-

quadruplex DNAs, we performed a series of CD titration experiments in which DMZ was
added to different G-quadruplexes. Figure 2.9 and 2.10 show the CD spectra for the
titration of DMZ into three different G-quadruplexes, bcl-2, c-MYC, and hTel22. These
CD titrations were performed in K+ Tris buffer. Under these experimental buffer
conditions (K+ salt), the CD spectra for the free WT bcl-2, WT c-MYC, and hTel22Gquadruplexes exhibited characteristic CD spectral features that are similar to those
previously reported in the literature.[49-51,62] However, upon complexation with DMZ,
the CD signals for both 27mer WT bcl-2 and 24mer WT c-MYC dramatically attenuated
as DMZ is added. A plausible explanation for this is that the inherent G-tetrad π–π
stacking interactions in both the 27mer WT bcl-2 and 24mer WT c-MYC G-quadruplexes
is weakened upon DMZ binding. In comparison to TMyP4, DMZ does not have the
extended π-surfaces, which can interact extensively with the π system of the G-tetrad in
either an end-stacking or intercalation mode. Perhaps the explanation for the surprisingly
tight binding to specific G-quadruplexes is that DMZ is binding in the G-quadruplex
groove or interacting in some way with loop bases. In the case of DMZ binding to
K+hTel22, the addition of the DMZ appears to have very little effect on the parallel
structure of hTel22 G-quadruplex, see Figure 2.10. In the case of binding DMZ to duplex
DNA, an induced DMZ CD signal is observed (see Figure A.6). However, there was no
evidence for an induced ligand CD signal when DMZ was bound to the different Gquadruplexes. This lack of an induced CD is suggestive of end stacking or intercalative
binding but not groove binding.[73] A more detailed structural study of the DMZ G47

quadruplex complexes could clarify these observations and help in the development of
even more potent DMZ-based G-quadruplex binders.

Figure 2.9

CD spectra obtained from titration experiments for the additions of DMZ
into a 27mer WT bcl-2 (4.5 μM, panel A) and into 24mer WT c-MYC (3.9
μM, panel B).
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Figure 2.10
2.5

CD spectra obtained from titration experiment for the additions of DMZ
into a hTel22 (5.1 μM).

Conclusion
The finding that DMZ binds tightly to G-quadruplexes DNA is exciting for the

following reasons: (a) DMZ does not readily form π-aggregates[74] and hence it is not as
prone to non-specific binding to other biomolecules as other aromatic-containing Gquadruplex ligands; (b) the amidine groups on DMZ, improve aqueous solubility (an
important factor for drugs); (c) unlike other structurally complex minor groove binders
such as netropsin, DMZ has a simple structure and could be readily diversified and
synthesized cheaply on a large scale and (d) the amidine group, which is protonated at
physiological pH, would facilitate drug permeation across lipid membranes that are
externally decorated with anionic phosphates.
This work suggests that some of the toxicity or even the clinical benefits of DMZ
may be due to its binding to G-quadruplexes, which has so far been overlooked. It is
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ironic that a ligand such as DMZ, which has long been considered as AT-rich specific
minor groove binder does in fact strongly bind to G-quadruplexes. Future work will
concentrate on making structural variants of DMZ that will include expanded aromatic
systems and increased amidine groups for specific and potent G-quadruplex targeting.
New classes of G-quadruplex ligands, which have low affinity for duplex DNA, are
predicted to have potential applications in cancer therapy.[75–77]
2.6
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CHAPTER III
ALKYNE-SUBSTITUTED DIMINAZENE AS G-QUADRUPLEX
BINDERS WITH ANTICANCER ACTIVITIES
Reproduced from Changhao Wang, Brandon Carter-Cooper, Yixuan Du, Jie Zhou,
Musabbir A. Saeed, Jinbing Liu, Min Guo, Benjamin Roembke, Clinton Mikek, Edwin
A. Lewis, Rena G. Lapidus and Herman O. Sintim. “Alkyne-substituted diminazene as
G-quadruplex binders with anticancer activities.” European Journal of Medicinal
Chemistry 2016, 118, 266-275. Copyright © 2016 Elsevier Masson SAS. All rights
reserved.
3.1

Abstract
G-quadruplex ligands have been touted as potential anticancer agents, however,

none of the reported G-quadruplex-interactive small molecules have gone past phase II
clinical trials. Recently it was revealed that diminazene (berenil, DMZ) actually binds to
G-quadruplexes 1000 times better than DNA duplexes, with dissociation constants
approaching 1 nM. DMZ however does not have strong anticancer activities. In this
paper, using a panel of biophysical tools, including NMR, FRET melting assay and FRET
competition assay, we discovered that monoamidine analogues of DMZ bearing alkyne
substitutes selectively bind to G-quadruplexes. The lead DMZ analogues were shown to
be able to target c-MYC G-quadruplex both in vitro and in vivo. Alkyne DMZ analogues
display respectable anticancer activities (single digit micromolar GI50) against ovarian
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(OVCAR-3), prostate (PC-3) and triple negative breast (MDA-MB-231) cancer cell lines
and represent interesting new leads to develop anticancer agents.
3.2

Introduction
Cancers of the human reproductive organs, such as ovarian, prostate and breast,

kill millions of people annually worldwide. Although there are several therapeutics
against these cancers [1-2], aggressive forms remain problematic to treat. For example,
although there are myriad hormone-based therapeutics against breast cancer [3], hormone
insensitive breast cancer such as triple negative breast cancer remains difficult to
treat [4].
G-quadruplex structures in both DNA and RNA are emerging as important
regulatory elements that control diverse processes in the cell, ranging from telomere
maintenance [5], gene expression [6], translation [7], alternative splicing [8], RNA
metabolism [9] and protein sequestration [10]. Additionally G-quadruplex elements (both
DNA and RNA) in the cell have been postulated to bind to and activate heme to promote
oxidative damage [11]. Such enzymatic function of G-quadruplexes [12-14] could
exacerbate neurodegenerative diseases [11]. Due to the expanding role of G-quadruplexes
in biology [15], there has been an explosion of research activities dedicated to the
discovery of G-quadruplex ligands [16-19]. Small molecules that stabilize the Gquadruplex structure have been shown to inhibit telomere extension [20] and
transcription of oncogenic genes (such as c-MYC, [21]c-kit, [22]KRAS) and hence these
molecules have the potential to be used as antineoplastics [5, 23-24]. Beyond potential
use as anticancer agents, G-quadruplex ligands have also been shown to inhibit HIV
replication [25].
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We have been interested in repurposing drugs that are used in both human and
veterinary medicine for other indications for anticancer therapy because we believe that
the translational potential for such drugs or analogues thereof is high, since the molecules
are already in clinical use. Along this line, we recently reported that diminazene (DMZ in
Figure 3.1), a drug used to treat sleeping sickness (animal trypanosomiasis), and which
was formerly considered as selective AT-rich duplex binder (via minor groove) is indeed
a potent G-quadruplex binder with nanomolar dissociation constant (Kd) [2627]. DMZ binds to DNA minor groove with a Kd of 1 μM so it appears that DMZ is more
selective for G-quadruplex than duplex DNA [26]. Nonetheless a Kd of 1 μM for duplex
DNA would limit the targeting of G-quadruplexes by DMZ in the complex cellular
environment, where the concentration of duplex DNA is several orders of magnitude
greater than G-quadruplexes. We had earlier observed that the monoamidine analogue
of DMZ (DMZ1 in Figure 3.1) could also bind to G-quadruplexes, albeit not as potent
as DMZ [26]. Importantly DMZ1 only had a weak affinity for duplex DNA (Kd = 34 μM
for AT-rich duplex DNA) [26], suggesting that perhaps DMZ1 was a better starting point
for developing G-quadruplex interactive anti-cancer agents. A focused library
of DMZ1analogues (Figure 3.1), whereby a π-moiety was appended to the parent DMZ1,
were easily prepared via Sonogashira coupling and then triazene formation. Herein, we
reveal that DMZ and monoamidine analogue, DMZ1, do not have anticancer properties
but alkyne analogues of DMZ have respectable to good anticancer properties against
ovarian, prostate and triple negative breast cancers.
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Figure 3.1
3.3
3.3.1

The structures of diminazene (DMZ) analogues.

Results and discussion
Design and synthesis of alkyne-substituted DMZ analogues as Gquadruplex binders
To aid future optimizations of the alkyne DMZ analogues as anticancer agents,

we sought to verify that like the parent DMZ, these compounds also bind to Gquadruplexes. Also, we asked if the compounds were selective for G-quadruplexes over
DNA duplexes. Since DMZ requires both amidine groups to bind to duplex DNA,
removing one amidine group will reduce duplex DNA binding affinity. However, the Gquadruplex surface has more room to accommodate on extended pi-surface. We therefore
extended the parent DMZ with additional aromatic surface while maintaining one
amidine for solubility concerns. Sonogashira coupling strategy allowed us to generate
alkyne-substituted DMZ analogues in a timely and economic manner. The details of the
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synthetic pathway are illustrated in the experimental section. We also explored the effects
of substitutions on the aromatic rings by incorporating fragments such as pyridine,
fluorine and methoxy groups. These groups are commonly found in drugs. Pyridine is a
mimic of phenyl group, but has an enhanced aqueous solubility arising from the nitrogen
in the pyridine forming hydrogen bonds with water. Additionally the nitrogen in the
pyridine ring could interact with the DNA nucleobases via hydrogen bonding. Fluorine
and the methoxy groups could also accept hydrogen bonds from water and/or the DNA
target. A second criteria that we used for selecting the analogs was synthetic tractability
and the commercial availability of starting materials.
Initial attempts to characterize the binding of the analogues using isothermal
titration calorimetry (ITC) was not very successful due to the low solubility of the
compounds in buffer (see Appendix A, Table A.2, Figs. A.1 and A.2). Poor solubility,
even in 5% DMSO, resulted in very small injection heats that were not suitable for
nonlinear regression fitting. CD titration (data not shown) of DMSO into dilute G4-DNA
samples demonstrated that the G-quadruplex structure remained folded in the presence of
30% DMSO (see Chapter V Figure 5.8 for an example c-MYC G-quadruplex CD Spectra
collected in buffer containing 30% DMSO). The 30% DMSO buffer improved solubility
of the ligands and resulted in sufficiently high concentrations to generate injection heats
suitable for nonlinear regression fitting to obtain thermodynamic data. Of the compounds
that were able to be fit, most exhibited a Gibbs free energy of approximately -7 kcal mol-1
which is slightly weaker than the lowers affinity binding mode of DMZ (mode 3 ΔG = 7.4 kcal mol-1). The thermodynamic signatures of DMZ5 and DMZ11 are reminiscent of
DMZ mode 3 binding values. DMZ13 exhibited an enthalpic contribution of -7 kcal mol59

1

, which is nearly double the enthalpic contribution of DMZ mode 3 binding. The raw

injection heats shown in Figure 3.2 do not definitively support this fit, as the injection
heats appear similar to DMZ5 and DMZ11. DMZ8, on the other hand, clearly shows a
much larger enthalpic contribution to binding, with a change in enthalpy of -20 kcal mol-1
upon binding to the c-MYC G-quadruplex. This binding is compensated by a large
entropic penalty (-TΔS) of 13 kcal mol-1 to yield a Gibbs free energy of -7.34 kcal mol-1,
approximately the same affinity as DMZ mode 3.
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ITC experiments of c-MYC G-quadruplex complexation reactions with
DMZ analogues (DMZ5, DMZ13, DMZ11, and DMZ8). Buffer contains
30% DMSO to alleviate ligand solubility issues.
60

Table 3.1

Thermodynamic parameters for the binding of DMZ analogs to the c-MYC
WT promoter sequence G-quadruplex.

Compound
1

DMZ (Mode 3)
DMZ5
DMZ11
DMZ13
DMZ8
DMZ9
DMZ1

ΔG
(kcal/mol)
-7.4

ΔH
(kcal/mol)
-3.8

-TΔS
(kcal/mol)
-3.6

-7.3 ± 0.1
-7.05 ± 0.1
-6.8 ± 0.1
-7.34 ± 0.06
ND
-6.2

-3 ± 1
-4.20 ± 0.01
-7 ± 1
-20. ± 2
ND
-1.1

-4
-2.85
-0
13
ND
-5.1

Others have used FRET melting of fluorophore-labeled G-quadruplexes to
determine the binding of ligands to G-quadruplexes and also selectivity between Gquadruplexes and duplexes, so we decided to adopt this protocol [28-29]. Thus, we
investigated the change in melting temperature (T1/2) by fluorescence resonance energy
transfer (FRET) assay (Figure 3.3 and Figure 3.4). We chose dual-labeled F21T, c-MYC,
c-kit2 and k-RAS21R because c-MYC G-quadruplex affects the c-MYC transcriptional
activity [30] while c-kit and k-RAS G-quadruplexes control the expression of
oncogenic c-kit [22] and KRAS [6] proteins and F21T is a good model for telomere [6].
26-mer DNA (hairpin) is a good model to determine if the ligands could also bind to
duplexes [31]. The FRET-labeled oligonucleotides used in this study have also been used
by others and shown to be well-behaved in determining the potency of G-quadruplex
ligands [28-29].
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Figure 3.3

FRET model of study.

Figure 3.4

FRET stabilization temperature (△T1/2) of various G-quadruplex DNA
with DMZ analogues and TMPyP4.

a

G-quadruplex DNA: F21T (5′–FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA–
3′), c-kit2 (5′–FAM-CCC GGG CGG GCG CGA GGG AGG GGA GG-TAMRA–3′), kRAS21R (5′–FAM-AGG GCG GTG TGG GAA GAG GGA-TAMRA–3′), c-MYC (5′FAM-TGA GGG TGG GTA GGG TGG GTA A-TAMRA-3′). Duplex 26-mer (5′–FAMTAT AGC TAT ATT TTT TTA TAG CTA TA-TAMRA–3′). Conditions: dual-labeled
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DNA (0.4 μM), DMZ analogues (4 μM), potassium cacodylate buffer (60 mM, pH 7.2).
ΔT1/2 is calculated by melting temperature in the presence and absence
of DMZ analogues. bFor TMPyP4, 0.4 μM dual-labeled DNA and TMPyP4 were applied
to get meaningful melting temperatures. *△T1/2 is larger than 5 °C.
TMPyP4, a prototypical G-quadruplex ligand was the most stabilizing ligand
(note that a lower concentration of TMPyP4 was used in the FRET melting assay,
compared to the amidine ligands). Of the tested triazenes, DMZ, which has two amidine
groups, was the best stabilizer of the tested G-quadruplexes but showed low selectivity
between G-quadruplexes and duplex DNA. For example, DMZ could stabilize kRAS21R but could also stabilize double-stranded DNA, see Figure 3.4. Removing one of
the amidine groups from DMZ to afford compound DMZ1 reduced affinity for duplex
DNA (△T1/2 < 1 °C for double-stranded DNA). Contrary to our initial hypothesis that
adding a π-moiety to DMZ1would increase G-quadruplex binding, the addition of an
alkyne, cyano or phenyl groups to compound DMZ1 did not afford an analogue with a
more superior G-quadruplex stabilization property than DMZ1 (see Figure 3.4 and Table
B1 in Appendix B). Encouraging, however, was the observation that DMZ1 and alkyne
analogues (but not the control compound TMPyP4 or DMZ) were more selective for Gquadruplex over duplex DNA (see Figure 3.5 and Table B1). We determined the melting
temperature of fluorescently-labeled c-MYC in the presence of fixed ligand concentration
and increasing concentrations of non-fluorescent double-stranded DNA. When
compound DMZ1 or alkyne derivatives were used as ligands, adding up to 500
equivalences of double-stranded DNA did not affect the T1/2 of c-MYC, in agreement
with the FRET melting data (Figure 3.4), which showed that the compounds stabilized G-
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quadruplexes but not duplex DNA. For DMZ or TMPyP4 however, increasing the
amount of duplex DNA resulted in a lower ΔT1/2 (see Figure 3.5)

Figure 3.5

FRET-melting competition results at 4 μM DMZ analogues in the presence
of dual-labeled c-MYC (0.4 μM) and competitor unlabeled ds-DNA (0 μM,
4 μM, 40 μM and 200 μM).

ΔT1/2 is calculated by melting temperature in the presence and absence
of DMZ analogues. 0.4 μM TMPyP4 was added to get meaningful melting temperature.
3.3.2

Viability assay
The alkyne DMZ analogues only have moderate affinity for G-quadruplexes and

so the key question was whether they could inhibit the proliferation of cancer cells, and if
that happens to be the case whether the proliferation inhibition would be via Gquadruplex stabilization inside cells. We evaluated the compounds against three human
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cancer cell lines, ovarian cancer cell (OVCAR-3), prostate cancer cell (PC-3) and triple
negative breast cancer cell (MDA-MB-231), using WST-1 assay. A select few
compounds were also tested against two human normal cell lines, normal bone marrow
(NBM) and normal fibroblast cell (MCR5A) for cytotoxicity. Amongst the first set
of DMZ analogues (compounds DMZ1 to 6, and DMZ11), bearing different substituents
(cyano, amidine, alkyne and aryl groups), only the alkyne derivatives
(DMZ3, DMZ5 and DMZ11) were active (see Table 3.1, entries iv, vi and xii), albeit not
very potent. Interestingly DMZ, which potently binds to G-quadruplexes, and the
monoamidine analogue DMZ1 were also not effective at inhibiting cancer proliferation.
Encouraged by the initial positive results with the alkynes analogues we sought to
optimize the anticancer potency and made further alkyne analogues by appending various
aromatic moieties to the alkyne to give compounds DMZ7 to 10 and DMZ12 to 14
(see Figure 3.1). We initially rationalized that by adding aromatic appendages to the
initial alkyne compounds, stacking interactions between the G-quadruplex tetrad and the
compounds would increase.
This hypothesis did not pan out as the new alkyne analogues (DMZ7 to 10
and DMZ12 to 14) did not display enhanced G-quadruplex stabilization (see Figure 3.5)
but the analogues had improved anticancer properties (see Table 3.1). Of note, the
GI50 values of some of the DMZ analogues (DMZ7, DMZ9, DMZ10, DMZ12 and
DMZ13) are similar to or better than those of cisplatin against the three tested cancer cell
lines (compare entries viii, x, xi, xiii, xiv with xvi in Table 3.1). Also the GI50 values of
some of these analogues were better than TMPyP4, a potent G-quadruplex binder,
underscoring the fact that G-quadruplex binding potency alone does not define the
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potency of these drugs. Cisplatin is an anticancer drug that is still used in the clinic to
treat various cancers so the GI50 values that we have obtained for some of the alkyne
DMZ derivatives are encouraging and calls for further development of alkyne
DMZ analogues as anticancer agents.
Anticancer activity of DMZ analogues with different cancer cell lines.
Entry

i
ii
iii
iv
v
vi
vii
viii
ix
x
xi
xii
xiii
xiv
xv
Xvic
xvii
xviii
xix

Compound

Anticancer activities for different cancer cell lines(GI50 ± SD, μM)a

DMZ
DMZ1
DMZ2
DMZ3
DMZ4
DMZ5
DMZ6
DMZ7
DMZ8
DMZ9
DMZ10
DMZ11
DMZ12
DMZ13
DMZ14
Cisplatin
15
19
TMPyP4

OVCAR-3
>25
NE
NE
11.8 ± 1.7
NE
16.8 ± 3.1
NE
6.5 ± 2.1
10.7 ± 1.5
5.0 ± 0.1
5.2 ± 0.4
>25
8.1 ± 0.5
9.5 ± 2.2
NE
4.1 ± 1.8
NE
NE
14.6 ± 5.7

PC-3
NEb
NE
NE
22.5 ± 8.8
NE
18.0 ± 5.7
NE
5.8 ± 0.2
10.4 ± 1.4
5.3 ± 1.6
5.0 ± 0.9
>50
5.3 ± 0.2
7.4 ± 0.2
NE
10.5 ± 1.3
NE
NE
14.0 ± 5.4

MDA-MB-231
NE
NE
NE
30.2 ± 1.8
NE
20.5 ± 4.2
NE
9.5 ± 1.3
14.4 ± 0.9
5.5 ± 0.1
5.5
23.2
5.1 ± 0.4
6.2 ± 1.0
NE
11.7 ± 1.0
NE
NE
14.3 ± 4.0

NBM
–d
–
–
–
–
–
–
–
–
5.6
–
–
–
NE
–
>10
–
–
16.8

MCR5A
–
–
–
–
–
–
–
–
–
8.3 ± 4.0
–
–
–
NE
–
0.41 ± 0.27
–
–
15.2 ± 6.6

a) Human cancer cell lines: ovarian cancer cell (OVCAR-3), prostate cancer cell (PC-3)
and breast cancer cell (MDA-MB-231). b) NE means not effective. Cell viability was the
same or greater than 75% of the DMSO control at 20 μM compound concentration so
accurate GI50 values for these compounds were not determined. c) Cisplatin as a control
compound. d) Not determined.
To gain some insights into potential toxicities of these DMZ analogues, we
proceeded to evaluate analogues DMZ9, DMZ13 TMPyP4 and cisplatin (a control)
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against two human normal cell lines (NBM and MCR5A) (see entries x, xiv and xix
in Table 3.1). For analogues DMZ9 and TMPyP4, the GI50 values against NBM and
MCR5A cells are similar to the three tested cancer cells (hence these compounds might
have low therapeutic window). However, and pleasingly, analogue DMZ13 killed the
three tested cancer cells with single digit GI50 but was not effective against NBM and
MCR5A cells. Cisplatin is used to treat several cancers yet it has a higher toxicity against
MCR5A than DMZ9 and DMZ13 (Table 3.1). To rule out the possibility that the antiproliferative properties of the alkyne DMZ analogues are not derived from their amine
metabolism products, we also tested the anticancer properties of 4-aminobenzamidine
and amino alkyne 15 but none of these were active.
Having demonstrated that G-quadruplex-interactive DMZ analogues, bearing
alkyne moieties, have anticancer properties and with an eye towards the future
development of these molecules, we sought further experiments to cement our belief that
these molecules do indeed bind to G-quadruplexes and do so selectively. The
aforementioned experiments (FRET melting) that investigated the interactions of alkyne
analogues of DMZ with G-quadruplexes are indirect. NMR has been demonstrated to be
a direct tool to study the interaction between DNA and ligands [32-34]. We have used
NMR to show that both DMZ9 and DMZ13 interacted with c-kit1, c-MYC G-quadruplex
but not duplex (see Figures B3, B4, and B5). Since c-MYC is a key oncogene we
performed additional experiments, PCR stop assay [8] (in vitro) and Western analysis of
c-MYC expression [35] (in vivo) in the presence and absence of some of our DMZ
analogues (DMZ, DMZ1, DMZ9, DMZ13 and TMPyP4, as control) to determine if the
pharmacology of the analogues is at least derived from c-MYC inhibition.
67

3.3.3

PCR stop assay
A PCR stop assay, using templates that contain G-quadruplex sequences, has been

used by several investigators to demonstrate the binding of ligands to G-quadruplex [3638]. We investigated the effects of analogues DMZ9, DMZ13, DMZ, DMZ1 and
TMPyP4 on c-MYC G-quadruplex stabilization via the PCR stop assay. Pu27, Pu2713,14 and Pu-mutant were used as templates [39]. Pu27 is contained in the nuclear
hypersensitivity element III1 (NHE III1), which controls 80–90% transcription level of cMYC [40]. Pu27-13,14 [39] and Pu-mutant (see SI) are two mutated Pu27 strands used as
control.
In the PCR reaction system, 5 μM of Pu27, 5 μM of Pu27rev and various
concentrations of DMZ1, DMZ9, DMZ13 (1 μM, 10 μM, 25 μM, 50 μM and
100 μM), DMZ (1 μM, 10 μM and 25 μM) and TMPyP4 (1 μM and 10 μM) were added.
The polymerization/extension of oligomers Pu27 and Pu27rev was completely inhibited
in the presence of 100 μM DMZ9 and DMZ13 (see Figure 3.6). Also, DMZ and TMPyP4
showed inhibition at 25 μM and 10 μM, respectively. To eliminate the possibility that the
inhibition of DNA extension was caused by the direct inhibition of the polymerase
enzyme by the ligands, Pu27-13,14 (see Figure 3.6) and Pu-mutant were extended in the
presence of various concentrations of DMZ9, DMZ13, DMZ and TMPyP4. In both
controls, amplified PCR product was observed in the presence of 100 μM DMZ9,
DMZ13 (see Figure 3.7). However, no PCR product or reduced product was observed in
the presence of 10 μM TMPyP4 for Pu27-13,14 and Pu-mutant, respectively. On the
other hand, the amount of PCR products obtained in the presence of 25 μM DMZ was
lower than in the absence of DMZ for Pu27-13,14(see Figure 3.7). No changes were
68

observed in Pu-mutant reaction (see Figure 3.8). These results were unexpected because
both DMZ and TMPyP4 had been shown to bind to both G-quadruplexes and duplex
DNA (See Figure 3.5) so both compounds would inhibit the extension of Pu27
(containing a G-quadruplex) and Pu27-13,14 (containing duplex). Based on these results,
we conclude that the DMZ analogues inhibit the extension of a template containing cMYC sequences via the stabilization of a G-quadruplex structure in the template and not
via direct polymerase inhibition, as observed with the TMPyP4 case[41].
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Figure 3.6

Effects of DMZ analogues (DMZ1, DMZ 9, DMZ13), DMZ and TMPyP4
on the PCR stop assay with c-MYC Pu27.

Compounds were added to the reaction mixture containing 1x PCR buffer (New England
Biolabs), 5 μM Pu27, 5 μM Pu27rev, 200 μM dNTPs and 5 units of Taq polymerase
(New England Biolabs) separately. No compound added was treated as control.
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Figure 3.7

Effects of DMZ analogues (DMZ1, DMZ 9, DMZ13), DMZ and TMPyP4
on the PCR stop assay with mutated c-MYC template Pu27-13,14.

Compounds were added to the reaction mixture containing 1x PCR buffer (New England
Biolabs), 5 μM Pu27–13.14, 5 μM Pu27rev, 200 μM dNTPs and 5 units
of Taqpolymerase (New England Biolabs) separately. No compound added was treated as
control.
The aforementioned experiments were performed to determine if alkynesubstituted analogues of DMZ, some of which have anti-cancer properties interacted with
G-quadruplex DNAs selectively (i.e. did not have affinity for duplex DNA). Although
our in vitro studies revealed that these compounds are moderate G-quadruplex binders, it
remained to be shown if the pharmacology of these compounds were via G-quadruplex
stabilization inside cells. We proceeded to perform two classic experiments, which are
traditionally done to show the in vivo efficacy of compounds via G-quadruplex
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stabilization: telomerase activity assay [42] or Western analysis of c-MYC
expression [35].
3.3.4

Inhibition of telomerase activity in breast cancer cells
Some G-quadruplex interactive ligands have been shown to achieve cancer cell

killing via the inhibition of telomerase expression and/or inhibition of telomere
extension [42]. We therefore investigated if the anticancer activities of some of our
analogues are derived (at least partially) from telomerase or telomere extension
inhibition. We evaluated the effect of compounds DMZ9 and DMZ13 at various
concentrations (0.5 × GI50, 1 × GI50, 2 × GI50) on telomerase activity in human breast
cancer cell line (MDA-MB-231) using TRAPeze XL Telomerase Detection Kit
(Intergen). TMPyP4 was evaluated at higher concentrations (1 × GI50, 2 × GI50, 4 × GI50)
since it was less efficacious at cancer cell killing and so higher concentrations could be
used and yet adequate amounts of cells would remain for post-treatment analysis. Cells
were treated with compounds for 48 h and 72 h respectively. Inhibition of telomerase was
evaluated by comparing the telomerase activity in untreated cells. The results showed that
telomerase activity in MDA-MB-231 could be inhibited by up to 50% after treating the
cell lines with 11 μM (2 × GI50) DMZ9 for 48 h or 72 h (see Figure 3.8). For TMPyP4,
25 μM (2 × GI50) could inhibit telomerase activity in MDA-MB-231 by ∼ 60 and 80%
for 48 h and 72 h respectively. It appears that the effect of DMZ9 on telomerase
expression deceases over time whereas that of TMPyP4 increases over time. This could
probably due to differential metabolism or degradation. Importantly the effects of
both DMZ9 and TMPyP4 were dose-dependent. This was however not the case
for DMZ13, which at 12.4 μM could inhibit about 20% and 30% of telomerase activity in
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MDA-MB-231 after treating the cells for 48 h and 72 h respectively (see Figure 3.8). At
48 h, the inhibition of telomerase activity by DMZ13 was not dose dependent. We
currently do not have a hypothesis to explain this phenomenon but the low level of
telomerase inhibition by DMZ13 suggests that its anti-cancer properties might be derived
from the stabilization of other G-quadruplexes or even via a non-G-quadruplex
stabilization pathway.

Figure 3.8

Telomerase activity in lysates of TMPyP4-, DMZ9-or DMZ13-treated
MDA-MB-231 cells for 48 h (upper panel) and 72 h (lower panel).

Telomerase activity was determined using the TRAPeze XL Telomerase Detection Kit
(Intergen). Lysate (1000 cell-equivalents) was mixed with TRAPeze XL reaction mix
containing Amplifuor primers, and incubated for 30 min at 30 °C. Telomerase products
were quantitated using a Fluorescence plate reader. A) percentage inhibition of
Telomerase activity in TMPyP4 treated MDA-MB-231 cells relative to untreated control
after 48 h. B) percentage inhibition of telomerase activity in DMZ9-treated MDA-MB231 cells relative to untreated control after 48 h. C) percentage inhibition of telomerase
activity in DMZ13-treated MDA-MB-231 cells relative to untreated control after 48 h. D)
percentage inhibition of Telomerase activity in TMPyP4 treated MDA-MB-231 cells
relative to untreated control after 72 h. E) percentage inhibition of telomerase activity in
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DMZ9-treated MDA-MB-231 cells relative to untreated control after 72 h. F) percentage
inhibition of telomerase activity in DMZ13-treated MDA-MB-231 cells relative to
untreated control after 72 h.
The inhibition of telomerase expression could occur via several pathways. It has
been proposed that this inhibition may be caused by the stabilization of G-quadruplex in
the core promoter of hTERT (catalytic domain of telomerase) [43]. Also, hTERT is
activated by c-MYC protein [44] so the effects of analogue on telomerase inhibition
could be an indirect one. Next, we performed a Western blot analysis of
analogue DMZ9 and TMPyP4 on reducing c-MYC protein levels in MDA-MB-231 cells
(see Figure 3.9).

Figure 3.9

Western blot analysis of c-MYC protein expression in MDA-MB-231 after
treated with DMZ9, DMZ13 and TMPyP4.

MDA-MB-231 cells were treated with DMSO vehicle, DMZ9 (5.45 μM and 27.25 μM)
and TMPyP4 (22.3 μM and 111.5 μM) for 2 h, 6 h and 24 h. DMZ13 (19.5 μM) for 6 h
and 24 h. Total protein was extracted and analyzed by Western blot with 1:1000 c-MYC
(Cell Signaling) and 1:10,000 HRP-linked anti-rabbit IgG (Cell Signaling). *Observed
high level of cytotoxicity and low protein levels. The graphs show the relative density as
compared with the DMSO vehicle. Scanned images were analyzed using image J
software.
3.3.5

Western blot analysis of c-MYC protein expression
c-MYC protein levels in MDA-MB-231 cells were evaluated by performing

Western blot. MDA-MB-231 breast cancer cells were treated with 22.3 or 111.5 μM
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TMPyP4, 5.45 or 27.25 μM DMZ9 for 2, 6 or 24 h and 19.5 μM DMZ13 for 6 or 24 h.
Here too, higher concentrations of TMPyP4 and DMZ13 than DMZ9 could be used
because TMPyP4 is not as efficacious as DMZ9 so higher concentrations could be used
without killing all of the cells. TMPyP4 has previously been shown to down regulate cMYC protein expression level [35] so TMPyP4 was included in this experiment as a
positive control. The results showed that at 19.5 μM DMZ13 had no effect on c-MYC
expression at 6 h while at 27.25 μM DMZ9 and 22.3 μM TMPyP4 caused an
approximately 40% decrease in the c-MYC protein expression at 6 h. After
24 h, DMZ13, DMZ9 and TMPyP4 caused 100%, 67% and 92% reductions in c-MYC
expression respectively. At a higher concentration of 111.5 μM, TMPyP4 caused a 100%
reduction in c-MYC expression after 24 h (see Figure 3.9). We conclude that
both DMZ9 and DMZ13 down regulate c-MYC protein expression. Whether this is solely
due to G-quadruplex stabilization or due to a combination of G-quadruplex stabilization
and yet to be identified mechanism remains to be elucidated in future studies.
3.4

Conclusion
DMZ analogues are easy to synthesize and monoamidine analogues that bear

alkyne moieties are selective G-quadruplex binders with good anticancer properties.
These alkyne derivatives of DMZ therefore serve as good lead molecules that warrant
further studies. Key insights from this study are, G-quadruplex binding or selectivity are
not sole determinants of anticancer efficacy, a fact that is increasingly being appreciated
by the many workers in the field. For example TMPyP4 and DMZ stabilized Gquadruplexes far better than all of the alkyne-substituted DMZ analogues yet they were
not the most efficacious anti-cancer agents. In fact DMZ was not effective at killing any
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of the three tested cancer cell lines. Secondly the majority of the DMZ analogues tested
had similar G-quadruplex binding profile and selectivity yet the anticancer properties of
these DMZ analogues varied greatly. Other factors, such as cell permeation or
metabolism or sub-cellular localization or even alternative therapeutic target(s) could all
come into play to modulate the efficacy of a particular agent. The synthetic tractability of
the DMZ analogues makes it easy to make diverse libraries to screen and future efforts
will be directed at expanding the DMZ library members and to increase the solubility
profiles of the analogues. G-quadruplexes are emerging as important structural elements
that regulate other disease states and so we anticipate that the molecules described in this
manuscript and variants thereof could find utility in diverse areas, such as anti-HIV
therapy.
3.5
3.5.1

Experimental
General information
Diminazene aceturate (DMZ), 4-aminobenzamidine dihydrochloride, cisplatin and

most of aromatic amines were purchased from Sigma–Aldrich and used without further
purification. DMZ1 was obtained following published procedure [26]. α,β,γ,δ-Tetrakis(1methylpyridinium-4-yl)porphyrin p-Toluenesulfonate (TMPyP4) was purchased from
TCI America. 3-(Phenylethynyl)aniline and 3-(pyridin-2-ylethynyl)aniline were
purchased from EnamineStore Ltd. c-kit1 22-mer (5′-AGG GAG GGC GCT GGG AGG
GAG G-3′), F21T 21-mer (5′–FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA–
3′), c-kit2 26-mer (5′–FAM-CCC GGG CGG GCG CGA GGG AGG GGA GGTAMRA–3′), k-RAS21R 21-mer (5′–FAM-AGG GCG GTG TGG GAA GAG GGATAMRA–3′), c-MYC 22-mer (5′-FAM-TGA GGG TGG GTA GGG TGG GTA A76

TAMRA-3′), duplex 26-mer (5′–FAM-TAT AGC TAT ATT TTT TTA TAG CTA TATAMRA–3′) and duplex competitor 26-mer DNA (5′-CAA TCG GAT CGA ATT CGA
TCC GAT TG-3′) were purchased from IDT, where FAM is 6-carboxyfluorescein and
TAMRA is 6-carboxytetramethylrhodamine. The concentrations of DNA stock solutions
were determined by measuring the absorbance at 260 nm using the extinction coefficient
values published in the literature [45]. Nuclear magnetic resonance (NMR) spectra were
recorded on Bruker DRX-400 MHz instrument (1H, 400 MHz; 13C, 100 MHz) or Bruker
DRX-500 MHz instrument (1H, 500 MHz; 13C, 125 MHz). Data for 1H NMR and 13C
spectra were recorded as follows: chemical shift (δ, ppm), multiplicity (s, singlet; d,
doublet; t, triplet; q, quartet; m, multiplet), integration, coupling constant (Hz). Highresolution mass spectra (HRMS) have been obtained by a TOF instrument with ESI
positive mode as the ionization method.
3.5.2
3.5.2.1

Synthesis of the DMZ analogues
Synthesis of alkyne-substituted aromatic amines via Sonogashira
coupling
The syntheses of alkyne-substituted aromatic amines (15–18) followed the

general Scheme 3.1. A 50 mL Schlenk flask was charged with aryl iodide (2 mmol, 1.0
eq.), bis-(triphenylphosphine) palladium dichloride (70 mg, 0.05 eq.), cuprous iodide
(10 mg, 0.05 eq.), triphenylphosphine (13 mg, 0.025 eq.), and a stir bar and sealed with
rubber septum [46]. The flask was evacuated and refilled three times with Argon.
Ethynylaniline (1.1 eq.) was added to 10 mL of distilled dry iPr2NH and degassed
together in a separated round bottom flask for 15 min and then transferred to the Schlenk
flask through cannula. The mixture was stirred for 16 h at room temperature (65 °C in the
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case of aryl bromide). After completion of the reaction, the mixture was diluted with
ethyl acetate (50 mL) and the slurry was filtered through a pad of Celite in a sintered
glass funnel (medium frit). The tan solids were additionally washed with ethyl acetate
until the filtrate was nearly colorless. The filtrate was washed with H2O and brine and
dried over magnesium sulfate. The combined organic fraction filtrates were concentrated
in vacuum, yielding a black solid. The residue was further purified by flash column
chromatography on silica gel using ethyl acetate/hexane mixture as eluent.

Scheme 3.1
3.5.2.2

Sonogashira coupling to prepare compounds 15–18.
4.2.2. General procedure for the synthesis of DMZ analogues

The synthesis of DMZ analogues followed previously reported procedure [26],
see Scheme 3.2. 4-Aminobenzamidine dihydrochloride (212 mg, 1.0 mmol) was added to
a stirred solution of 12 N HCl (0.27 mL) and water (1.5 mL) in a 10 mL flask at 0 °C and
stirring was continued for 15 min. To the mixture was added (dropwise) cold (∼0 °C)
NaNO2 solution (76 mg in 0.27 mL water, 1.1 eq.) and stirring was continued for 15 min
before cold (∼0 °C) NaOAc solution (328 mg in 1.5 mL water, 4.0 eq.) was added
78

dropwise over 15 min to adjust the pH to 6.0. Cold (∼0 °C) aromatic amine solution
(1.0 mmol in 1.0 mL methanol) was added dropwise to the above solution and stirring
was continued for another 1–12 h at 0 °C. After the reaction was completed, the solvent
was removed under reduced pressure. Water (100 mL) was added to the residue and the
aqueous mixture was washed with dichloromethane (2 × 15 mL). The aqueous layer was
then basified with 2.5% NaOH solution to make the pH > 10.0. The desired compound
was then extracted from the aqueous layer with ethyl acetate (2 × 100 mL). The organic
layer was washed with brine and dried with sodium sulfate. Finally, the solvent was
removed under reduced pressure and the final product was obtained with purity >95%.

Scheme 3.2

Facile synthesis of DMZ analogues via diazonium intermediates.

Stability test is shown in Figure B6.
3.5.3

Cell lines and culturing
The following human cell lines were purchased from ATCC (ATCC, Manassas,

VA): prostate cancer cells (PC-3), triple negative breast cancer cells (MDA-MB-231),
ovarian cancer cells (OVCAR-3), and normal fibroblast cells (MCR5A). Normal bone
marrow (NBM) was purchased from Lonza (Maryland). MDA-MB-231 cells were grown
at 37 °C with 5% CO2 atmosphere with DMEM (Life technologies, Carlsbad, CA)
supplemented with heat-inactivated 10% (V/V) fetal bovine serum. NBM was cultured in
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RPMI and OVCAR-3 and PC-3 cells were grown at 37 °C with 5% CO2 atmosphere with
RPMI (Life technologies, Carlsbad, CA) supplemented with heat-inactivated 10% (V/V)
fetal bovine serum. Cell lines were grown and maintained according to ATCC
recommendations.
3.5.4

GI50 determination
Cell lines were seeded into 96-well plates the afternoon prior to treatment. Cell

seeding number was determined by growing cells in log phase growth during drug
treatment. Approximately 18 h later, compounds were semi-serially diluted in dimethyl
sulfoxide (DMSO) and then growth medium, and added to cells. Plates were incubated
for 72 h prior to addition of WST-1 (Promega, Madison WI). Plates were read after 4
additional hours of incubation at 37 °C using a Bio-Tek Synergy HT plate reader (BioTek, Winooski, VT). Data was analyzed, graphed and GI50s generated using GraphPad
Prism Software (Graphpad, La Jolla, CA).
3.5.5

Fluorescence resonance energy transfer (FRET) assay to determine T1/2 in
absence and presence of ligands
All dual-labeled DNAs were diluted from stock (50 μM) to 800 nM in 60 mM

potassium cacodylate buffer (pH 7.2) and then annealed by heating at 85 °C for 10 min
followed by cooling to room temperature in the heating block, following literature
precedent [31]. Compounds were diluted from stock (20 mM in DMSO) to 8 μM in
60 mM cacodylate buffer (pH 7.2). 25 μL annealed DNA was added to 96-well plate
followed by 25 μL diluted compounds. Samples were then allowed to incubate for at least
12 h at 4 °C to come to equilibrium. Measurements were made in triplicate by using a
LightCycler 480 System RT-PCR machine (Roche) and average values were reported.
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Fluorescence readings were made with excitation at 450–495 nm and detection at 515–
545 nm, taken at intervals of 1.2 °C/min in the range 25 °C–95 °C. The sequences of
labeled oligonucleotides were as follows: F21T 21-mer (5′–FAM-GGG TTA GGG TTA
GGG TTA GGG-TAMRA–3′), c-kit2 26-mer (5′–FAM-CCC GGG CGG GCG CGA
GGG AGG GGA GG-TAMRA–3′), k-RAS21R 21-mer (5′–FAM-AGG GCG GTG TGG
GAA GAG GGA-TAMRA–3′), c-MYC 22-mer (5′-FAM-TGA GGG TGG GTA GGG
TGG GTA A-TAMRA-3′) and duplex 26-mer (5′–FAM-TAT AGC TAT ATT TTT TTA
TAG CTA TA-TAMRA–3′).
3.5.6

4.6. FRET DNA melting in competition with duplex DNA
FRET competition assay was performed by adding 4 μM, 40 μM and 200 μM

duplex competitor 26-mer DNA (5′-CAA TCG GAT CGA ATT CGA TCC GAT TG-3′)
in the presence of 0.4 μM c-MYC G-quadruplex and 4 μM DMZ analogues. Both cMYC G-quadruplex and duplex competitor 26-mer DNA were diluted in 60 mM
potassium cacodylate buffer (pH 7.2) and then annealed by heating at 85 °C for 10 min
followed by cooling to room temperature in the heating block. Experiments were
performed in triplicate.
3.5.7

PCR stop assay
This assay was performed by modifying a previously published protocol [47].

Sequences of the tested oligomers, Pu27, Pu27-13,14, Pu-mutant and the corresponding
complementary oligomer Pu27rev were presented in Table 3.2.
To the PCR reaction mixture (25 μL), 1x PCR buffer (New England Biolabs),
5 μM Pu27 and Pu27rev oligomers, various concentrations of ligands (DMZ,
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TMPyP4, DMZ1, DMZ9and DMZ13) were added and incubated at 4 °C for 6 h. After
that, 200 μM dNTPs, 5 units of Taq DNA polymerase (New England Biolabs) were
Table 3.2

Sequences of Oligomers used in the PCR Stop Assay.

Name of
oligomers
Pu27
Pu27-13,14

Sequence

Description

5′-TGG GGA GGG TGG GGA
GGG TGG GGA AGG-3′
5′-TGG GGA GGG TGG AAA
GGG TGG GGA AGG-3′

Partial sequence of promoter of
oncogene c-MYC.
A mutated Pu27 (a control template)
whose guanines at 13th and 14th
positions were changed to adenosines.
Another mutated Pu27 (another control
template) whose qunines at 4th, 8th,
13th, 14th and 17th positions were
changed to adenosines.
Complementary sequence of Pu27

Pu-mutant

5′- TGG AGA GAG TGG AAA
GAG TGG GGA AGG-3′

Pu27rev

5′-ATC GAT CGC TTC TCG
TCC TTC CCC A-3′

added and PCR reactions were performed in a thermocycler, with the following
conditions: 94 °C for 3 min, followed by 20 repeated cycles each having 94 °C for 30 s,
58 °C for 30 s, and 72 °C for 30 s. After PCR, amplified products were analyzed on 12%
polyacrylamide gel with 1 × TBE and SYBR Gold stained. This assay was also
performed under the same conditions with Pu27-13,14 and Pu27rev, and Pu-mutant and
Pu27rev.
3.5.8

Telomerase activity assay
MDA-MB-231 cells were routinely cultured in DMEM with 10% FBS and 1% l-

glutamine. The evening prior to treatment, actively growing MDA-MB-231 cells were
sub-cultured and seeded into T-25 flasks at 2 × 105 cells/flask. The following morning,
cells were treated with vehicle, DMZ9, DMZ13, or TMPyP4 at 0.5 × , 1 × , or 2 × GI50.
At 48 and 72 h after treatment, cells were harvested, washed with PBS, and pelleted. Cell
82

pellets were resuspended in 200 μL CHAPS lysis buffer with 200 units/mL RNase
inhibitor, mixed by pipetting, and incubated on ice for 30 min. Lysates were then
centrifuged at 12,000 × g for 20 min at 4 °C, and supernatants were collected, snap frozen
and stored at −80 °C until analysis. Telomerase activity was assayed using a
fluorescence-based TRAPeze XL telomerase detection kit (Intergen, Purchase, NY).
According to manufacturer, lysates (1000 cell-equivalents) were mixed with TRAPeze
XL reaction mix containing Amplifuor primers and incubated at 30 °C for 30 min to
allow the elongation of “TS” primer by telomerase. Amplified telomerase products were
quantitated with a fluorescence plate reader. Telomerase activity (in TPG units) was
calculated by comparing the ratio of telomerase products to an internal standard for each
lysate, as described by the manufacturer. Each unit of TPG (Total Product Generated)
corresponds to the number of TS primers extended with at least 3 telomeric repeats by
telomerase in the extract in a 30 min incubation at 30 °C.
3.5.9

Western blot
MDA-MB-231 cells in exponential growth were treated with either DMSO

vehicle, DMZ9 at 5.45 or 27.25 μM, or DMZ13 at 19.5 μM or TMPYP4 at 22.3 or
111.5 μM, for a period of 2, 6, or 24 h. At each time point the cells were harvested,
washed with 1x PBS and lysed in radioimmunoprecipitation (RIPA) buffer with protease
inhibitors. The protein in the resulting lysates was quantified using BCA (Pierce) and
subjected to SDS PAGE, then subsequently transferred to Nylon for Western blot
analysis with 1:1000 c-MYC (Cell Signaling) and 1:10,000 HRP-linked anti-rabbit IgG
(Cell Signaling). Scanned images were analyzed for densitometry using ImageJ software
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and β-actin as a loading control. Conditions were compared by percent to vehicle control
for each time point.
3.6
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CHAPTER IV
THE THERMODYNAMIC EFFECTS OF LIGAND STRUCTURE ON THE
MOLECULAR RECOGNITION OF MONONUCLEAR RUTHENIUM
POLYPYRIDYL COMPLEXES WITH B-DNA
Reproduced from Clinton G. Mikek, Jesse I. DuPont, Venkata R. Machha, Jake C. White,
Logan R. Martin, Nagham Alatrash, Frederick M. MacDonnell and Edwin A. Lewis.
“The Thermodynamic Effects of Ligand Structure on the Molecular Recognition of
Mononuclear Ruthenium Polypyridyl Complexes with B-DNA”. European Journal of
Inorganic Chemistry DOI 10.1002/ejic.201700462. Copyright © 2017 Wiley-VCH. All
rights reserved.
4.1

Abstract
The ruthenium(II) polypyridyl complexes (RPCs), [(phen)2Ru(tatpp)]Cl2 (3Cl2)

and [(phen)2Ru (tatpp)Ru(phen)2]Cl4 (4Cl4), containing the large planar and redox-active
tetraazatetrapyrido- pentacene (tatpp) ligand, cleave DNA in the presence of reducing
agents in cell-free assays and show significant tumor regression in mouse tumor models
with human non-small cell lung carcinoma xenografts.
ITC, CD, and ESI-MS techniques were used to study the thermodynamics of
RPC•DNA complex formation and the complex structure for binding three different
RPCs to duplex DNA. The specific RPCs were [Ru(phen)3]2+ (12+), [Ru(phen)2(dppz)]2+
(22+), and [Ru(phen)2(tatpp)]2+ (32+). We examined the enatiomerically pure Δ-RPC and
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Λ-RPC isomers as well as the racemic mixture in terms of their binding to B-DNA. BDNA binding of the three RPCs is characterized by a combination of groove binding
(including electrostatic effects) and intercalation, with the thermodynamics being very
similar for binding both the enantiomerically pure compounds and the racemic mixture.
12+ is the weakest DNA binder, exhibiting a Ka = 1.3 x 104 M-1 while 22+ binds with
significantly higher affinity, Ka,1 = 1.4 x 106 M-1, and 32+ exhibits the tightest binding, Ka
= 4.7 x 106 M-1. The trend is to increase the affinity as longer bridging ligands engage in
additional π-bonding with the DNA base pairs via an intercalative binding mode. A
second binding mode, two orders of magnitude weaker was also seen for 22+. The ITC
values for binding the racemic mixtures exhibit ΔGs ranging from -5.6 to -9.1 kcal mol-1
(12+•DNA and 32+•DNA respectively), while the ITC values for ΔH range from +4.9 to 5.0 kcal mol-1 (32+•DNA and mode 2 binding for 22+•DNA respectively). All of the
primary complexes exhibit very negative values for –TΔS ranging from -7.3 to -14.0 kcal
mol-1 (mode 1 binding for 22+•DNA and 32+•DNA respectively). To further understand
the intercalation versus groove binding contributions to the overall binding energy we
compared the thermodynamics for formation of the 12+•DNA, 22+•DNA, and 32+•DNA
complexes to the thermodynamics for formation of the 44+•DNA complex. The RPC
binding affinities to duplex DNA follow the trend: 12+ < 44+ < 22+ < 32+. Differences in
the affinity for binding 12+ versus 22+ or 32+ are almost entirely due to the size of the
intercalating moiety, e.g. phen which can only be partially intercalated in comparison to
dppz and tatpp which can be completely intercalated. The lower affinity for the dinuclear
ruthenium 44+ is due to the solvation penalty for the second Ru core complex that extends
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out from the major groove. Comparing these results, we have begun to develop the
structure function relationships for the interaction of RPCs with B-DNA.
4.2

Introduction
Ruthenium-based anticancer drugs have been showing increasing promise over

the last 20 years with two such drugs, KP1019 (a salt of trans-[tetrachlorobis(1 Hindazole)ruthenate(III)]-) and NAMI-A (a salt of [trans-RuCl4(DMSO)(Him)]-), making it
to Phase I clinical trials in just the last few years. [1] Both KP1019 and NAMI-A are
thought to be activated by reduction to Ru(II) complexes in cells, however it is not clear
how they act beyond this with activity postulated in the mitochondria, endoplasmic
reticulum and even possibly in the nucleus.[1-3] Compared to platinum drugs, these
ruthenium complexes are often identified as less toxic and capable of overcoming the
resistance induced by platinum drugs in cancer cells.[4-7]
More recently, the ruthenium polypyridyl complexes (RPCs), [(phen)2Ru(tatpp)]Cl2
(3Cl2) and [(phen)2Ru(tatpp)Ru(phen)2]Cl4 (4Cl4) have also shown promising anti-cancer
activity with observed DNA cleavage activity in vitro, selective cytotoxicity towards
malignant cultured human cell lines, and demonstrable tumor regression in animal tumor
models.[7] Note: When the numerical abbreviation for RPCs in this work is indicated as
a charged species, i.e. 32+ and 44+, the notation refers to the cation only. When it is
important to specify the counterion, it will be written as a salt, i.e. 3Cl2 and 4Cl4. RPCs
32+ and 44+ are also thought to be activated by reduction in situ, however in this case the
reduction is ligand-based and reversible, leading to a catalytic activation of
dioxygen.[8,9] As these ruthenium(II) complexes bind to DNA, the short-lived reactive
oxygen species (ROS) generated locally can damage the DNA, ultimately leading to
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apoptosis. Intriguingly, while these RPCs generate both superoxide and H2O2, they do so
in a manner that preferentially generates the longer lived and more cytotoxic H2O2 as the
O2 concentration is lowered. Subsequent Fenton-like chemistry results in DNA strandscission by the reactive hydroxyl radical for both 3 and 4 in cell-free assays and which is
seen as DNA double strand breaks in H358 cell nuclei for 4 and to a lesser extent 3.[9]
As a class, RPCs have been extensively studied as non-covalent DNA binding agents and
as luminescent probes of DNA structure,11 ever since the early studies of Barton and
coworkers with [Ru(phen)3]2+ (12+) and later [(phen)2Ru(dppz)]2+ (22+).[10-13] Studies of
the modes and thermodynamics of mononuclear RPCs binding to DNA show
electrostatics and intercalation as the dominant driving forces for binding, with binding
constants ranging from 103 to 108 M-1.(14-18) Chaires and coworkers showed that RPC
12+ is predominantly bound via electrostatic interactions in the DNA minor groove
whereas extending the planarity of the 1,10-phenanthroline (phen) ligand, for example
the dipyridophenazine (dppz) ligand in 22+, results in intercalation which can add
considerably to the binding affinity of these complexes. [19] For dinuclear complexes
with the intercalating ligand bridging the two metal centers, as seen for
[(phen)2Ru(tpphz)Ru(phen)2]4+,[20] [(phen)2Ru(bis-dppz)Ru(phen)2]4+, [20,22]
44+,[20,23,24] and others,[17,18] insertion into the DNA duplex can be rapid and facile or
slow, with binding constants ranging from 105 to 1012 M-1!
We previously reported that [(phen)2Ru(tatpp)Ru(phen)2]4+ (formerly P4+) bound to DNA
through an intercalative binding mode that took advantage of the dynamic “breathing”
exhibited by duplex DNA.(10) This present work sets out to examine how increasing the
size of the modified phenanthroline to dppz and then tetraazatetrapyrido-pentacene
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(tatpp) affects the binding of the mononuclear ruthenium(II) complexes, 12+, 22+, and 32+.
DNA binding is examined via a combination of ITC, to extract the entirety of the binding
thermodynamics, and CD experiments, to validate the changes in structure. To our
knowledge, this is the first systematic study using isothermal titration calorimetry and
circular dichroism to examine the structure function relationship of racemic and
enantiomerically pure mononuclear RPCs with increasingly larger intercalating ligands
binding to model duplex DNA.
4.3

Results and Discussion
Le et al. previously reported on 44+ binding to B-DNA with an average affinity of

~4 × 105 M−1 through an entropically driven intercalative mechanism.[10] This work
seeks to present data on structural derivatives of this parent compound. RPCs 12+, 22+,
and 32+ are structurally similar to the original dinuclear complex 44+ and are shown in
Figure 4.1. As seen, 32+, 22+ and 12+ represent successive truncations of the dinuclear 44+
structure.

Figure 4.1

Ruthenium polypyridyl complexes examined in this study
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4.3.1

ITC
Table 4.1 summarizes the thermodynamic data obtained for formation of the

racemic-RPC•25 bp DNA complexes, as well as for the formation of the Δ-RPC•25 bp
DNA and Λ-RPC•25 bp DNA complexes from the nonlinear regression fits of the
RPC/DNA ITC titrations. All of the ITC titration endpoints yielded saturation n values
for binding RPC compounds to 25 bp duplex DNA of approximately 6 or 12. Typical
ITC thermograms for the racemic-RPC, Δ-RPC, and Λ-RPC titrations of 25 bp DNA
along with the nonlinear regression best fit lines for a multiple independent sites binding
model are shown in Figure 4.2. The 32+and 12+titrations were fit to a model having only
one binding mode while the 22+ titrations were fit to a model having two distinctly
different binding modes with the mode 2 sites exhibiting much lower binding affinity.
The titration data shown have been corrected for a continuously variable heat of dilution
for the ligand and as is typical in ITC titrations, the first one or two points have not been
included in the fit.
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Typical ITC thermograms for the addition of racemic-, Δ-, and ΛRuthenium polypyridyl complexes to 25 bp DNA.

The binding of 32+ to duplex DNA exhibited an n value of approximately 12-13
sites which is consistent with a nearest neighbor exclusion binding model for RPC
binding to an intercalation extended 25 bp duplex. RPC 32+ binding is characterized in
this study by a small unfavorable enthalpy change and a larger favorable entropy change
resulting in a favorable change in free energy (ΔG = -9.1 kcal mol-1). The thermodynamic
profile for 32+ binding to 25 bp duplex DNA is similar to that reported previously for
binding 44+.[10] In both cases RPC•DNA complex formation is entropically driven
(−TΔS ≈ −14.0 kcal mol−1for 32+; −TΔS ≈ −10.0 kcal mol−1for 44+). The approximate -2
kcal mol-1 increase in DNA affinity for the 32+ compound over the 44+ compound is the
result of a larger increase in the favorable entropy term for complex formation, δ(-TΔS =
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-4 kcal mol-1), in comparison to a smaller increase in the unfavorable enthalpy term for
complex formation, δ(ΔH = +2 kcal mol-1). The thermodynamic profile for binding 32+ to
duplex DNA is unusual for an intercalation process in that intercalation is more typically
enthalpy driven.
The binding of 22+ to 25 bp duplex DNA is more complicated in that it interacts
through two distinctly different binding modes exhibiting different affinities (K1 ≈ 1.4 x
106 M-1 and K2 ≈ 8 x 104 M-1). The binding of 22+ to duplex DNA exhibited a total n
value (n1 + n2), saturation stoichiometry, of approximately 12-13 sites which is again
consistent with a nearest neighbor exclusion binding model for RPC binding to an
intercalation elongated 25 bp duplex. The higher affinity binding process (K1) is
principally entropically driven (-TΔS1 ≈ -7.3 kcal mol-1) while the lower affinity process
(K2) is principally enthalpically driven (ΔH2 ≈ -5.0 kcal mol-1). In both cases, the
additional term (ΔH1 or –TΔS2) although smaller is also favorable (ΔH1 ≈ -1.0 kcal mol-1
and –TΔS2 ≈ -2.0 kcal mol-1) and thus both the enthalpy and entropy terms are driving
complex formation. Overall, the thermodynamic profiles for binding 22+ to duplex DNA
look like a combination of the classical thermodynamic profiles for groove binding
(mode 1) plus intercalation (mode 2).
The binding of 12+ to duplex DNA exhibited an n value of only 4-6 sites which is
consistent with a minor groove binding model in which the binding of each individual
RPC molecule removes 3-4 bp from the DNA binding lattice. RPC 12+ binding is
characterized in this study by a small unfavorable enthalpy change (ΔH ≈ + 4 kcal mol-1)
and a larger favorable entropy change (–TΔS ≈ -10.0 kcal mol-1) resulting in a favorable
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change in free energy (ΔG = -5.6 kcal mol-1) for complex formation. In the case of 12+
binding to DNA, the thermodynamic profile is typical for groove binding.
Table 4.1

ITC derived thermodynamic parameters for the formation of rac-RPC•25
bp DNA, Δ-RPC•25 bp DNA, and Λ-RPC•25 bp DNA complexes.

13
13
13
7
9
6
5
5
4
5
6
4

Ka x 10-6
(M-1)
4.7 ± 0.5
5.3 ± 0.6
15.2 ± 8
1.4 ± 0.5
17 ± 11
1.6 ± 0.5
0.08 ± 0.02
0.02 ± 0.01
0.043 ± 0.001
0.013 ± 0.001
0.012 ± 0.001
0.022 ± 0.001

12

0.38 ± 0.07

n
rac-32+
Δ-32+
Λ-32+
rac-22+, mode 1
Δ-22+, mode 1
Λ-22+, mode 1
rac-22+ , mode 2
Δ-22+, mode 2
Λ-22+, mode 2
rac-12+
Δ-12+
Λ-12+
rac 44+

4.3.2

ΔG
(kcal mol-1)
-9.1 ± 0.1
-9.2 ± 0.1
-9.7 ± 0.3
-8.4 ± 0.3
-9.7 ± 0.6
-8.5 ± 0.2
-6.7 ± 0.1
-6.0 ± 0.1
-6.3 ± 0.1

ΔH
(kcal mol-1)
4.9 ± 0.1
4.5 ± 0.2
4.22 ± 0.06
-1.1 ± 0.1
-0.65 ± 0.07
-1.7 ± 0.2
-5.0 ± 2.0
-3 ± 1
-7.8 ± 1

-TΔS
(kcal mol-1)
-14.0 ± 0.1
-13.7 ± 0.1
-14.0 ± 0.3
-7.3 ± 0.2
-9.1 ± 0.6
-6.8 ± 0.3
-2.0 ± 2.0
-3 ± 1
1.5 ± 1

-5.6 ± 0.1
-5.54 ± 0.04
-5.9 ± 0.03
-7.1 ± 0.3

3.9 ± 0.1
3.8 ± 0.3
3.8 ± 0.4
2.6 ± 0.4

-9.5 ± 0.1
-9.4 ± 0.3
-9.6 ± 0.4
-9.7 ± 0.7

CD
Typical CD spectra for the racemic-RPC titrations of 25 bp DNA are shown in

Figure 4.3. The CD spectra shown have been corrected for the CD signal of the added
rac-RPC ligand. The corrections are small but assume that the binding of the Δ and Λ
isomers are equal and self-canceling. The CD spectra for the racemic-, Δ- and ΛRuthenium polypyridyl compounds are shown in Figure C.1 in Appendix C. If this
assumption is invalid, the corrections could be much larger and small changes in the CD
signals for the complexed DNA would be difficult to interpret. However, in comparing
the “DNA” CD spectra for the three different complexes, it appears that only binding 32+
or 22+ are unwinding and elongating the target DNA structure while binding 12+ has a
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much smaller effect on the DNA structure. Figures 4.3A and 4.3B show CD results for
the binding of RPC 32+ or RPC 22+ to the target 25 bp duplex DNA while Figure 4.3C
shows CD results for the binding of RPC 12+ to the target 25 bp duplex DNA. The
addition of either 32+ or 22+ to a dilute DNA solution results in the almost complete
attenuation of the DNA molar ellipticity at 274 nm as the mole ratio of RPC to DNA
exceeds 6:1. This change in the CD spectrum is similar to the change in the DNA CD
spectrum seen previously in experiments in which RPC 44+ was titrated into a dilute
solution of a 7 bp DNA hairpin.[10] Titrations with RPC 12+ do not exhibit any
significant changes in the CD spectrum in either shape or intensity of the CD signal as a
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Modeling
Figure 4.4A shows a model for RPC 32+ interacting with duplex DNA in which

the 32+ tatpp moiety is fully intercalated into the DNA helix and in which the ruthenium
core domain is located in the minor grove. Figure 4.4B shows a model exhibiting two
binding modes for the interaction of RPC 22+ and DNA. In this model structure, the RPC
22+ molecule is docked in two orientations, one in which the RPC is bound directionally

97

into the stacked bases from the minor groove (classic intercalation) and a second
orientation in which the dppz moiety is occupying the major groove.
Figure 4.4C show a model for the 12+•DNA complex in which the RPC molecule
is sitting in either the minor groove or the major groove.

A

Figure 4.4
4.3.4

B

C

Minimized Models of 32+ (A), 22+ (B), and 12+ (C) interacting with duplex
DNA.

ESI-MS
ESI-MS experiments were employed to verify the stoichiometries of the

RPC•DNA complexes formed in the ITC and CD titration experiments. Mass spectra
obtained on the 7 bp hairpin DNA (without added ligand) and on the 32+, 22+, and 12+
hairpin DNA complexes are shown in panels A, B, C, and D of Figure C2, C3, and C4
respectively in Appendix C. RPC•DNA complex mass spectra were obtained on
solutions having an excess of the RPC (4:1 or greater). In all of these experiments, new
peaks representative of specific RPC•DNA complexes were observed when the mass
spectra for the target DNA were compared to the mass spectra for solutions of the target
DNA with added RPC. Figures C2, C3, and C4 show signals from low to high m/z
regions of the mass spectrum in order to magnify the peaks having lower relative
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abundance. New peaks having m/z values consistent with RPC•DNA complexes having
up to 3 molecules of RPC bound per molecule of the target DNA were found in the
32+•DNA, 22+•DNA, and 12+•DNA complex mass spectra. The 2:1 saturation
stoichiometry is consistent with a nearest neighbor exclusion binding model for
intercalation (n=12 to 13 for binding to the 25 bp DNA), while the 3:1 saturation
stoichiometry is more consistent with a groove binding model in which the bound ligand
overlaps 3-4 base pairs (n=6 for binding to the 25 bp DNA).
4.3.5

Discussion
Previous reports have indicated that 1,10-phenanthroline and related analogs are

capable of interacting with DNA through an intercalative binding mode. Haq et al. was
able to demonstrate that 12+ binding does not proceed through the classical intercalative
mode, but rather through van der Waals contacts, electrostatic interactions, and/or effects
related to the solvation of DNA.[25] Le et al. reported that 44+ was able to interact with
DNA with an affinity one order of magnitude greater than the 12+ binding, but that the
enthalpy was similar to that reported by Haq et al. Le et al. proposed that 44+ was able to
thread through the DNA base pairs by taking advantage of the “breathing” motion of
DNA.[10] To further understand the energetics of 44+ binding to duplex DNA and to
differentiate between the possible groove binding and intercalation contributions to
formation of the 44+•DNA complex we determined the thermodynamics for the binding of
12+, 22+, and 32+ to a 25bp duplex DNA. These three compounds differ in the size of the
potential intercalating moiety by varying one of the three Ru ligands from a 1,10phenanthroline to a dppz, or a tatpp ligand, on going from 12+ to 22+ to 32+. 32+ differs
from 44+ only in the lack of the second Ru core domain.
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In this study we determined a value of Ka = 1.3 x 104 M-1 for binding the racemic
mixture of 12+ to a 25 bp DNA. Satyanarayana et al. had previously reported values of
Ka = 0.97 x 104 M-1 and Ka = 1.07 x 104 M-1 for the binding of the Δ and Λ isomers of 12+
respectively to calf thymus DNA.[19] These results are in reasonable agreement and it
appears that any differences between the affinity of enantiomerically pure compounds
and the racemic mixture with either of the target DNAs are small. Haq et al. reported
values of ΔH = 2.6 kcal mol-1 and –TΔS = -7.9 kcal mol-1 for formation of the racemic
12+•DNA complex.[25] The Haq et al. values for both the enthalpy and entropy changes
for formation of the racemic 12+•DNA complex compare less favorably with the values
determined in this study (ΔH = 3.9 ± 0.1 kcal mol-1, and –TΔS = -9.5 ± 0.1 kcal mol-1).
The differences between our results and Haq’s in ΔH and in –TΔS are +1.3 and -1.6 kcal
mol-1 respectively. The changes in the measured enthalpy and entropy changes in the two
studies compensate one another, explaining the better agreement between the affinities in
this study versus Haq’s (ΔG = -5.6 kcal mol-1, and ΔG = -5.3 kcal mol-1). A plausible
explanation for the differences in any of the thermodynamic parameters determined in the
two studies may stem from the fact that the buffers were different (BPES vs. Tris), the
temperatures were different (298 vs. 293 K), the DNAs were different (25 bp vs. calf
thymus), and the 12+ compound was from a different source. That being said, both
studies demonstrate that the binding of 12+ to duplex DNA is entropically driven which is
more typical of groove binding. CD titration results are consistent with this structure for
the 12+•DNA complex (see Figure 4.3C). The binding of 12+ produces little to no change
in the structure of the duplex DNA as evidenced by the unchanged DNA CD spectrum in
the absence or the presence of saturating amounts of 12+. The saturation stoichiometry of
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5 or 6:1 also indicates that the DNA helix is not elongated upon 12+ binding thus limiting
the binding to one 12+ per 3 to 4 base pairs as was determined previously by
Satyanarayana et. al.[19]
As noted in the results section, the binding of 22+ to ds DNA exhibits an increased
affinity over 12+. The increase in binding affinity is largely due to the intercalation of the
dppz moiety which is larger than the phenanthroline it replaces and which can be inserted
between stacked bases in the DNA.

The CD spectra and changes in the CD spectra in

22+ titrations are proof that the binding of 22+induces structural changes in the target DNA
through both steric interactions between the two bulky phenanthroline groups Ru core
complex and the DNA backbone as well as elongation of the DNA helix which is
necessary to accommodate intercalation of the 22+ dppz group. Although the CD spectra
for the racemic-22+•DNA complex may be complicated by induced CD signals from the
differential binding of the Δ-RPC and Λ-RPC ligands in the racemic mixture, we have
assumed that the corrections are small enough to allow us to speculate that the changes in
the DNA CD spectrum for the racemic-22+•DNA complex are consistent with a widening
of the minor groove which is similar to A-form DNA. This is evident from the
emergence of a positive peak near 260-270 nm, which is indicative of A-form
DNA.[26,27] Figure 4.4B models 22+ intercalating into DNA from the minor groove and
widening it to accommodate the phenanthroline groups lying in the grove. Changing the
width of the minor and major grooves is necessary for relaxation of the torsional strain
induced by intercalation.[28]
The binding of 22+ is more complicated than the binding of any of the other RPCs
examined in this study in that two distinct binding modes were observed. The higher
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affinity binding mode for a racemic mixture of the 22+ compound binding to the 25 bp
DNA target is characterized by a Ka,1 = 1.2 x 106 M-1. This value although similar in
magnitude is smaller than either of the Ka values reported by Haq et al. for binding the Δ22+ isomer (Ka = 3.2 x 106 M-1) or the Λ-22+ isomer (Ka = 1.7 x 106 M-1) to calf thymus
DNA.[25] Haq et al. observed only a single binding mode for each isomer whereas we
observed two binding modes for the racemic mixture with the second binding mode
exhibiting a significantly lower affinity, Ka = 0.08 x 106 M-1. The two binding modes are
not the result of the two isomers present in the racemic mixture binding with different
affinity but the result of the 22+ compound binding in two orientations (see Figure 4.3B).
We speculate that the higher affinity mode includes the energetic contributions from
intercalation of the dppz moiety while the lower affinity mode includes only the groove
interaction of the Ru core complex and a small intercalative energy for the partial
insertion of a phenanthroline ligand into the stacked DNA bases.
Haq et al. also reported ΔH and ΔS values for the formation of both the Δ-22+ and
the Λ-22+•DNA complexes.[25] Their reported values for the Δ-22+•DNA complex were
ΔH = 0.2 kcal mol-1 and ΔS = 30.8 cal mol-1 K-1, and values for the formation of the Λ22+•DNA complex of ΔH = 2.9 kcal mol-1 and ΔS = 38.1 cal mol-1 K-1.[25] Our mode
one values are ΔH = -1.1 kcal mol-1 and ΔS = 24.5 cal mol-1 K-1. Although the enthalpy
and entropy changes reported here and by Haq et al. are quite different, both sets of
results indicate that the binding of the 22+ to ds DNA is entropically driven.[25] Again,
the difference in enthalpy is small and possibly negligible, but could arise from a number
of factors including differences in the buffer (BPES vs. Tris), in the temperature (298 vs.
293 K), in the DNAs (25 bp vs. calf thymus), and the fact that the 22+ compound was
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from a different source. Another plausible source of the differences in the enthalpy and
entropy change values may be that the data in these two studies were obtained using
different techniques (ITC here versus a combination of fluorescence and ITC in Haq et
al.). However it is important to note that very similar binding affinities were obtained in
both studies.
Although the weaker binding mode was apparently not observed by Haq et al., the
second binding mode has been reported by Biver et al., and more recently by Andersson
et al. in an ITC/photophysics study of the binding of 22+ to a model synthetic ds DNA
(poly[dAdT])2.[29,30]
Andersson et al. has used a more sophisticated binding model, the McGhee-von
Hippel model for one ligand having multiple modes of interaction to an infinite one
dimensional lattice, to fit their ITC and fluorescence lifetime data for the interaction of
22+ to ds DNA, whereas we have used a simpler model employing two distinctly different
binding modes for the interaction of 22+ to ds DNA. We believe that both models reduce
to the same result, the binding of 22+ to ds DNA in two different orientations and having
two unique sets of thermodynamic parameters. Even though Anderson et al. observed
the lower affinity interaction, they did not report any of the thermodynamic values for the
formation of the mode 2 complex.[29] However, they do report that the second binding
event, observed near saturation, exhibits a more negative enthalpy change than the first
binding event. Andersson et al. reported free energy, enthalpy, and entropy change
values for formation of both the Δ-22+ and the Λ-22+•(poly[dAdT])2 complexes.[29]
Their reported values of ΔG for mode 1 binding for formation of the Δ-22+ and Λ22+•(poly[dAdT])2 complexes are -8.1 kcal mol-1 and -7.1 kcal mol-1 respectively. Our
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value for the free energy change for formation of the racemic 22+•DNA complex is ΔG1 =
-8.4 kcal mol-1, which is in good agreement with the free energy change reported for
formation of the Δ-22+•(poly[dAdT])2 complex.[29] More importantly the formation of
the high affinity 22+•DNA complex is reported here and in both Haq et al. and Andersson
et al. to be entropically driven. On the other hand, the formation of the lower affinity
22+•DNA complex is reported here and in Andersson et al. to be driven by a favorable
change in enthalpy. While Andersson et al. have not reported on the thermodynamic
parameters for formation of the lower affinity complex, our mode 2 thermodynamic
parameters are ΔG2 = -6.7 kcal mol-1, ΔH2 = -5.0 kcal mol-1, and -TΔS2 = -2.0 kcal mol-1.
In contrast to the mode 1 interaction, the mode 2 interaction is driven by a favorable
enthalpy change.
We agree with Andersson et al. that the higher affinity 22+•DNA complex is
consistent with intercalation of the dppz ligand into the DNA stacked bases, and that the
mode 2 complex is structurally different from the mode 1 complex. However, we do not
believe that we have sufficient data to assign a specific “canted” structure to the mode 2
complex as suggested by Andersson et al.[29] We speculate that the second binding
mode may be the result of a side-on interaction with the backbone of the DNA or a new
intercalative association arising from the original intercalation which caused a widening
of the minor groove (see Figure 4.4.3B).[30,31] The normal and canted intercalation
interactions would be expected to exhibit similar thermodynamics (i.e. similar values for
ΔG, ΔH, and -TΔS) and similar thermodynamic profiles (e.g. entropy driven versus
enthalpy driven processes) and would not yield distinctly different free energy, enthalpy,
and entropy changes as observed for the two binding modes.[32] X-ray crystal structures
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of both the ∆-22+ and Λ-22+•DNA complexes are available and show two different
binding modes for the racemic mixture.[33] Additional crystal structures of a Λ[Ru(TAP)2(dppz)]2+•DNA complex, where TAP = 1,4,5,8-tetraazaphenanthrene, show
that structure of the complex varies from an A/B hybrid DNA to the A-DNA
conformation at high relative humidity.[31]
To further the study of the relative importance of intercalation versus groove
binding in an RPC having a larger tatpp (vs dppz) intercalating moiety, the interaction of
32+ with the model duplex DNA was examined. To the best of our knowledge, no
previous thermodynamic data have been reported for the interaction of 32+ with duplex
DNA. In comparison to 22+, 32+ exhibits a 3-fold higher affinity for duplex DNA, Ka =
4.7 x 106 M-1, suggesting that an increase in intercalation (or burial) of the larger tatpp
ligand provides additional favorable entropy to drive the 32+•DNA complex formation.
We speculate that differences in the binding of 32+ versus 22+ are due to two effects, an
increase in the favorable π-π interactions of the extended conjugated system and the
desolvation of the RPC. CD titrations exhibit a dramatic attenuation in molar ellipticity in
the 275 nm region which is consistent with the disruption of base stacking needed to
accommodate intercalation of the tatpp moiety of the 32+ compound. At mole ratios
approaching saturation, the CD spectra show an emerging peak in the 260-270 nm region.
This is consistent with the elongation of the helix which is necessary to intercalate the 32+
compound in alternating sites and providing more than 6 binding sites for the 25 bp
DNA. In fact we observe 12 to 13 binding sites on the 25 bp DNA when the RPC is 22+,
32+, or 44+, but only 5 sites when the RPC is 12+. Molecular docking and energy
minimization studies show that the ruthenium(II) center in the 32+•DNA complex is closer
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to the groove floor than we reported previously for the molecular model of 44+ complexed
with the same DNA.[10] The energetics of the closer association of the 32+ compound
with the DNA groove floor or with the DNA backbone also contribute to the higher
binding affinity. Lastly, as reported previously for dinuclear polypyridyl ruthenium
compounds, the thermodynamics for formation of the enantiomerically pure ΔΔ- or ΛΛRPC•DNA complexes is similar for both isomers and the racemic mixture.[34] We find
the same result here for the mononuclear RPCs interacting with duplex DNA.
4.4

Conclusions
The ITC, CD, and ESI-MS results reported here serve to characterize the

formation thermodynamics and structures for three different RPC•DNA complexes and in
comparing these results to those for formation of the 44+•DNA complex,[10] we have
begun to develop the structure function relationships for the interaction of these RPCs
with duplex DNA. RPC 12+ is found to bind in the DNA minor groove covering
approximately 3-4 base pairs.[19] The energetics for formation of the 12+•DNA complex
indicate that the interaction is predominantly electrostatic as was previously suggested by
Satyanarayana et al.[19] Marked increases in RPC DNA binding affinity are observed in
the mononuclear ruthenium(II) compounds in which one of the phenanthroline ligands is
replaced by a larger ligand, e.g. dppz or tatpp. The increase in DNA affinity is due to the
additional intercalation binding energy that stems from the insertion of the dppz or tatpp
ligands between the stacked base pairs in the target DNA. The favorable entropic
contributions which are attributed to intercalation, result from the displacement of solvent
(water) from the intercalating dppz or tatpp moieties of the 22+ and 32+ compounds. The
partial unwinding of the duplex that accompanies intercalation increases the number of
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RPC binding sites from n/3 (or n/4) to n/2, where n is the number of base pairs in the
target DNA. ESI-MS data support the “neighbor exclusion principle” for binding
intercalating RPCs (22+ and 32+) to duplex DNA.[10,19] The free energy changes for
formation of the 22+ and 32+•DNA complexes relative to the free energy change for
formation of the 44+•DNA are more favorable by 1.5 kcal mol-1 and 2.0 kcal mol-1
respectively. This is due to the destabilizing effect of the second ruthenium(II) center in
the 44+ compound. In the 44+•DNA complex, one of the ruthenium(II) centers is down in
the groove, similar to the 12+•DNA complex, while the second Ru core complex appears
to be protruding into the solvent (water). The lower affinity for the 44+ compound results
from the unfavorable solvation of the protruding –[Ru(phen)2] moiety which cannot lie in
the major groove because the tatpp bridging ligand is too long. We speculate that
optimizing the length of the intercalating bridge so that both Ru core complexes could lie
in the grooves would yield a dinuclear Ru complex with an even higher affinity for ds
DNA.
4.5
4.5.1

Experimental Section
DNA and Ligand Preparation
The target DNAs were either a 7 base pair hairpin (7bpHP) (5’-

GCAGTCCTCTCGGACTGC-3’) or a 25 base pair dsDNA (25bp duplex) (5′-ATC AAG
CTA CGG TCT GTG AGC AAG T-3′/5′-ACT TGC TCA CAG ACC GTA GCT TGA
T-3′) purchased from Midland Certified Reagent Co. as the RP grade and used without
further purification. The RPC DNA binding compounds, 12+, 22+, 32+ and 44+, were
prepared in our group by previously reported procedures.[35] All RPC compounds were
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obtained and used as either a racemic mixture or as the enantiomerically pure Δ and Λ
isomers.
RPCs were dissolved in the final dialysate buffer and their concentrations
calculated using the following molar masses: 3Cl2 = 1018.9 g/mol; 2Cl2 = 814.69 g/mol;
1Cl2 = 712.59 g/mol. Working solutions were freshly prepared prior to experiments by
dissolution of the weighed solid into the final dialysate and kept at RT away from
ambient light. 2Cl2 required substantial heat and sonication to dissolve completely into
the buffer. 3Cl2 required initial heat and sonication to dissolve. 1Cl2 readily dissolved in
the buffer.
4.5.2

ITC
ITC experiments were performed using a Microcal VP-ITC (Malvern) at 25 °C. A

typical experiment involved injection of 28 aliquots of dilute RPC (nominally 120 to 850
μM) into a dilute solution of the 25 bp duplex DNA in the calorimeter cell. The 25bp
duplex DNA was exhaustively dialyzed against 80 mM Na+ BPES buffer (50 mM NaCl;
10 mM Na2HPO4; 10 mM NaH2PO4; 1 mM EDTA) at pH=7.0 and annealed by heating to
95 °C and holding for 10 minutes followed by cooling to 5 °C at a rate of 0.5 °C min-1.
Both the DNA stock solution concentration and the dilute titrate concentration were
verified using the following extinction coefficient: 25bp duplex DNA ε260= 3.97 x 105 M1

cm-1. The calorimeter cell contained 1.45 mL of the dilute (10 μM) DNA titrate

solution and 10 μL injections of the dilute RPC titrant were made at 200 second intervals.
The ITC thermograms were corrected for titrate and titrant dilution effects by performing
the appropriate blank experiments and correcting the observed heats by subtracting the
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heats of dilution. Corrected ITC titrations were fit with a nonlinear regression algorithm
using CHASM, an ITC data analysis program developed in the Lewis laboratory.[36]
4.5.3

CD
CD experiments were performed using an Olis DSM-20 spectropolarimeter

(Bogart, GA). Typical experiments involved the titration of RPC into a DNA sample with
a nominal A260 ≈1. The RPC titrant and 25 bp DNA solutions used in the CD
experiments were the same as those used in the ITC experiments. Corrections were made
by subtracting the signal of RPC titrated into buffer from its respective sample, correcting
for dilution, and converting to molar ellipticity.
4.5.4

ESI-MS
ESI-MS experiments employed a lower molecular weight DNA target in a 50 mM

ammonium acetate buffer (pH 7.0) containing 20% HPLC grade methanol. The ESI-MS
experiments on 7 base pair hairpin (7bpHP) DNA and the (RPC•7bpHP) complexes were
carried out on a Bruker MicrOTOFQ mass spectrometer. Data acquisition was set to
operate in negative ion mode. The DNA and RPC•DNA samples were prepared at a
nominal concentration of 40 μM and the concentration verified using an extinction
coefficient of ε260= 1.76 x 105 M-1cm-1. Stock solutions of the ligands were prepared in
the same final dialysate buffer. The ESI-MS samples were prepared by mixing the hairpin
DNA (300 µL) and RPC stock solutions (2 µL) to yield a mixture containing 4
equivalents of RPC per molecule of hairpin DNA. The MS capillary voltage was set to
+4000 V, dry N2 gas flow was adjusted to 4 L min-1 at 190 °C, and the sample was
directly infused into the MS by using a kD Scientific syringe pump set to a flow rate of
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180 μL h-1. Data processing was performed by using the Bruker Daltonics Data Analysis
program.
4.5.5

Modeling
Molecular modeling was performed utilizing Discovery Studio 3.1. DNA•RPC

complexes were constructed by building a strand of B-DNA using the internal build
functions. The RPC ligands were either imported from existing PDB files or constructed
in Discovery Studio. The ligands were manually placed in a potential interactive site and
the RPC•DNA complex was calculated with the AMBER force field, and minimized
with an implicit solvent model dielectric constant of 80.
4.6
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CHAPTER V
THE THERMODYNAMIC EFFECTS OF LIGAND STRUCTURE ON THE
MOLECULAR RECOGNITION OF MONO- AND BI-RUTHENIUM
POLYPYRIDYL COMPLEXES WITH G4-DNA
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5.1

Abstract
ITC and CD were used to study the thermodynamics of RPC•G-quadruplex DNA

(G4) complex formation. RPCs were [Ru(phen)3]2+ (12+), [Ru(phen)2(dppz)]2+ (22+),
[Ru(phen)2(tatpp)]2+ (32+), and [Ru(phen)2(tatpp)(phen)2Ru]4+ (44+) and target DNAs
were c-MYC NHE-III1 promoter sequence mutants forming 1-2-1 and 1-6-1 Gquadruplexes. Formation of the 2:1 RPC•G4 complexes is characterized by entropy
driven RPC binding to the top and bottom of G-tetrad faces. 12+ appears to bind very
weakly or not at all to G4-DNA. 22+, having a dipyridophenazine group to stack on the
top and bottom of the G4 core, exhibits an average Ka = 6.7 x 104 M-1. 32+, with a larger
G4 interactive tetraazatetrapyrido-pentacene group, binds with significantly higher
affinity, Ka = 1.1 x 106 M-1. 22+ and 32+ appear to bind independently of G4 folding
topology and RPC conformation. The thermograms for the titration of G4-DNA with
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rac-44+ are characterized by two binding modes exhibiting higher and lower affinity (Ka,1
= 3.6 x 107 M-1 and Ka,2 = 3.2 x 105 M-1). The two binding modes are attributed to
preferential binding of one of the 44+ enantiomers (e.g. ΛΛ) over the other isomers (e.g.
ΔΔ or ΔΛ). Tighter binding of the preferred 44+ enantiomer, in comparison to 32+, is due
to additional favorable entropy for locating a second [(phen)2Ru-]2+ moiety in a G4
groove. Weaker binding of the disfavored 44+ isomers must be due to a poorer fit of these
isomers with the G4 faces.
5.2

Introduction
Resistance induced by platinum drugs in cancer cells and the toxicity has led to

recent interest in Ruthenium complexes, which are often identified as less toxic.[1-4] In
the last 20 years Ruthenium based anticancer drugs have shown some progress and two
such drug candidates, KP1019 (a salt of trans-[tetrachlorobis(1 Hindazole)ruthenate(III)]-) and NAMI-A (a salt of [trans-RuCl4(DMSO)(Him)]-), have
made it into Phase I clinical trials.[5] There exists an uncertainty in the actual mechanism
of the anticancer activity of KP1019 and NAMI-A but current postulates suggest the
activation by reduction to Ru(II) complexes in cells with possible activity in the
mitochondria, endoplasmic reticulum, and the nucleus.[5-7]
In vitro DNA cleavage activity, selective cytotoxicity towards malignant cultured
human cell lines, and demonstrable tumor regression in animal tumor models are some of
the promising anti-cancer activities recently reported for ruthenium polypyridyl
complexes (RPCs), [(phen)2Ru(tatpp)]Cl2 (3Cl2) and [(phen)2Ru(tatpp)Ru(phen)2]Cl4
(4Cl4).[4]
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RPCs 32+ and 44+ are thought to be ‘activated by reduction’ in situ via a ligand
based reversible process that leads to a catalytic activation of dioxygen.[8-9] Newly
generated and short lived reactive oxygen species produced are in intimate contact with
B-DNA as reported recently with the tatpp ligand intercalating into the DNA stacked
base pairs with the Ru(II) core(s) positioned in the DNA groove(s).[10] Tatpp containing
RPCs generate both superoxide and H2O2 with preferential formation of the longer lived
and more cytotoxic H2O2 as the O2 concentration is lowered (e.g. in the environment of a
cancerous cell) which may lead to DNA damage responses and ultimately apoptosis.
DNA strand-scission by the reactive hydroxyl radical for both 3 and 4 in cell free assays
has demonstrated DNA double strand breaks in H358 cell nuclei for 4 and to a lesser
extent 3.[9]
RPCs [Ru(phen)3]2+ (12+) and [(phen)2Ru(dppz)]2+ (22+) are commonly used as
luminescent probes of DNA structure and have been studied extensively as non-covalent
DNA binding agents.[11-14] Satyanarayana showed that electrostatic interactions in the
minor groove of DNA are responsible for 12+ binding to B-DNA and the dppz substituted
moiety 22+ added an intercalative binding mode which considerably increased
affinity.[15] Thermodynamic studies of mononuclear RPCs interacting with DNA
exhibit electrostatics and intercalation as the dominant driving forces for binding, with
binding constants ranging from 103 to 108 M-1.[16-20]
Shi et.al previously reported [Ru(bpy)2(dppz)]2+ stacking on the ends of human
telomere G-quadruplex DNA but asserted that the RPC•DNA binding modes are not clear
and deserve further investigation. They reported that RPC binds preferentially to G4DNA in comparison to either B-DNA or i-motif DNA.[21] They also proposed that
116

[Ru(bpy)2(dppz)]2+ could act as a molecular “light switch” for luminescent signaling
upon binding to G-quadruplexes. Ma et al. examined binding of 22+ to G4-DNA and
found modest binding affinity (ΔG = -6.43 kcal mol-1).[22] Wilson et al. reported
complexation of a dinuclear RPC by a human telomere G-quadruplex DNA construct and
found the binding constants varied by several kcal mol-1 depending on the
stereochemistry of the dinuclear [(phen)2Ru-tpphz-Ru(phen)2]4+ (54+) examined (e.g. ΔΛ,
ΔΔ, ΛΛ) (tpphz = tetrapyrido phenazine).[23] They determined that the affinity for
binding the unresolved complex, a 1:2:1 mixture of (ΔΔ, ΔΛ, ΛΛ) isomers, to an
antiparallel human telomere sequence was similar to the affinity for binding the
enantiomerically pure ΛΛ-RPC to the same target DNA. They attributed this to the
ability of the ΔΛ species to bind to the higher affinity site indicating that Δ
stereochemistry was tolerated at a single ruthenium in the complex but not at both ends.
Here we present a systematic study using isothermal titration calorimetry and
circular dichroism to examine the structure function relationship of RPCs, [(phen)2RuL]2+, having increasingly larger ligands, e.g. phen, dppz, tattp, and tattp-Ru(phen)22+,
complexed with model G-quadruplex DNAs. G4-DNA binding is examined via a
combination of ITC, to extract the entirety of the binding thermodynamics, and CD
experiments, to survey changes in structure. Both racemic and enantiomerically pure
RPCs were examined.
5.3

Results and Discussion
Le et al. previously reported on 44+ binding to B-DNA with an average affinity of

~4 × 105 M−1 through an entropically driven intercalative mechanism.[11] In chapter IV,
B-DNA complexation was reported with racemic and enantiomerically pure mononuclear
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RPCs 12+, 22+, and 32+, which are structurally similar to the original dinuclear complex
44+ but vary by successive truncations of the bridging ligand in the parent dinuclear RPC
structure.[10] The present work examines the thermodynamics for the binding of the
same RPCs to two different G-quadruplex DNA constructs assembled from the c-MYC
NHE-III1 promoter sequence and mutated to restrict their folding topologies to form
either the parallel 1-6-1 or 1-2-1 G4 motifs.[24]

Figure 5.1
5.3.2

Ruthenium polypyridyl complexes examined in this study.

ITC
Typical ITC thermograms for the racemic-RPC, Δ-RPC, and Λ-RPC titrations of

G4-DNA along with the nonlinear regression best fit lines for a multiple independent
sites binding model are shown in Figures 2-4. The binding of RPCs 22+ and 32+ were fit
to thermodynamic model having two equivalent or independent binding sites while the
binding of 44+ was fit to a thermodynamic model having two distinctly different binding
sites. The stoichiometry term, n, was not used as a fitting parameter and was set equal to
a value of 2. Fixing n=2 (or ntotal = n1 + n2 =2) is consistent with both the ITC titration
endpoints and with NMR data suggesting the top and bottom of a G-quadruplex bind one
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dinuclear RPC each.[23] Reducing the number of fitting parameters from either six (K1,
K2, ΔH1, ΔH2, n1, and n2) to four (K1, K2, ΔH1, and ΔH2) or from three (K1, ΔH1, and n) to
two (K1 and ΔH1) results in better fits without any loss of important thermodynamic
information. The highest affinity binding mode (K1 or K) for each RPC DNA interaction
exhibits a thermodynamic signature that is characterized by a large favorable entropy
change and a smaller favorable enthalpic contribution. Only the formation of the mode 2
rac-44+ G4 complexes exhibit a thermodynamic signature that is characterized by a larger
favorable enthalpy change and a smaller favorable entropy contribution. In sharp
contrast, the thermodynamic signatures for formation of the RPC B-DNA complexes are
typically accompanied by unfavorable changes in enthalpy and are almost completely the
result of very favorable changes in entropy.

c -M Y C 1 -2 -1

c -M Y C 1 -6 -1
0

 H ( k c a l/m o l)

 H ( k c a l/m o l)

0

-1

-2

-3

-4

-1

-2

-3

-4
0

1

2

3

4

5

M o le R a tio

Figure 5.2

0

1

2

3

4

5

M o le R a tio

Nonlinear regression fits of integrated heats from ITC titrations of 44+ into
G4-DNA.

119

2+

 -3

-2

-3

-4

-1

-2

-3

-4
1

2

3

4

ra c -3

-1

-2

-3

-4
0

1

2

3

4

0

2+

 -3

2+

 3

-2

-3

-4

-1

-2

-3

6

0

1

M o le R a tio

Figure 5.3

4

2+

-1

-2

-3

-4

-4
4

3

0

 H ( k c a l/m o l)

 H ( k c a l/m o l)

-1

2

2

M o le R a tio

0

0

1

M o le R a tio

0

2+

0

M o le R a tio

 H ( k c a l/m o l)

 -3

 H ( k c a l/m o l)

-1

0

c -M Y C 1 -6 -1

2+

0

 H ( k c a l/m o l)

0

 H ( k c a l/m o l)

c -M Y C 1 -2 -1

ra c -3

2

3

0

4

1

2

3

4

5

M o le R a tio

M o le R a tio

Nonlinear regression fits of integrated heats from ITC titrations of 32+ into
G4-DNA.

The excess heat at low mole ratios (n>1) is attributed to ligand induced folding of a small
unfolded G4 DNA population.
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Table 5.1

Thermodynamic parameters for the formation of the indicated RPC/G4DNA complexes at 298 K.a
c-MYC
Ligand
G4-DNA
1-2-1

rac-22+

-6.6±0.1

-1.9±0.7

-4.7

Δ 22+

-6.4±0.1

-1.3±0.2

-5.1

-6.8±0.1

-1.5±0.3

-5.2

-6.5±0.1

-2.0±0.2

-4.5

-6.4±0.2

-1.2±0.2

-5.1

-6.8±0.3

-1.4±0.5

-5.4

-8.1±0.1

-1.7±0.2

-6.4

-7.4±0.2

-1.4±0.1

-5.9

-8.1±0.1

-2.2±0.2

-5.9

-8.0±0.3

-1.5±0.2

-6.5

-8.7±0.3

-0.8±0.1

-7.8

-8.7±0.1

-1.5±0.1

-7.1

rac-4 mode 1

-10.2±0.1

-2.7±0.1

-7.4

rac-44+ mode 2

Λ2

2+

rac-2
1-6-1

2+

Δ 22+
Λ2

2+

rac-3
1-2-1

Δ3

2+

2+

Λ 32+
rac-3
1-6-1

Δ3

2+

2+

Λ3

2+
4+

1-2-1
1-6-1

ΔG
ΔH
-TΔS
(kcal mol-1) (kcal mol-1) (kcal mol-1)

-7.2±0.1

-4.3±0.1

-2.9

4+

-10.3±0.3

-1.2±0.1

-9.1

4+

-7.7±0.2

-2.7±0.5

-5.0

rac-4 mode 1
rac-4 mode 2

aThe

values for K and ΔH were obtained from the non-linear regression fitting of the ITC
thermograms to the binding models described in the text. Values for ΔG and –TΔS were
obtained from the equations ΔG = -RTlnK and ΔG = ΔH –TΔS. Error values are
calculated as the standard deviation of the mean for each individual parameter.
5.3.2.2

44+ Binding to G4-DNA
Rac-44+ was found to bind with 2 distinct binding modes to both c-MYC 1-2-1

and c-MYC 1-6-1 G4-DNAs. The mode 1 interactions are driven by large positive
changes in entropy or large negative changes in –TΔS (-7.4 kcal mol-1 and -9.1 kcal mol-1
for c-MYC 1-2-1 and c-MYC 1-6-1 respectively). The mode 1 interactions are also
accompanied by smaller but still favorable negative changes in enthalpy (-2.7 kcal mol-1
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and -1.2 kcal mol-1 for c-MYC 1-2-1 and c-MYC 1-6-1 respectively). In combination,
the enthalpy and entropy changes yield very favorable Gibbs free energy changes, ΔG,
for formation of the mode 1 complexes (-10.2 kcal mol-1 and -10.3 kcal mol-1).
The lower affinity mode 2 interactions are characterized by smaller but still
favorable entropic contributions or negative changes in -TΔS (-2.9 kcal mol-1 and -5.0
kcal mol-1 for c-MYC 1-2-1 and c-MYC 1-6-1 respectively). However, the mode 2
enthalpy changes are more negative than the mode 1 enthalpy changes (ΔH2 < ΔH1) for
both complexes (-4.3 kcal mol-1 and -2.7 kcal mol-1 for c-MYC 1-2-1 and c-MYC 1-6-1
respectively). In combination, the enthalpy and entropy changes again yield very
favorable Gibbs free energy changes, ΔG, for formation of the mode 2 complexes (-7.2
kcal mol-1 and -7.7 kcal mol-1). The 44+ mode 2 enthalpy changes for formation of the
G4-DNA complexes are more favorable than the ΔH values for any of the other RPCs.
As shown in Figure 5, the Gibbs free energy change for the mode 1 interaction
between rac-44+ and G4-DNA is stronger by approximately 3 kcal mol-1 than for rac-44+
binding to B-DNA.[10] The lower affinity, rac-44+•G4 (mode 2), interaction is
energetically equivalent to the formation of the rac-44+•B-DNA complex. However,
parsing the free energy change into its enthalpy and entropy contributions presents a very
different picture. The lower affinity, rac-44+•G4 (mode 2) interaction has a more
favorable change in enthalpy compared to B-DNA (δΔH = -6.3 and 4.7 kcal mol-1 for cMYC 1-2-1 and c-MYC 1-6-1 respectively). The difference in the enthalpy change
between binding 44+ to B-DNA vs. G4-DNA may be explained on the basis of the
favorable change in enthalpy for π-stacking of the tatpp moiety in the 44+ ligand on the
face of the a G-tetrad where it will cover two guanines rather than the intercalation of the
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tatpp moiety between two base pairs in duplex DNA.[11,23] In addition the lower
affinity, rac-44+•G4 (mode 2), interaction is accompanied by a less favorable change in
entropy when compared to B-DNA (δ-TΔS = 6.7 and 4.6 kcal mol-1 for c-MYC 1-2-1 and
c-MYC 1-6-1 respectively). The decrease in entropy for either G4 binding mode is likely
due to the fact that only one face of the tatpp will be desolvated for binding to a G-tetrad
face while both sides of the bridging ligand would be stripped of solvent to intercalate
into B-DNA.
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Thermodynamic signature of 44+ binding to various DNAs. B-DNA data
from previous work.[10]
32+ Binding to G4-DNA

The thermodynamic profiles for binding rac-32+, Δ-32+, and Λ-32+ to c-MYC 1-21, c-MYC 1-6-1, B-DNA are shown in Figure 5.6. The most notable difference between
binding the mononuclear rac-32+ and the dinuclear rac-44+ ligands to G4-DNA is that rac123

32+ and its pure enantiomers Δ-32+ and Λ-32+ exhibit only a single binding mode with a
total stoichiometry of 2:1 for both G4-DNAs. In effect, rac-32+, Δ-32+, and Λ-32+ bind
similarly to both ends of the quadruplex without interference from the dissimilar end
loops. Even though there are subtle differences in the values of thermodynamic
parameters (ΔG, ΔH, and –TΔS) for binding the rac-32+, Δ-32+ and Λ-32+ isomers to G4DNA, the thermodynamic profiles are very similar. It is clear from the data summarized
in Figure 5.6 that there is no real preference in binding of either the Δ-32+ or Λ-32+
isomers. Even though the free energy changes are similar for binding all of the 32+
compounds to both G4-DNA and B-DNA, the entropy changes for the B-DNA
interactions are significantly more favorable (typically in excess of -7 kcal mol-1 in –
TΔS).[10] In addition, the enthalpy changes for formation of all of the G4-DNA
complexes are exothermic (ΔH ≈ - 1.5 kcal mol-1) while all of the B-DNA complexes
exhibit endothermic heats of formation (ΔH ≈ + 4.5 kcal mol-1). Again the differences in
binding to G4-DNA vs. B-DNA must be attributed to binding the 32+ ligand on a G-tetrad
face vs. intercalation between stacked bases in the B-DNA structure. Intercalation is
apparently accompanied by larger changes in ligand solvation and smaller π-stacking
interactions than those brought about by binding to a tetrad face.

124

c-M Y C 1 -2 -1

c-M Y C 1 -6 -1

2 5 b p d u p le x
G

0

k c a l/m o l

H
-T  S
-5

-1 0

Figure 5.6
5.3.2.4

+

+

2

2

3

-3


2

-3
c
ra

-

2

-3

3

+

+

+
2



2

-

-3
c
ra

-3

2

+

+

+
2

3
-



ra

c

-3

2

+

-1 5
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22+ Binding to G4-DNA

The thermodynamic profiles for binding rac-22+, Δ-22+, and Λ-22+ to c-MYC 1-21, c-MYC 1-6-1, and B-DNA are shown in Figure 5.7. Again, all of the 22+ isomers
exhibit only a single binding mode with a total stoichiometry of 2:1 for binding to both
target G4-DNAs. Apparently rac-22+, Δ-22+, and Λ-22+ bind similarly to both ends of the
quadruplex without interference from the dissimilar end loops. The numerical values of
the thermodynamic parameters (ΔG, ΔH, and –TΔS) for binding both the Δ-22+ and Λ-22+
isomers to either G4-DNA are very similar. It is clear from the data summarized in
Figure 5.7 that there is no real preference in binding the unresolved 22+ or either of its
enantiomers to the c-MYC 1-2-1 and c-MYC 1-6-1 G4-DNAs.
In comparing the thermodynamics for binding 22+ to B-DNA vs. G4-DNA, it
appears that the enthalpy changes are similar but that the entropy change for formation of
the B-DNA complexes is much more favorable. This leads us to speculate that the π125

stacking interaction for locating 22+ on a G-tetrad face is similar to two π-stacking
interactions that occur when 22+ is intercalated into duplex DNA. In other words the Gtetrad surface that is interacting with the 22+ ligand is similar in area to the π-surfaces of
the bases that are located above and below the intercalated 22+ in the B-DNA complex.
The increase in the favorable free energy for binding 22+ to B-DNA is entirely due to a
more positive ΔS for formation of the intercalated B-DNA complex. The increase in the
entropy change (decrease in –TΔS) must reflect an increase in the number of solvent
molecules released in the formation of the intercalated 22+•B-DNA complex in
comparison to formation of the end stacked 22+•G4-DNA complex.
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Thermodynamic signature of 22+ binding to various DNAs. B-DNA data
from previous work.[10]
12+ Binding to G4-DNA

ITC titrations of 12+ into either c-MYC 1-2-1 or c-MYC 1-6-1 G4-DNAs were
calorimetrically silent. Binding affinity could therefore not be determined but if it occurs
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would be expected to be very weak. We previously found 12+ to bind only weakly to the
groove of the B-DNA constructs with an unfavorable enthalpy of ≈ +4 kcal mol-1. The
phenanthroline ligand is apparently not long enough to engage in π-stacking interactions
with the G-tetrad face and the G4 grooves appear to be too different from the minor
groove of B-DNA to support entropy driven binding similar to the interactions taking
place between 12+ and B-DNA.[10]
5.3.3

CD
The CD spectra shown in Figure 5.8 are for the G4-DNA constructs and RPC•G4-

DNA complexes formed with the racemic RPC and have been corrected for the CD signal
of the added rac-RPC ligand. The corrections for the racemic species are small but
assume that the binding of the Δ and Λ isomers are equal and self-canceling. CD spectra
showing this phenomenon for rac-, Δ-, and Λ- RPCs are shown in Figure S1 in the
Supplemental Information section. As shown in Figure 5.8, changes in the CD spectra of
the RPC•G4-DNA complexes are observed at the λmax (265 nm) for the parallel Gquadruplex structure. With the exception of the rac-44+•1-6-1 c-MYC G4 complex, the
decrease in [θ]265 is typically small (< 10%). We attribute the attenuation in the CD
signal at 265 nm to preferential binding of the RPC enantiomer having a negative molar
ellipticity in the 265 nm region. Selective binding of the Λ-RPC enantiomer compared
to Δ-RPC (indicated by the ITC results summarized in Table 1) is consistent with the
attenuation in [θ]265 exhibited for several of the RPC•G4-DNA complexes shown in
Figure 5.8. RPC binding to either or both ends of the G-quadruplex does not appear to
result in any disruption of the G-quadruplex structure. The most important information
that is obtained from the CD data is that the target DNA is initially a parallel G127

quadruplex and the DNA in the final RPC complex is still folded into a parallel G-
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5.3.4

Modeling
Molecular modeling was performed utilizing Discovery Studio 3.1 Client and is

found in Figures 9 and 10. G4-DNA•RPC complexes were constructed using the internal
build functions and ligands were manually placed into the c-MYC G-quadruplexes as
suggested by ITC and CD experimental results in addition to available crystal structures
of similar compounds interacting with telomeric G4-DNA.[23] The top bound ligand
from left to right is ΛΛ-44+, Λ-32+, and Λ-22+. The bottom bound ligand is ΔΔ-44+, Δ-32+,
and Δ-22+.

Figure 5.9

Models of ΛΛ-44+, Λ-32+, and Λ-22+ (top bound) and ΔΔ-44+, Δ-32+, and Δ22+ (bottom bound) in complex with c-MYC 1-2-1 G-quadruplex forming
oligonucleotide construct.
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Figure 5.10

5.3.5

Models of ΛΛ-44+, Λ-32+, and Λ-22+ (top bound) and ΔΔ-44+, Δ-32+, and Δ22+ (bottom bound) in complex with c-MYC 1-6-1 G-quadruplex forming
oligonucleotide construct.

Affinity and Stereoselectivity
We report here that the dinuclear ruthenium polypyridyl compound 44+ exhibits

selectivity for G-quadruplex DNA over B-DNA with an increase in affinity of at least
two orders of magnitude (107 vs. 105).[10] 44+ has the highest affinity for G4-DNA
reported to date, by a factor of approximately 2 (K = 4.2 x 107 for 44+ vs. K = 1.8 x 107
for 54+).[23] Wilson et al. attributed their high affinity binding mode for 54+ interacting
with human telomere G4-DNA to a combination of end binding and an overlapping
diagonal loop interaction. They also attributed their observed enantiomeric selectivity
(ΛΛ, ΛΔ > ΔΔ) to the quadruplex diagonal loop interfering with binding of the ΔΔ-54+
isomer. Although not discussed, it would seem that 54+•htel DNA complex would have a
different stoichiometry for the ΛΛ-54+ and the ΔΔ-54+•htel DNA complexes (i.e. 2:1 and
1:1 respectively). We also observed two binding modes, a higher and a lower affinity
mode, for the interaction of rac-44+ with the parallel c-MYC quadruplexes studied here.
Following the lead of Wilson et al., we initially attributed these affinity differences to
differences in the loop structure adjacent to the two G-tetrad faces. It is interesting to
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note that we find similar high affinity and low affinity sites for binding 44+ to parallel cMYC quadruplexes where there are no diagonal end loops. In the model 44+•G4 c-MYC
complexes shown in Figures 9 and 10, it is difficult to see where the difference in affinity
between the two quadruplex ends originates.
A subtle difference found in fitting the thermograms for the rac-44+ titrations is
that while the total stoichiometry agreed with the formation of a 2:1 RPC:DNA complex,
the number of high affinity sites was found to be only 0.5 out of a total of 2.0 binding
sites. This leads to a second explanation for the two affinities that are observed in these
titrations. The differences in affinity found in fitting the 44+ titration data could result
from the preferential binding of one of the enantiomers, either ΔΔ or ΛΛ in the racemic
mixture, rather than invoking a loop interaction to create the high affinity site. Based on
the work of Wilson et al., the higher affinity binding event might be due to binding the
ΛΛ-44+ isomer which represents 25% of the total 44+ present in the unresolved 1:2:1
mixture of the ΛΛ, ΛΔ and ΔΔ isomers.[23] Although Wilson et al. attribute the higher
affinity for binding the ΛΛ-54+ enantiomer to its fitting under a diagonal loop at the top
of the antiparallel human telomere quadruplex, they don’t discuss whether ΛΛ-54+
enantiomer binds only to the end with the overlapping diagonal loop or to both of the
quadruplex faces with different affinity. We think that knowing the complex
stoichiometry is critically important to sorting out these differences.
Rajput et al. examined the binding of rac-54+ to a parallel human telomere Gquadruplex construct at low mole ratios of ligand using ITC and they determined that rac54+ binding was driven largely by a favorable change in entropy (-TΔS= -6.7 kcal mol-1)
with a small enthalpic contribution (ΔH= -0.8 kcal mol-1). They report a free energy
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change for the formation of the rac-54+•G4 human telomere parallel complex (ΔG = -7.5
kcal mol-1) that is similar to the free energy change reported by Wilson et al. for the
formation of the ΔΔ-54+•G4 human telomere antiparallel complex, but more than 2.0 kcal
mol-1 weaker than the free energy change for the formation of the ΛΛ-54+•G4 human
telomere antiparallel complex.[25] The thermodynamic signature for rac-54+ binding to
a parallel G-quadruplex is similar to what we have observed here for the binding of rac44+ to a parallel G-quadruplex in that both are driven by large favorable changes in
entropy with smaller favorable enthalpic contributions.

The biggest difference is that

the free energy is as much as 3 kcal mol-1 more favorable for the formation of the rac44+•1-2-1 and rac-44+•1-6-1 parallel complexes than for formation of the rac-54+•G4
human telomere parallel complex. Having also examined B-DNA and G4-DNA
complexation with rac-54+, Rajput et al. were able to determine that in contrast to the
entirely entropically driven binding to duplex DNA, there is a small favorable enthalpic
contribution for the interaction of rac-54+ and G4-DNA consistent with a favorable πstacking interaction with the G-tetrad faces.[25] They found that binding rac-54+ to either
B-DNA or G4-DNA resulted in approximately the same free energy.[25] This result is
in sharp contrast to our result that rac-44+ binds much more tightly to G4-DNA than to BDNA by at least two orders of magnitude and to the higher affinity reported by Wilson et
al. for formation of the rac-54+•G4 and ΛΛ-54+•G4 human telomere parallel
complexes.[10]
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5.4

Conclusions
We have shown that 44+ binds preferentially to G4-DNA over B-DNA by

approximately 3.0 kcal mol-1 and have confirmed that the 44+•G4 interaction exhibits at
least modest stereoselectivity. These findings suggest that mononuclear and/or dinuclear
ruthenium polypyridyl compounds like 44+ might be a good platform from which to
develop new ligands with enhanced specificity for recognition of G-quadruplex DNA
structure including folding topology. The continued development of RPCs similar to 44+
having enhanced specificity and selectivity for G4-DNA and further studies of the
potential cleavage of G4-DNA in the vicinity of bound 44+ in the hypoxic environment
found of a cancerous cell could lead to new avenues for cancer treatment as well as new
opportunities to study the biological occurrence and activity of G-quadruplex DNA
motifs.
5.5
5.5.1

Experimental Section
DNA and Ligand Preparation
Target DNAs were c-MYC G4 forming mutants with restricted folding topologies

purchased from Midland Certified Reagent Co. The G-quadruplex forming DNA was
purchased as the RP grade and used without further purification. The sequences are as
follows: c-MYC 1-6-1: 5’-TGGGGAGGGTTTTTAGGGTGGGGA-3’; c-MYC 1-2-1:
5’-TTTTTAGGGTGGGGAGGGTGGGGA-3’. The DNA was exhaustively dialyzed
against K+ Tris buffer (150 mM KCl, 20 mM Tris, 1 mM EDTA, 30% DMSO, pH 7.2)
and annealed by heating to 95 oC and holding for 10 minutes and then cooling to 5 oC at a
rate of 0.5 oC/min. DNA stock concentrations were verified using the following
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extinction coefficients: c-MYC 1-6-1 ε260=270300 µM-1cm-1; c-MYC 1-2-1 ε260=270300
µM-1cm-1.
The RPC DNA binding compounds, 12+, 22+, 32+ and 44+, were prepared in our
group by previously reported procedures.26 All RPC compounds were obtained and used
as either a racemic mixture or as the enantiomerically pure Δ and Λ isomers. RPCs were
dissolved in the final dialysate buffer and their concentrations calculated using the
following molar masses: 4Cl4 = 1551.3 g/mol; 3Cl2 = 1018.9 g/mol; 2Cl2 = 814.69
g/mol; 1Cl2 = 712.59 g/mol. Working solutions were freshly prepared prior to
experiments by dissolution of the weighed solid into the final dialysate and kept at RT
away from ambient light. Sonication and gentle heat were used to help the RPC dissolve
completely when needed.
5.5.2

ITC
ITC experiments were performed using a Microcal VP-ITC (Malvern) at 25 °C. A

typical experiment involved injection of 35 aliquots of RPC (nominally 1 mM) into a
dilute solution of the G-quadruplex forming DNA (~10 μM) in the calorimeter cell. The
ITC thermograms were corrected for titrate and titrant dilution effects by performing the
appropriate blank experiments and correcting the observed heats by subtracting the heats
of dilution. Corrected ITC titrations were fit with a nonlinear regression algorithm using
CHASM, an ITC data analysis program developed in the Lewis laboratory.[27]
5.5.3

CD
CD experiments were performed using an Olis DSM-20 spectropolarimeter

(Bogart, GA). Typical experiments involved the titration of RPC into a DNA sample with
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a nominal A260 ≈1. The RPC titrant and DNA solutions used in the CD experiments were
the same as those used in the ITC experiments. Corrections were made by subtracting the
signal of RPC titrated into buffer from its respective sample, correcting for dilution, and
converting to molar ellipticity.
5.5.4

Modeling
Molecular modeling was performed utilizing Discovery Studio 3.1 Client. G4-

DNA•RPC complexes were constructed using the internal build functions and ligands
were placed into the G-quadruplexes as suggested by ITC and CD experimental results in
addition to available crystal structures of similar compounds interacting with telomeric
G4-DNA.[11] Structures were calculated with the AMBER force field and minimized
with an implicit solvent model dielectric constant of 80.
5.6
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A.1

Displacement assays with the G-quadruplex binder, NMM
In these assays, the triazene ligand was used at various concentrations: 0, 5, 10,

20, 50, 100, and 200 μM; and the DNA concentration was kept at 10 μM, whereas the
concentration of NMM was 1 μM. The experiments were performed in 50 mM Tris-HCl
buffer (pH 7.5) in the presence of 50 mM KCl. The excitation wavelength used for NMM
was 400 nm and the emission was monitored between 550 and 700 nm (slit width = 5 nm,
scan speed = 600 nm/min, averaging time = 0.1 sec, data interval = 1 nm, PMT detector
voltage = 600 V, measurement temperature = 20 °C). The sample was initially heated to
95 °C and kept at this temperature for 5 min without ligand or NMM and then cooled
down to room temperature for 15 min. Subsequently, the triazene ligand was added to the
DNA and incubated for ~12 h.

140

Figure A.1

Displacement of G4 ligand, NMM (A and B), by triazine ligands.

(Left) Displacement of NMM (1 µM) upon titration of triazene ligands (A) DMZ, (B)
Triazene-1 on c-kit1 (10 µM). The concentration of ligand is 0, 5, 10, 20, 50, 100, 200
µM. In the figure, 200 µM ligand concentration is emphasized with red line. Buffer = 50
mM Tris-HCl (pH 7.5), [KCl] = 50 mM. Fluorescence was measured with excitation
wavelength = 400 nm for NMM, emission wavelength = 550-700 nm. (Right)
Fluorescence emission intensity at 608 nm ( ) and 670 nm ( ) against ligand (A) DMZ,
(B) Triazene-1concentrations. The concentrations of ligand are 0, 5, 10, 20, 50, 100, 200
µM.
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A.2

UV spectroscopy studies of DMZ binding to G quadruplexes and duplex
DNA

Figure A.2

UV-titration studies showing binding of DMZ with DNA.

(Left) Absorption sprectra of DMZ (10 µM) upon titration with (A) VEGF, (B) bcl-2
2345, (C) TBA, (D) 8bp AT. The concentrations of DNA are 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9,
10, 20, 30, 40, 50, 100, 150 µM. In the graph, 10 µM and 150 µM DNA concentrations
are specifically emphasized as cyan and red line respectively. [KCl] = 250 mM, Buffer =
50 mM Tris-HCl (pH 7.5). UV was measured at 20 °C. (Right) Plot of absorbance at 360
nm against concentration ratio of DNA and Ligand (DMZ). Ligand concentration is 10
µM, DNA = (A) VEGF, (B) bcl-2 2345, (C) TBA and (D) 8bp AT. The concentrations of
DNA are 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150 µM.
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A.3

UV spectroscopy studies of Triazene-1 binding to G quadruplexes and
duplex DNA

Figure A.3

UV-titration studies of binding of Triazine-1 with DNA.

(Left) Absorption spectra of Triazene-1 (10 µM) upon titration with (A) VEGF, (B) bcl-2
2345, (C) TBA, (D) 8bp AT. The concentrations of DNA are 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9,
10, 20, 30, 40, 50, 100, 150 µM. In the graph, 10 µM and 150 µM DNA concentration is
specifically emphasized as cyan and red line. [KCl] = 250 mM, Buffer = 50 Mm TrisHCl (pH 7.5). UV was measured at 20 °C. (Right) Plot of absorbance at 360 nm against
concentration ratio of DNA and Ligand (Triazene-1). Ligand concentration is 10 µM,
DNA = (A) VEGF, (B) bcl-2 2345, (C) TBA, (D) 8bp AT. The concentration of DNA is 0,
0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150 µM.
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A.4

Isothermal titration calorimetry studies of DMZ binding to G quadruplexes
and duplex DNA

Figure A.4

Heat data obtained from ITC titration experiments for the interactions
between DMZ and indicated sample.

A) 7bp HP•AT, B) 7 bp HP, C) 27mer bcl-2, D) 24mer c-MYC, E) Tris buffer, F) 22mer
hTel Na+, and G)22mer hTel K+.
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A.5

Isothermal titration calorimetry studies of Triazene-1 binding to G
quadruplexes and duplex DNA

Figure A.5

Heat data obtained from ITC titration experiments for the interactions
between Triazene-1 and indicated sample.

A) Tris buffer, B) 22mer hTel Na+ , C) 22mer hTel K+, D) 7bp HP•AT, E) 27mer bcl-2,
and F) 24mer c-MYC.
A.6

CD experiments for binding of ligands with duplex DNA (AT-rich)
CD titration experiments, monitoring in the wavelength region corresponding to

the bound ligand, were performed with different concentrations of 8bp AT (0-50 µM)
added to a fixed concentration of either DMZ or Triazene-1 (40 µM). No induced CD
was observed for Triazene-1 but a large positive induced CD was observed upon
incubating 8bp AT (0-50 µM) with DMZ (compare Figures A1A and A1B). The resulting
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large positive signal in the CD spectrum of DMZ, upon addition of AT-rich duplex DNA,
suggests a groove-binding mode of DMZ with duplex DNA, consistent with literature (1).
The lack of induced CD of Triazene-1 suggests that Triazene-1 does not bind to the
minor groove of AT-rich DNA.

Figure A.6

CD titration studies.

Increasing concentrations of duplex DNA were added to (A) DMZ (40 µM), (B)
Triazene-1 (40 µM). The concentrations of added duplex DNA were 0, 5, 10, 15, 20, 25,
30, 50 µM. Buffer = 50 mM Tris-HCl (pH 7.5), [KCl] = 250 mM. CD measurement was
done at 20 °C.
A.7

NMR structure verification
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Figure A.7

1

Figure A.8

13

H-NMR of Triazene-1.

C-NMR of Triazene-1.
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Figure A.9

1

Figure A.10

13

H-NMR of Triazene-2.

C-NMR of Triazene-2.
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Table B.1

Change in melting temperatures of G-quadruplex and duplex DNA in the
presence of various DMZ analogues.a
T1/2 (oC )b

Entry

Compound

i

DMZ

16.60.3

ii

DMZ1

NE

iii

DMZ2

iv

F21T

c-MYC

k-RAS21R

duplex

18.30.3 11.70±0.26

24.10.3

6.80.3

7.10.8

6.40±0.26

6.40.0

NEd

5.10.7

9.70.3

5.30±0.26

8.20.9

NE

DMZ3

NE

6.60.0

5.30±0.26

4.20.0

NE

v

DMZ4

NE

6.20.3

6.22±0.26

2.20.3

NE

vi

DMZ5

NE

8.20.4

5.48±0.45

7.10.3

NE

vii

DMZ6

NE

8.80.4

5.48±0.45

15.00.3

NE

viii

DMZ7

NE

7.10.4

6.40±0.26

3.70.8

NE

ix

DMZ8

7.30.5

9.70.3

8.04±0.26

13.20.3

NE

x

DMZ9

NE

8.60.3

5.67±0.26

6.90.4

NE

xi

DMZ10

NE

7.31.0

5.48±0.00

2.61.2

NE

xiii

DMZ11

NE

7.01.4

7.68±0.00

4.20.0

NE

xiv

DMZ12

NE

6.40.3

5.12±0.26

1.80.3

NE

xv

DMZ13

NE

8.80.0

5.12±0.26

2.71.0

NE

xvi

DMZ14

NE

6.10.0

6.58±0.78

4.30.3

NE

xvii

TMPyP4c

NE

24.10.0

NDe

46.72.7

NE

a

c-kit2

G-quadruplex DNA: F21T (5’–FAM-GGG TTA GGG TTA GGG TTA GGGTAMRA–3’), c-kit2 (5’–FAM-CCC GGG CGG GCG CGA GGG AGG GGA GGTAMRA–3’), k-RAS21R (5’–FAM-AGG GCG GTG TGG GAA GAG GGA-TAMRA–
3’), c-MYC (5’-FAM-TGA GGG TGG GTA GGG TGG GTA A-TAMRA-3’). Duplex
DNA: duplex (5’–FAM-TAT AGC TAT ATT TTT TTA TAG CTA TA-TAMRA–3’).
Conditions: dual-labeled DNA (0.4 M), DMZ analogues (4 M), potassium cacodylate
buffer (60 mM, pH 7.2). b T1/2 is calculated by melting temperature in the presence and
absence of DMZ analogues. c For TMPyP4, 0.4 M dual-labeled DNA and TMPyP4
were applied to get meaningful melting temperatures. d NE means not effective binding
(T1/2 < 5C). e ND means not determined.
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B.1.2
B.1.2.1

Isothermal titration calorimetry (ITC) Experiments
Method
ITC experiments were performed using a Microcal VP-ITC (Malvern) at 25 oC. A

typical experiment involved injection of 20 aliquots of dilute ligand (nominally 120 to
850 μM) into the calorimeter cell containing 1.45 mL of 6 μM DNA. Injection volumes
were 14 μL and injections were made at 200 second intervals. The ITC thermograms
were corrected for titrate and titrant dilution effects by performing the appropriate blank
experiments and correcting the observed heats by subtracting the heats of dilution.
B.1.2.2

Material
Target DNA was 24-mer WT c-MYC promoter sequence DNA purchased from

Midland Certified Reagent Co. The G-Quadruplex forming DNA (24-mer WT c-MYC,
5’-TGG GGA GGG TGG GGA GGG TGG GGA-3’), was purchased as the RP grade and
used without further purification. The DNA was exhaustively dialyzed against K+ Tris
buffer (150 mM KCl, 20 mM Tris, 1 mM EDTA, 5% DMSO, pH 7.2) and annealed by
heating to 95 oC and holding for 10 minutes and then cooling to 5 oC at a rate of 0.5
o

C/min. Ligands (DMZ analogues) were dissolved in the final dialysate buffer and heated

and sonicated to assist in dissolution. Ligand stock solutions were centrifuged to pellet
any undissolved material and the clarified solution was used as the titrant. Ligand
concentrations were verified by UV-Vis using the following extinction coefficients:
DMZ9 (at 364 nm) 8000 cm-1M-1; DMZ13 (at 378 nm) 14500 cm-1M-1; DMZ11 (at 365
nm) 24600 cm-1M-1; DMZ5 (at 360 nm) 23900 cm-1M-1; DMZ8 (at 362 nm) 25800 cm1

M-1.
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B.1.2.3

Results
DMZ analogues (DMZ5, DMZ11, DMZ8, DMZ9, DMZ13 and DMZ1) were

tested. Only two of the five ligands tested, DMZ5 and DMZ11, exhibited measureable
heat effects in these ITC titrations. It is difficult to know whether this is due to the low
solubility of the compounds (low titrant concentrations), whether they are not binding, or
whether ΔH≈0. Reverse titrations in which the DNA was added to a solution of the
compound in the ITC cell have not been helpful. It is therefore not possible to conclude
definitely, based on the ITC experiments, that the other three compounds did not bind to
G-quadruplexes. Typical ITC titration curves are shown for DMZ5, DMZ11, and DMZ9
in Figure B1.
Ligands DMZ5 and DMZ11 were found to bind to the c-MYC WT promoter
sequence G-quadruplex with similar affinities to DMZ (Mode 3 binding) and DMZ1.
The thermodynamic values reported previously1 for binding of DMZ and DMZ1 to the cMYC 24-mer oligonucleotide were for titrations done in Tris buffer in water. The
titrations for the DMZ5 ligand reported here were done in both water (100 mM KCl, 20
mM Tris, 0% DMSO, pH 7.2) and in 5% DMSO (100 mM KCl, 20 mM Tris, 5% DMSO,
pH 7.2). The data collected in the DMSO/water mixed solvent were in excellent
agreement, essentially the ΔG for binding DMZ5 was unaffected by the presence of 5%
DMSO. The ITC derived thermodynamic data for binding of DMZ5 and DMZ8 to the cMYC WT promoter sequence G-quadruplex are listed in Table B2. Previously reported
data1 for the interactions of DMZ and DMZ1 are listed for comparison.
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Figure B.1

ITC titration curves of DMZ analogues (DMZ5, DMZ11, and DMZ9)
with G-quadruplex.

Table B.2

Thermodynamic parameters for binding the listed compounds to the cMYC WT promoter sequence G-quadruplex.
Compound

ΔG

ΔH

-TΔS

(kcal/mol)

(kcal/mol)

(kcal/mol)

-7.4

-3.8

-3.6

DMZ5

-6.5 ± 0.2

-2.9 ± 1.2

-3.6

DMZ8

-7.3 ± 0.1

-3.8 ± 1.4

-3.5

DMZ11

NDa

ND

ND

DMZ9

ND

ND

ND

DMZ13

ND

ND

ND

DMZ1

-6.2

-1.1

-5.1

DMZ (Mode 3)1

a

ND: Not determined.
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The low solubility of DMZ11 (and other compounds listed as not determined,
ND, in Table B2) present two problems in the ITC titrations, 1) the inability to achieve
the larger mole ratios of ligand/DNA needed to saturate the DNA, and 2) the production
of very small injection heats. Despite these limitations, saturation of the DNA was
observed for DMZ5 and DMZ11 as shown in Figure B2. The inflection points from the
nonlinear regression fits for these titrations are approximately equal to 2 and the DNA
appears to be saturated with ligand at a mole ratio of 4. This is consistent with binding of
2 ligand molecules to each end of the G-quadruplex core. The thermodynamics are
consistent with this dimer end-stacking model and Triazene-1 had previously shown the
same 4:1 saturation stoichiometry. It does not appear that any of these compounds are
binding by intercalation.
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Figure B.2

Saturations were observed for c-MYC WT DNA titrated with DMZ5 and
DMZ11.
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B.1.3

NMR
NMR of spectra (c-kit1, c-MYC2345 or 8bp AT) in absence or presence of ligands

were obtained following precedent.19(a), 22 The sample solution containing DNA (c-kit1 or
8pb AT 300 μM), D2O (10%, v/v), NaCl (137 mM), EDTA (1 mM) and potassium
phosphate buffer (10 mM, pH 7.5) was heated up to 95 oC for 5 min, then cooled down to
room temperature, and subsequently incubated for another 12 h at 4 oC. DNA cMYC2345 (300 μM) was annealed in 70 mM of KCl and 20 mM of potassium phosphate
(pH 7) containing 10% D2O. The DMZ analogue (150 μM) was then added and
incubated for 2 h at 4 oC. The 1H NMR spectra were recorded at 25 oC, using NaOAc as
an internal standard (NaOAc was in a sealed capillary tube that was inserted in the NMR
tube). The 1H NMR spectra was recorded on Bruker Avance III HD 800 MHz
spectrometer with a CPQCI cryoprobe. c-kit1 (5’- AGG GAG GGC GCT GGG AGG
AGG G-3’), 8bp AT (5’-CGA ATT TCA AAA GAA ATT CG-3’) and c-MYC2345 (5’TGA GGG TGG GGA GGG TGG GGA A-3’)
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Figure B.3

1

H NMR spectra of 8bp AT with alkyne-substituted DMZ analogues
(DMZ9 and 13).

Conditions: DMZ analogue 9 and 13 (150 μM), 8bp AT (300 μM), D2O (10 %, V/V),
NaCl (137 mM), EDTA (1 mM), K-phosphate buffer (10 mM, pH 7.5). The DMZ
analogue was added to sample solution for 2 h in advance at 4 oC. The NMR spectra were
recorded on an 800 MHz instrument at 25 oC with acetate salt in an internal standard
capillary tube.
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Figure B.4

1

H NMR spectra of c-kit1 with alkyne-substituted DMZ analogues (DMZ9
and 13).

Conditions: DMZ analogue 9 and 13 (150 μM), c-kit1 (300 μM), D2O (10 %, V/V), NaCl
(137 mM), EDTA (1 mM), K-phosphate buffer (10 mM, pH 7.5). The DMZ analogue
was added to sample solution for 2 h in advance at 4 oC. The NMR spectra were recorded
on an 800 MHz instrument at 25 oC with acetate salt in an internal standard capillary
tube.
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Figure B.5

1

H NMR spectra of c-MYC2345 with alkyne-substituted DMZ analogues
(DMZ9 and 13).

Conditions: DMZ analogue 9 and 13 (150 μM), c-MYC2345 (300 μM), D2O (10 %,
V/V), KCl (70 mM) and K-phosphate (20 mM, pH 7). The DMZ analogue was added to
sample solution for 2 h in advance at 4 oC. The NMR spectra were recorded on an 800
MHz instrument at 25 oC with acetate salt in an internal standard capillary tube.
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B.1.3.2

Figure B.6

Stability

Stability test of ligand DMZ13 over time through 1H NMR study.

2mg DMZ13 was dissolved in 500 L D2O and 200L DMSO. Conditions: in NMR tube
at lab benchtop, room temperature, uncovered.
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B.1.3.3

Figure B.7

PCR stop assay-Pu-mutant used as control template

Effects of DMZ analogues (DMZ1, DMZ 9, DMZ13), DMZ and TMPyP4
on the PCR stop assay with mutated c-MYC template Pu-mutant

Compounds were added to the reaction mixture containing 1x PCR buffer (New England
Biolabs), 5 μM Pu-mutant, 5 µM Pu27rev, 200 µM dNTPs and 5 units of Taq polymerase
(New England Biolabs) separately. No compound added was treated as control.
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B.1.3.4

Characterizations

B.1.3.4.1

(E)-4-(3-(4-cyanophenyl)triaz-1-enyl)benzimidamide (DMZ2).

(E)-4-(3-(4-cyanophenyl)triaz-1-enyl)benzimidamide (DMZ2). Following by
the described general procedure, a yellow solid was obtained (70.2 mg, 26%). 1H NMR
(400 MHz, MeOD) δ = 7.87 (d, J=8.8, 2H), 7.75 (d, J=8.8, 2H), 7.65 (dd, J=14.2, 8.8,
4H). 13C NMR (100 MHz, MeOD) δ 167.68, 134.75, 130.50, 120.22, 120.20, 119.87,
119.53, 108.69, 108.63. HRMS (ESI+) [M+H] calcd for C16H15N6 265.1202, found
265.1218
B.1.3.4.2

(E)-4-(3-(4-ethynylphenyl)triaz-2-enyl)benzimidamide (DMZ3).

Following by the described general procedure, a brown solid was obtained (63.1
mg, 25%). 1H NMR (400 MHz, MeOD) δ = 7.80 – 7.75 (m, 2H), 7.53 – 7.49 (m, 2H),
7.47 (s, 4H). 13C NMR (100 MHz, MeOD) δ 167.51, 150.72, 149.17, 134.14, 130.04,
126.89, 121.05, 120.27, 117.81, 84.11, 79.09. HRMS (ESI+) [M+H] calcd for C15H14N5
264.1249, found 264.1266.
B.1.3.4.3

(E)-4-(3-(3-cyanophenyl)triaz-1-enyl)benzimidamide (DMZ4).

Following by the described general procedure, a yellow solid was obtained (96.8
mg, 37%). 1H NMR (400 MHz, DMSO) δ = 7.78 – 7.72 (m, 3H), 7.72 – 7.67 (m, 1H),
7.49 (t, J=7.8, 1H), 7.47 – 7.41 (m, 3H). 13C NMR (100 MHz, DMSO) δ 173.76, 161.23,
139.95, 138.38, 136.25, 133.22, 132.18, 131.19, 128.86, 126.73, 121.55. HRMS (ESI+)
[M+H] calcd for C15H13N6 265.1202, found 265.1212.
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B.1.3.4.4

(E)-4-(3-(3-ethynylphenyl)triaz-1-enyl)benzimidamide (DMZ5).

Following by the described general procedure, a red solid was obtained (106.0
mg, 40%). 1H NMR (400 MHz, MeOD) δ = 7.80 – 7.74 (m, 2H), 7.56 (t, J=1.6, 1H), 7.52
– 7.45 (m, 3H), 7.34 (t, J=7.8, 1H), 7.27 (dd, J=5.1, 3.8, 1H). 13C NMR (100 MHz,
MeOD) δ = 167.44, 150.48, 149.55, 130.44, 129.89, 127.34, 124.66, 123.67, 120.99,
117.55, 83.86, 79.01. HRMS (ESI+) [M+H] calcd for C15H14N5 264.1249, found
264.1232.
B.1.3.4.5

(E)-4-(3-(biphenyl-3-yl)triaz-1-enyl)benzimidamide (DMZ6).

Following by the described general procedure using 4-aminobenzamidine
dihydrochloride in 0.5 mmol, a brown solid was obtained (79.8 mg, 51%). 1H NMR (500
MHz, MeOD) δ = 7.79 – 7.76 (m, 3H), 7.71 – 7.66 (m, 2H), 7.45 (d, J=8.0, 3H), 7.42 –
7.34 (m, 3H), 6.77 (d, J=2.2, 1H), 6.71 (dd, J=8.9, 2.3, 1H). 13C NMR (125 MHz,
MeOD) δ 168.00, 157.51, 154.84, 147.74, 142.89, 141.56, 132.29, 130.41, 129.71,
128.91, 128.69, 128.53, 124.07, 118.88, 116.20, 115.62. HRMS (ESI+) [M+H] calcd for
C19H18N5 316.1562, found 316.1579.
B.1.3.4.6

(E)-4-(3-(3-(phenylethynyl)phenyl)triaz-1-enyl)benzimidamide
(DMZ7).

Following by the described general procedure using 4-aminobenzamidine
dihydrochloride in 0.25 mmol, a brown solid was obtained (45.2 mg, 53%). 1H NMR
(400 MHz, MeOD) δ = 7.75 – 7.71 (m, 2H), 7.60 (t, J=1.6, 1H), 7.53 – 7.49 (m, 2H),
7.48 – 7.43 (m, 3H), 7.35 – 7.31 (m, 4H), 7.31 – 7.28 (m, 1H).13C NMR (100 MHz,
MeOD) δ 167.48, 150.08, 149.35, 132.73, 130.52, 129.88, 129.68, 129.61, 128.81,
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125.48, 124.55, 122.89, 120.55, 117.68, 90.49, 90.13. HRMS (ESI+) [M+H] calcd for
C20H18N5 340.1562, found 340.1559.
B.1.3.4.7

(E)-4-(3-(3-(pyridin-2-ylethynyl)phenyl)triaz-1-enyl)benzimidamide
(DMZ8).

Following by the described general procedure using 4-aminobenzamidine
dihydrochloride in 0.25 mmol, a brown solid was obtained (30.0 mg, 35%). 1H NMR
(400 MHz, MeOD) δ = 8.54 (ddd, J=5.0, 1.7, 0.9, 1H), 7.89 – 7.82 (m, 1H), 7.77 – 7.72
(m, 2H), 7.69 (d, J=1.5, 1H), 7.64 (dt, J=7.8, 1.0, 1H), 7.53 (dt, J=7.4, 2.0, 1H), 7.50 –
7.45 (m, 2H), 7.44 – 7.35 (m, 3H). 13C NMR (100 MHz, MeOD) δ 167.46, 150.77,
150.10, 149.54, 144.08, 138.80, 130.73, 129.96, 129.76, 129.50, 128.90, 124.88, 124.13,
123.09, 121.42, 117.85, 90.77, 88.96. HRMS (ESI+) [M+H] calcd for C20H17N6
341.1515, found 341.1507.
B.1.3.4.8

(E)-4-(3-(3-((4-fluorophenyl)ethynyl)phenyl)triaz-1enyl)benzimidamide (DMZ9).

Following by the described general procedure using 4-aminobenzamidine
dihydrochloride in 0.25 mmol, a yellow solid was obtained (51.4 mg, 58%). 1H NMR
(400 MHz, MeOD) δ = 7.83 – 7.79 (m, 2H), 7.65 (t, J=1.5, 1H), 7.60 – 7.51 (m, 5H),
7.42 (t, J=7.7, 1H), 7.40 – 7.35 (m, 1H), 7.18 – 7.12 (m, 2H). 13C NMR (100 MHz,
MeOD) δ 167.65, 165.45, 162.98, 150.21, 149.50, 134.94, 134.86, 130.67, 130.58,
130.38, 125.69, 125.46, 123.35, 121.16, 120.84, 120.80, 117.28, 116.99, 116.77, 89.64,
89.46. HRMS (ESI+) [M+H] calcd for C21H17N5F 358.1468, found 358.1469.
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B.1.3.4.9

(E)-4-(3-(3-((4-methoxyphenyl)ethynyl)phenyl)triaz-1enyl)benzimidamide (DMZ10).

Following by the described general procedure using 4-aminobenzamidine
dihydrochloride in 0.25 mmol, a brown solid was obtained (28.3 mg, 31%). 1H NMR
(400 MHz, MeOD) δ = 7.85 – 7.79 (m, 2H), 7.63 (t, J=1.6, 1H), 7.59 – 7.54 (m, 2H),
7.54 – 7.49 (m, 1H), 7.49 – 7.45 (m, 2H), 7.41 (t, J=7.7, 1H), 7.36 (dt, J=7.6, 1.4, 1H),
6.97 – 6.93 (m, 2H), 3.83 (s, 3H). 13C NMR (100 MHz, MeOD) δ 167.71, 161.62,
157.22, 134.24, 130.61, 130.57, 126.09, 123.34, 120.92, 117.16, 116.47, 115.34, 90.79,
88.48, 55.97. HRMS (ESI+) [M+H] calcd for C22H20N5O 370.1668, found 370.1642.
B.1.3.4.10

(E)-4-(3-(2-ethynylphenyl)triaz-1-enyl)benzimidamide (DMZ11).

Following by the described general procedure, a brown solid was obtained (113.2
mg, 43%). 1H NMR (400 MHz, MeOD) δ = 7.79 – 7.73 (m, 2H), 7.62 (dd, J=8.3, 0.7,
1H), 7.53 – 7.45 (m, 3H), 7.40 – 7.33 (m, 1H), 7.13 (td, J=7.6, 1.1, 1H). 13C NMR (100
MHz, MeOD) δ 167.40, 149.88, 134.76, 130.91, 129.68, 129.18, 129.03, 126.51, 123.41,
118.04, 117.85, 116.10, 84.53, 81.10. HRMS (ESI+) [M+H] calcd for C15H14N5
264.1249, found 264.1240.
B.1.3.4.11

(E)-4-(3-(2-(phenylethynyl)phenyl)triaz-1-enyl)benzimidamide
(DMZ12).

Following the described general procedure using 4-aminobenzamidine
dihydrochloride in 0.2 mmol, a yellow solid was obtained (57.3 mg, 85%). 1H NMR (400
MHz, MeOD) δ = 7.73 (d, J=8.6, 2H), 7.64 (d, J=8.2, 1H), 7.56 – 7.46 (m, 5H), 7.40 –
7.31 (m, 4H), 7.18 (t, J=7.5, 1H). 13C NMR (100 MHz, MeOD) δ 167.42, 149.72, 134.36,
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132.72, 130.58, 129.75, 129.64, 126.91, 124.80, 118.37, 117.68, 95.60, 87.59. HRMS
(ESI+) calcd for C21H18N5 340.1562, found 340.1580.
B.1.3.4.12

(E)-4-(3-(2-((4-fluorophenyl)ethynyl)phenyl)triaz-1enyl)benzimidamide (DMZ13).

Following by the described general procedure using 4-aminobenzamidine
dihydrochloride in 0.2 mmol, a brown solid was obtained (35.0 mg, 49%). 1H NMR (400
MHz, MeOD) δ = 7.76 (d, J=8.8, 2H), 7.65 (d, J=7.6, 1H), 7.55 (ddd, J=16.4, 11.2, 7.1,
5H), 7.42 – 7.35 (m, 1H), 7.21 (td, J=7.6, 1.0, 1H), 7.14 – 7.06 (m, 2H). 13C NMR (100
MHz, MeOD) δ 167.47, 165.35, 162.88, 150.06, 149.70, 134.89, 134.81, 134.37, 133.08,
130.63, 130.04, 128.28, 127.25, 121.16, 121.13, 118.57, 117.39, 116.87, 116.65, 94.38,
87.45. HRMS (ESI+) calcd for C21H17N5F 358.1468, found 358.1439.
B.1.3.4.13

(E)-4-(3-(pyridin-4-yl)triaz-1-enyl)benzimidamide (DMZ14).

Following by the described general procedure, a yellow solid was obtained (121.6
mg, 51%). 1H NMR (400 MHz, MeOD) δ = 8.35 (d, J=4.2, 1H), 7.89 – 7.80 (m, 3H),
7.69 (d, J=8.7, 2H), 7.55 (d, J=8.3, 1H), 7.21 – 7.13 (m, 1H). 13C NMR (100 MHz,
MeOD) δ149.34, 140.22, 130.00, 121.48, 120.54. HRMS (ESI+) [M+H] calcd for
C12H13N6 241.1202, found 214.1190.
B.1.3.4.14

3-((4-Fluorophenyl)ethynyl)aniline (15).

Following the above general procedure, an off-white solid was obtained (350 mg,
83%). 1H NMR (400 MHz, CDCl3) δ = 7.54 – 7.45 (m, 2H), 7.13 (t, J=7.8, 1H), 7.08 –
6.99 (m, 2H), 6.96 – 6.90 (m, 1H), 6.87 – 6.82 (m, 1H), 6.67 (ddd, J=8.1, 2.4, 0.9, 1H),
3.72 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 164.10, 161.62, 146.76, 133.95, 133.87,
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129.78, 124.15, 122.42, 119.89, 119.85, 118.16, 116.17, 115.95, 115.88, 89.76, 89.74,
88.16. HRMS (ESI+) [M+H] calcd for C14H11NF 212.0876, found 212.0881.
B.1.3.4.15

3-((4-Methoxyphenyl)ethynyl)aniline (16).

Following the above general procedure, an off-white solid was obtained (352.3
mg, 79%). 1H NMR (400 MHz, CDCl3) δ = 7.48 – 7.42 (m, 2H), 7.12 (t, J=7.8, 1H), 6.92
(d, J=7.5, 1H), 6.89 – 6.85 (m, 2H), 6.84 (s, 1H), 6.64 (d, J=9.8, 1H), 3.83 (s, 3H). 13C
NMR (100 MHz, CDCl3) δ 159.66, 146.40, 133.19, 129.40, 124.37, 122.07, 117.83,
115.58, 115.21, 114.11, 88.92, 88.43, 55.45. HRMS (ESI+) [M+H] calcd for C15H14ON
224.1075, found 224.1080.
B.1.3.4.16

2-(Phenylethynyl)aniline (17).

Following the above general procedure, an off-white solid was obtained (316.5
mg, 82%). 1H NMR (400 MHz, CDCl3) δ = 7.58 – 7.53 (m, 2H), 7.41 – 7.34 (m, 4H),
7.16 (ddd, J=8.2, 7.4, 1.6, 1H), 6.78 – 6.71 (m, 2H), 4.31 (s, 2H). 13C NMR (100 MHz,
CDCl3) δ 147.93, 132.29, 131.61, 129.89, 128.53, 128.36, 123.45, 118.13, 114.49,
108.07, 94.84, 86.05. HRMS (ESI+) [M+H] calcd for C14H12N 194.0970, found
194.0978.
B.1.3.4.17

2-((4-Fluorophenyl)ethynyl)aniline (18).

Following the above general procedure, an off-white solid was obtained (375.6
mg, 89%). 1H NMR (400 MHz, CDCl3) δ = 7.55 – 7.48 (m, 2H), 7.39 – 7.34 (m, 1H),
7.16 (ddd, J=8.2, 7.4, 1.6, 1H), 7.09 – 7.02 (m, 2H), 6.74 (dtd, J=4.8, 3.5, 1.1, 2H), 4.28
(s, 2H). 13C NMR (100 MHz, CDCl3) δ 163.84, 161.36, 147.91, 133.52, 133.44, 132.29,
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129.96, 119.58, 119.54, 118.17, 115.93, 115.71, 114.53, 107.88, 93.72, 85.74, 85.73.
HRMS (ESI+) [M+H] calcd for C14H11NF 212.0876, found 212.0860.
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CD data for the dilution of rac-RPCs (left column), Δ-RPCs (center
column) and Λ-RPCs (right column). Note the rac-RPCs demonstrates a
near zero induced CD signal in the buffer titrations.
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C.2

ESI-MS

Figure C.2

ESI-MS of free hairpin DNA and hairpin DNA incubated with a slight
excess of the indicated RPC. DNA illustrated in C2B, C2C, and C2D were
prepared with DNA shown in C2A.
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Figure C.3

ESI-MS of free hairpin DNA and hairpin DNA incubated with a slight
excess of the indicated RPC. DNA illustrated in C3B, C3C, and C3D were
prepared with DNA shown in C3A.

Figure C.4

ESI-MS of free hairpin DNA and hairpin DNA incubated with a slight
excess of the indicated RPC. DNA illustrated in C4B, C4C, and C4D were
prepared with DNA shown in C4A.
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CD data for the dilution of rac-RPCs (left column), Δ-RPCs (center
column) and Λ-RPCs (right column). Note the rac-RPCs demonstrates a
near zero induced CD signal in the buffer titrations
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